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Introduction 
Part of this introduction was adapted from:
Dendritic Cells in Chronic Viral Hepatitis B and C: Victims or Guardian Angels?
Andrea M. Woltman
Andre Boonstra 
Harry L.A. Janssen
Gut 2010;59(1):115-25
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History
The discovery of the Hepatitis B virus (HBV) is a typical example of the role of serendipity in 
scientific progress. In 1967, Dr. Blumberg investigated the link between inherited traits and 
susceptibility to diseases by taking blood samples from native populations all over the world. 
These blood samples were tested for the presence of different serum proteins using antibodies 
derived from blood of haemophiliac patients. Dr. Blumberg reasoned that the immune system 
of these patients must recognize all blood serum proteins as a result of the blood transfusions 
they underwent. Using this technique, he discovered a match between an antibody from a hae-
mophiliac patient in New York and a blood serum protein from an Australian aboriginal, which 
he called Australian antigen. Combination of this finding with research and clinical observa-
tions led to the insight that the Australian antigen caused hepatitis or liver inflammation, which 
in turn led to the discovery of HBV by the virologist Dr. Dane in1970. Two years later, a blood 
test to identify HBV and a vaccine against the virus were invented. In 1976, Dr. Blumberg was 
rewarded the Nobel Prize in medicine for this discovery [1].
Hepatitis B virus
HBV is classified as the prototypic family member of the Hepadnaviridae and belongs to the 
genus Orthohepadnavirus within this family [2]. All members of this family infect the liver as 
primary target leading to acute or chronic hepatic infections. The infectious Hepatitis B virion, 
also called Dane particle, appears in electron microscopy as a 45 nm sphere. HBV contains an 
outer envelope, which surrounds the nucleocapsid containing the viral DNA. The HBV genome 
is relatively small. The 3200 bases of the partially double-stranded relaxed-circular DNA 
encode all viral proteins with four open reading frames: S (surface antigens), C (core antigen 
and HBeAg), P (polymerase) and X (HBx protein). HBV surface antigens, or HBsAg, consist of 
small, middle and large surface glycoproteins composed of three domains: preS1, preS2 and 
S (Fig. 1). The nucleocapsid comprises the viral DNA and the polymerase enzyme surrounded 
by the structural protein HBV core antigen (HBcAg) [2]. The function of HBeAg and HBx are still 
under debate. HBeAg is secreted in the circulation, but is dispensable for in vivo infection. HBx 
is required for the establishment of an infection in vivo, but is not necessary for viral replica-
tion in cell line models. HBV replication starts with the repair of the partially double-stranded 
genome into covalently closed circular DNA. HBV uses host polymerases to transcribe the viral 
DNA into several viral RNA intermediates. The smaller mRNAs are translated into viral proteins. 
Fig. 1 Introduction
small (S)
middle (S + preS2)
large (S + preS2 + preS1)
polymerase
viral DNA
core antigen
Nucleocapsid Viral envelope
fig. 1 schematic representation of 
HBV.
Indicated is the nucleocapsid containing 
viral DNA and polymerase, surrounded 
by the HBsAg envelope consisting of 
small, middle and large surface antigens.
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The largest viral mRNA or pregenomic RNA is packaged together with the viral polymerase 
into a core particle, where the viral polymerase converts the viral RNA into viral DNA by reverse 
transcriptase. Finally, these core particles bud through the endoplasmatic reticulum where 
they acquire the surface envelop and are released as progeny virus particles. Next to HBeAg 
and infectious virions, HBV infected hepatocytes secrete large amounts of nucleocapsid-free 
subviral particles, consisting of the small and middle surface antigens. These HBsAg subviral 
particles form spheres and filaments with a diameter of 22 nm and outnumber the infectious 
virions more than 100-fold, accumulating up to 100 µg/ml in peripheral blood of HBV infected 
patients [2].
Viral entry
One of the key questions in HBV biology focuses on the attachment and entry of HBV into the 
main target cell for infection, the hepatocyte. Several putative binding partners for HBV surface 
antigens have been described, such as human serum albumin [3], asialoglycoprotein receptor 
[4], heparin [5] and mannose binding lectin [6], but their exact role in HBV attachment and 
uptake remains unclear [7]. It is well known that the preS1 domain of the surface antigen is 
essential for infection of hepatocytes [8,9]. Inhibition of HBV infection can be achieved using 
preS1 peptides, but inhibition of binding of HBV particles to hepatocytes requires much more 
stringent conditions [10]. This discrepancy suggests that HBV is first trapped on the hepatocyte 
by an abundantly expressed low affinity receptor and subsequently enters the cell via a yet 
undefined high affinity receptor, which can be blocked by preS1 peptides [7]. Since HBV is 
known to interact with heparin, candidates for the low affinity docking receptor are heparan 
sulphate proteoglycans, enriched in the liver within the space of Dissé and indispensable for 
establishment of HBV infection in vitro [11]. 
Course of an HBV infection
HBV can be transmitted by perinatal, percutaneous or sexual exposure. Four to seven weeks 
post-infection, HBV can be detected in the liver and serum (up to 109-1010 copies/ml), and 
has infected most hepatocytes [12,13]. During the acute phase, an efficient anti-viral immune 
response of the patient will entirely clear the virus. This response involves both the innate 
and the adaptive immune system, leading to a self-limiting HBV infection. In the absence of a 
competent immune response, the acute infection can become chronic. The risk of developing 
chronic HBV infection after acute exposure is determined by age, the route of infection and the 
dose of inoculum, ranging from 90% in newborns to less than 10% in adults [14,15]. Worldwide, 
more than 2 billion people have been infected with HBV and in 400 million people this infec-
tion became chronic [16]. Although HBV is a non-cytopathic virus, the continuous attacks of 
infected hepatocytes by cells of the immune system attempting to clear the virus will cause 
chronic inflammation of the liver. Over the course of approximately 30 years, chronic HBV infec-
tion may as a result lead to progressive liver injury with an increased risk of developing liver 
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cirrhosis, liver failure and liver cancer [15]. Diagnostic liver function tests include histological 
examination of liver biopsies to determine liver inflammation and fibrosis state and serum mea-
surement of alanine transaminase (ALT), a liver enzyme that is released in the circulation upon 
liver damage. Approximately 500.000 to 1.2 million people die annually from the consequences 
of a chronic HBV infection [17].
Treatment of chronic HBV infections
The goal of antiviral therapy of chronic HBV patients is to achieve disease remission by suppress-
ing HBV replication before irreversible liver damage has occurred. The long term treatment goals 
are to eliminate the HBV infection, prevent progression of liver injury to liver cancer and pro-
mote patient survival. Clinical endpoints of antiviral therapy include HBeAg seroconversion (loss 
of HBeAg with appearance of anti-HBeAg), HBsAg seroconversion, decline in serum HBV DNA 
below the limit of detection, normalisation of ALT level and improvement of liver histology [18]. 
Treatment options for chronic HBV can be divided in two categories: immune modulators and 
HBV replication inhibitors. The first comprises therapy with the cytokine interferon alpha (IFN-α), 
which has immunomodulatory, anti-proliferative and anti-viral activity [19]. In 2001, a pegylated 
form of IFN-α (PEG-IFN-α) was developed which has a prolonged half life due to the presence of 
a polyethylene glycol polymer [20]. PEG-IFN-α treatment leads to sustained response in approxi-
mately 20 - 45% of patients, depending on HBV genotype and HBeAg positivity [21,22]. The 
major advantage of PEG-IFN-α therapy is the relative high rate of sustained response after treat-
ment discontinuation [23,24]. Major disadvantages are the subcutaneous administration and 
frequent side-effects, mainly flu-like symptoms, cytopenia and psychiatric adverse events [18]. 
Therefore it would be beneficial if response or non-response to therapy could be predicted at an 
early stage. Tenofovir, adefovir, entecavir, telbivudine and lamivudine are the current nucleos(t)
ide analoques on the market, belonging to the class of HBV replication inhibitors which directly 
inhibit HBV polymerase [22]. Advantages of this line of therapy are the oral administration, rapid 
decline in HBV viral load and minimal side effects. The main disadvantages are the risk of devel-
opment of resistant mutants and the likely need for indefinite therapy, since sustained response 
is not frequently achieved [18]. Thus, although the currently available treatment strategies are 
effective in the suppression of HBV replication and subsequent prevention of liver damage, 
new treatment strategies should be aimed at immunologic control and ultimately complete 
eradication of the virus. A better understanding of the immunological mechanisms of chronic 
HBV infection is essential in the development of new treatment strategies.
Dendritic cells in the anti-viral immune response
The first line of defence after infection of the host by a pathogen is formed by the innate 
immune system, which involves dendritic cells (DC), macrophages, natural killer cells, cytokines 
and complement components, limiting the spread of the pathogen and initiating an adaptive 
immune response. In contrast to the immediate and non-specific action of the innate immune 
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response, the adaptive immune response is specific, long-lasting and protective, mediated by B 
and T cells residing primarily in the lymph nodes.
Both macrophages and DC continuously sample the environment for potentially dangerous 
microbes. Upon recognition, the main role of macrophages is to phagocytose and destroy the 
pathogen, while DC are specialized in communication of the intruder signal to cells of the adaptive 
immune system. Viruses may activate DC directly through pattern recognition receptors on DC 
including C-type lectins and Toll-like receptors (TLR) [25,26], leading to internalization of the virus 
within early endosomes (Fig. 2). DC can also be indirectly activated by viruses through the capture 
of viral products and by responding to cytokines produced by other cells in response to viral infec-
tion [27]. DC integrate these signals and process the captured viral products into viral peptides by 
fusion of the early endosomes with lysosomes. The virus-derived peptide is then presented to T 
cells, leading to induction of virus-specific T and B cell responses. The DC is thus a key component 
in bridging innate and adaptive immunity [28,29]. They not only play a key role in initiating, but 
also in controlling the magnitude and the quality of adaptive immune responses [28-31]. 
 
CD40L
CD40
MHCII
TCR
CD28
B7
TCR
MHC I
CD28
B7
DC
CD8
CD4
e.g.  IL-12, IL-10
PRR
e.g.  IL-2, IFN-γ
L
virus
EE
ER
viral peptide
Fig. 2 Introduction 
fig. 2 the role of dendritic cells in pathogen recognition, uptake and presentation to t cells. 
Upon recognition of a pathogen by a pathogen recognition receptor on the surface of the dendritic cell, the com-
plex is internalized into early endosomes. After fusion with a lysosome, the pathogen is degraded into peptides 
which are presented on MCH II molecules to the T cell receptor of CD4 (or: helper) T cells. Pathogen recognition 
also leads to activation of the dendritic cell, leading to upregulation of co-stimulatory molecules B7 (CD80 or 
CD86) and CD40. T cell activation only occurs if a co-stimulatory signal is present, coming from either B7-CD28 or 
CD40-CD40L interaction. In case the pathogen is present in the cytosol of the dendritic cell, the proteasome will 
degrade it into peptides which are transported to the MHC I molecules in the endoplasmatic reticulum. Peptide-
MCH I complexes are transported to the dendritic cell surface, where the peptide is presented to the T cell receptor 
of CD8 (or: cytotoxic) T cells. CD8 T cell activation only occurs if the co-stimulatory signal and cytokines produced 
by activated CD4 T cells (IL-2, IFN-γ) are present. Cytokines produced by the dendritic cell can either stimulate 
(IL-12) or inhibit (IL-10) the immune response. DC=dendritic cell, PRR=pathogen recognition receptor, EE=early 
endosome, L=lysosome, ER=endoplasmatic reticulum, MHC=major histocompatibility complex, TCR=T cell recep-
tor, IL=interleukine, IFN=interferon.
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Induction of IFN-γ-producing T helper1 (Th1) cells, which are crucial in anti-viral immunity, 
requires recognition of viral peptide presented by major histocompatibility complex II (MHC II) 
by the T cell receptor on the CD4 T helper cell (signal 1; Fig. 2). Next, a co-stimulatory interaction 
between B7 molecules on the DC and CD28 on the T cells is required (signal 2). The co-stimulatory 
molecules CD80 and CD86 belong to the B7 family and are upregulated following DC activation. 
Co-stimulation may be enhanced through interaction between CD40 and CD40L. Next to signal 
1 and 2, cytokines including IL-12 and IFN-α produced by the DC further differentiate the acti-
vated CD4 T helper cells into potent effector Th1 cells (signal 3) [32]. In case the pathogen resides 
in the DC cytosol, it is processed into viral peptides by the proteosome. These viral peptides are 
then transported into the endoplasmatic reticulum, where they are incorporated within MHC I 
molecules and finally presented to the T cell receptor on cytotoxic T cells [33]. Cytotoxic T cells 
need both the co-stimulatory signal and the cytokines produced by the Th1 cells to expand 
and differentiate into effector cells that can directly kill virus-infected neighbouring cells. DC 
that are not properly activated and arrested at either an immature or a semi-mature state, lack 
their co-stimulatory function and production of pro-inflammatory cytokines, and may induce 
regulatory T cell responses [34]. These regulatory T cells modulate the activity of multiple cells of 
the immune system by suppressing their effector function [35]. In addition, regulatory cytokines 
e.g. IL-10 and TGF-β, produced by a wide range of cells strongly suppress DC and macrophage 
function, which further hampers the induction of an efficient anti-viral response.  
Dendritic cell subsets
Human DC can be categorized in two main subsets including myeloid DC (mDC) and plasmacy-
toid DCs (pDC) [36]. Blood contains both mDC and pDC at frequencies of 0.5-1.0% and 0.2-0.5% 
of peripheral blood mononuclear cells, respectively. The different DC subsets not only differ in 
surface markers, but also in their response to pathogens, antigen processing and their capac-
ity to activate T cells [37,38]. mDC induce strong T cell proliferation and initiate anti-viral Th1 
responses via the production of IL-12. In contrast to mDC, pDC are poor inducers of T cell pro-
liferation, but are best known for their rapid and high level of type I IFN production in response 
to TLR7 and TLR9 triggering by single-stranded RNA or DNA containing CpG motifs commonly 
found in viruses and bacteria [39]. The secretion of excessive amounts of IFN-α, but also other 
cytokines, has a strong direct anti-viral effect. In addition, type I IFN directly influences immune 
cells allowing further priming of anti-viral immunity [40].
Dendritic cells in the immunotolerant environment of the liver
The liver has a function in digestion, detoxification and production of plasma proteins. The 
parenchymal cells, the hepatocytes, are the main contributors to the metabolic function of 
the liver. Hepatocytes are separated from the sinusoidal lumen by the space of Dissé and an 
endothelial cell layer. Lymph is collected within the space of Dissé and transported to the 
celiac lymph nodes. The liver endothelial consists of liver sinusoidal endothelial cells (LSEC). 
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LSEC are fenestrated, thereby allowing molecules to diffuse from the sinusoidal blood to 
the hepatocytes. One of the proposed mechanisms by which HBV in the circulation reaches 
the hepatocytes is through these LSEC fenestrations [41]. Other non-parenchymal antigen 
presenting cells are the liver macrophages or Kupffer cells, which can penetrate the endothelial 
layer and the space of Dissé to reach the hepatocytes, and the hepatic DC [42]. These cell types 
might also be involved in HBV dissemination, similar to HIV transport by DC for trans-infection 
of T cells [43] and HCV capture by LSEC promoting infection of hepatocytes [44]. Hepatic DC 
are usually found in the portal triad and the central veins and can migrate through the LSEC 
into the space of Dissé to travel to the celiac lymph nodes while maintaining immature [45]. 
Blood coming from the portal vein is so rich in dietary proteins, components of commensal 
intestinal flora and environmental toxins that the local immune response in the liver is tightly 
regulated to prevent chronic inflammation of the liver. Several mechanisms may contribute to 
this tolerant liver environment: antigen presentation by LSEC to CD8 T cells leads to tolerance 
rather than effector functions, with low IL-2 and IFN-γ production [46]; Kupffer cells and LSEC 
continuously express the immunosuppressive cytokines IL-10 and TGF-β [47]; and hepatic DC 
show increased IL-10 production compared to blood-derived DC [48]. As a consequence of this 
tolerant environment, the liver is a relatively easy target for chronic viral and parasitic infections 
[49].
Dendritic cells in chronic hepatitis B patients
Several studies, especially those examining patients with advanced fibrosis or cirrhosis [50-53] 
describe a decrease in circulating blood DC numbers in chronic HBV patients compared to 
healthy individuals [50-55]. Liver inflammation, as reflected by increased serum ALT levels, was 
reciprocally correlated with the number of both circulating mDC [52,56] and pDC [57]. This is in 
line with the observed increased numbers of intrahepatic DC in the portal areas of the liver of 
chronic HBV patients [53,56]. Since no significant correlation with HBV DNA levels are reported, 
altered circulating DC numbers are most likely related to altered migration of the cells, which 
may in turn be related to the phase of disease.
In addition to a decrease in circulating DC numbers, functional deficits in DC or DC precur-
sors from chronic HBV patients may contribute to the impaired HBV-specific immune response 
as well. Indeed, ex vivo examination of mDC of chronic HBV patients showed some phenotypic 
and, more pronounced, functional alterations compared to mDC of healthy controls [54-56,58]. 
Upon stimulation, mDC of chronic HBV patients produced less IFN-ß and TNF-α compared to 
mDC of healthy controls, without significant changes in IL-6, IL-1ß and IL-12 [54]. Functional 
modulation of DC function may have important consequences for the regulation of T cell 
responses. Several studies showed indeed that mDC from chronic HBV patients are less efficient 
in inducing T cell proliferation in vitro than mDC isolated from healthy individuals [54,58,59].
Type I IFN production by pDC is characteristic during viral infections [39]. Impaired IFN-α 
production by pDC from chronic HBV patients has been shown after stimulation with SAC [54], 
16
C
ha
p
te
r 
1
HSV [51], or DNA containing CpG motifs [53,57,60] as compared to healthy controls. Loss of 
serum HBeAg during successful treatment of patients with potent anti-viral drugs was sug-
gested to be responsible for partial restoration of circulating pDC numbers and the impaired 
IFN-α production [51]. Whether PEG-IFN-α therapy will also enhance the impaired pDC function 
of chronic HBV patients is currently unknown.
The functionality of DC subsets could be affected by the interaction of surface receptors on 
DC with the virus or its viral proteins, but also as a consequence of infection of the cells or their 
precursors. Although HBV is generally considered to be highly hepatotropic, small amounts 
of HBV-specific nucleic acids can be detected in many extra-hepatic tissues during acute and 
chronic infection [61-64]. Whether human cells other than hepatocytes can support steps of 
HBV replication is still controversial. Even though DC are likely to be infected in animal models 
of hepadnavirus infection [65], productive HBV replication appears to be unlikely in chronic 
HBV patients, as only HBV DNA could be detected but no evidence was found for viral replica-
tion in circulating mDC and pDC [54,55], nor in monocyte-derived DC [66]. Thus, although HBV 
is incapable of replicating in DC, the binding and uptake of viral particles by these cells may be 
responsible for the impaired function of DC in HBV infected individuals. 
aIms anD oUtlInE of tHIs tHEsIs
This thesis focuses on the role of DC in chronic HBV infection. Many studies indicate a functional 
deficit in DC of chronic HBV patients, but it is unclear whether this is caused by a direct interac-
tion between the DC and the virus or viral proteins or by a more indirect effect of the chronic 
inflammation state of the liver. The DC-HBV interaction and the subsequent immunomodulatory 
effect on the anti-viral immune response are investigated and discussed here.  In addition to 
reported deficiencies in CD4 T cell stimulation, chapter 2 presents data on the reduced capacity 
to expand HBV-specific CD8 T cells displayed by mDC of chronic HBV patients. This reduced 
capacity to expand CD8 T cells could be abolished by neutralizing IL-10, suggesting that IL-10 is 
an important player in HBV induced viral persistence and disease chronicity. Chapter 3 describes 
the direct tolerogenic effect of HBV and HBsAg on mDC function: the T cell stimulatory capacity 
was reduced, as assessed by T cell proliferation and IFN-γ production. The receptors involved in 
the recognition of HBV and HBsAg by mDC were also investigated. Interaction between DC and 
viruses through the pathogen recognition receptor DC-SIGN has attracted much attention lately. 
Although HBV meets the criteria for DC-SIGN binding, DC-SIGN is excluded as a HBV receptor in 
chapter 4. In chapter 5 a role for the mannose receptor in the uptake of HBsAg by mDC is pre-
sented. Analysis of blood- and liver-derived DC of chronic HBV patients shows that interaction 
with HBsAg predominantly occurs at the main site of infection, the liver. Chapter 6 describes the 
inhibitory effect of HBV on pDC function. TLR9 triggering is directly inhibited by HBV, leading to 
reduced pDC activation and diminished levels of IFN-α and other pro-inflammatory cytokines. 
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The inhibitory effects on TLR9-mediated pDC function and activation are further enhanced in 
presence of monocytes. Chapter 7 presents the results of a longitudinal study on the effect of 
PEG-IFN-α-2a therapy on pDC function of chronic HBV patients. The response to TLR7 and TLR9 
specific ligands is differentially regulated during PEG-IFN-α-2a therapy by a direct effect on TLR7 
and TLR9 expression levels. This effect is directly caused by PEG-IFN-α therapy and could not 
be attributed to change in HBV viral load levels. Together, this thesis provides evidence for the 
direct interference of HBV with both mDC and pDC as part of the immune escape mechanism 
leading to maintenance of a chronic HBV infection.  
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aBstRaCt 
Chronic hepatitis B virus (HBV) infection is characterized by a relatively weak, antigen restricted 
or even undetectable T cell response to the virus. Dendritic cells (DC) play an important role in 
the induction of T cell responses. Previously, it was shown that mDC of chronic HBV patients 
are impaired in their maturation and allostimulatory capacity. It is unclear whether these 
hampered mDC can affect the expansion of HBV-specific CD8 T cells. We therefore analysed the 
capacity of mDC from chronic HBV patients to expand HBV-specific CD8 T cells. The expansion 
of HBV-specific CD8 T cells from a resolved HBV patient was significantly reduced by mDC of 
chronic HBV patients compared to mDC of healthy controls, both in whole PBMC cultures and 
in purified CD8 T cell cultures. Interestingly, purified mDC of chronic HBV patients produced 
more IL-10 compared to mDC of healthy controls. Neutralization of IL-10 completely restored 
the reduced expansion of HBV-specific CD8 T cells. In contrast to the reduced capacity of HBV-
specific CD8 expansion by HBV patient-derived mDC, the expansion of CMV-specific CD8 T cells 
was only slightly inhibited compared to healthy control-derived mDC. In conclusion, these 
preliminary results indicate that mDC of chronic HBV patients display a preferential reduced 
capacity to expand HBV-specific CD8 T cells, which was IL-10 dependent. 
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IntRoDUCtIon
Chronic infection with hepatitis B virus (HBV) leads to an inflammatory liver disease of vari-
able severity and is world-wide a major cause of liver failure and hepatocellular cancer [1,2]. 
The immunopathogenesis of chronic HBV infection is unclear up till now and considered 
to be the result of a complex interaction between a replicating non-cytopathic virus and a 
down-regulated antiviral immune response. To recover from an HBV infection, both a strong 
humoral and cellular immune response is required. During an acute infection the class I- and 
class II-restricted T cell responses to the virus are vigorous, polyclonal and multispecific [3-5], 
while such responses are relatively weak, antigen restricted or even undetectable in chronically 
infected patients [6,7]. 
Dendritic cells (DC) are specialized cells critical for the development of immunity to HBV. 
They are capable of directing the magnitude, polarity and effector function of the T cell response 
[8]. DC possess the capacity to capture and process antigens and present these in the context 
of co-stimulatory and HLA class II molecules to T cells. Depending on their maturation status, 
represented by the expression level of co-stimulatory and HLA molecules and the capacity to 
produce pro-inflammatory or anti-inflammatory cytokines, DC can induce either immunity or 
tolerance [9,10]. Immature and semi-mature DC are associated with tolerogenic responses. In 
the context of HBV a defect in the maturation process of DC may lead to tolerogenic T cell 
responses and HBV persistence. We and others have previously shown that a specific subset 
of DC, the myeloid dendritic cells (mDC), of chronic HBV patients are indeed impaired in their 
capacity to mature compared to mDC of healthy controls, as shown by a decreased capacity 
to upregulate co-stimulatory molecules, produce pro-inflammatory cytokines and stimulate 
allogeneic T cells [11,12]. Reducing the viral load by the nucleotide analogue adefovir dipivoxil 
resulted in an improvement of numbers and functionality of mDC. More specifically, virus 
reduction resulted in increased allostimulatory capacity and the capacity of mDC to produce 
IL-12 and TNF-α, while the capacity of mDC to produce IL-10 was decreased [13]. In a later study 
we have shown that the presence of both HBV particles and HBV proteins has a direct effect 
on mDC function [14]. Taken together this indicates an important role for the presence of viral 
particles and/or viral proteins in dampening the immune response with viral persistence as a 
result. 
Up till now, it is unknown what the contribution is of dysfunctional mDC from chronic HBV 
patients to the presence and expansion of HBV-specific CD8 T cells. CD8 T cells are extremely 
important for clearance of HBV infected hepatocytes, but in chronic HBV patients they are usu-
ally very difficult to find [15-17]. In this study we have therefore developed an experimental 
setup to determine the capacity of mDC of chronic HBV patients to expand HBV-specific CD8 
T cells.  
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matERIals anD mEtHoDs
Patients
Peripheral heparinized blood samples were obtained from 14 HLA-A2+ patients with chronic 
hepatitis B (Table 1). All patients were negative for antibodies against human immune 
deficiency virus, hepatitis C and hepatitis D. None of the patients were treated for chronic HBV 
infection or received any other medication 6 months previous to blood sampling. All patients 
had biopsy proven active chronic hepatitis. The median serum HBV DNA load was 2.0x106 
copies/mL (range 1.0x103 – 4.9x109) and median alanine transaminase level (ALT) was 28 U/L 
(range 15 – 262). Seven patients were HBV envelope antigen (HBeAg) positive and 7 patients 
were HBeAg negative and had antibodies to HBeAg. A control group, matched for age and 
gender, consisted of 14 healthy subjects who had no evidence of exposure to HBV (HBV surface 
antigen (HBsAg) negative). In addition, peripheral blood was obtained from a HLA-A2+ person 
that had resolved an acute HBV infection and has antibodies to HBsAg and a HLA-A2+ person 
with positive serology for cytomegalovirus (CMV). The study was approved by the local ethics 
committee and all patients and controls in the study gave informed consent before blood 
donation.
Virological assessments
Serum HBsAg, HBeAg, and anti-HBe were determined quantitatively using the IMX system (Abbot 
Laboratories, North Chicago, IL, USA) according to the manufacturers’ instructions. Serum HBV 
DNA was determined using a HBV monitor assay (Roche Applied Science, Penzberg, Germany; 
detection limit 1x103 geq/mL). When the serum HBV DNA was below 1x103 geq/mL HBV DNA the 
assay was repeated using an in-house developed TaqMan PCR (detection limit 373 geq/mL) [18].
HLA typing
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood samples by 
density gradient centrifugation on Ficoll-Hypaque (Amersham Pharmacia Biotech AB, Uppsala, 
Sweden). Screening for HLA-A2 haplotype positivity was performed by staining PBMC with an 
anti-HLA-A2 antibody derived from a hybridoma (clone BB7.2, ATCC HB-82). Staining was fol-
table 1 Characteristics of chronic HBV patients and healthy controls 
Chronic HBV patients Healthy controls
Sex (m/f ) 14 (10/4) 14 (9/5)
Age (years)* 36 (21-49) 28 (24-53)
HBV DNA* 2.0x106 (1.0x103 -4.9x109) -
ALT* 28 (15-262) -
HBeAg+/anti-HBeAg+ 7/7 -
* median (range)
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lowed by an FITC-conjugated rabbit anti-mouse anti-IgG (Dako, Glostrup, Denmark) secondary 
antibody and flow cytometric analysis (FACScalibur, Becton Dickinson, San Jose, CA, USA).
Isolation of myeloid dendritic cells and CD8 T cells
MDC were isolated from fresh PBMC of HLA-A2+ chronic HBV patients and healthy controls 
by positive immunomagnetic selection using the mini-MACS system (Miltenyi Biotec, Bergisch 
Gladbach, Germany) according to manufacturers’ instructions as previously described [11]. The 
cells were resuspended in culture medium consisting of RPMI 1640 (Bio Whittaker, Verviers, Bel-
gium) containing 10% fetal calf serum (Hyclone, Logan, UT) and penicillin/streptomycin (Gibco, 
Paisley, UK). PBMC and purified CD8 T cells were isolated from a HLA-A2+ healthy individual 
who resolved an acute HBV infection and a HLA-A2+ CMV-positive healthy individual. CD8 T 
cells were isolated from fresh PBMC by negative selection using the CD8 T cell isolation kit II 
(Miltenyi Biotec). Isolation was performed according to the manufacturers’ instructions. After 
isolation the cells were immediately frozen in medium containing 10% DMSO and stored at 
–135°C until further use. Purity of BDCA1+CD19- mDC and CD8 T cells was determined by flow 
cytometry and the purity of the cells was more than 90%.
Coculture of myeloid dendritic cells and CD8 T cells 
Freshly isolated mDC were cultured in a concentration of 1x104 in 200 mL culture medium 
and pulsed with HBV core peptide (HBc18-27 (FLPSDFFPSV); ProImmune, Oxford, UK) or a CMV 
peptide (CMV510-522 pp65; kindly provided by Dr. van Baarle) in a flat bottom 96-wells plate. 
The HBc18-27 peptide was used at 4 mM and the CMV510-522 pp65 peptide at 10 mg/mL. After 
2 hours the cells were washed and maturated for 24 hours in culture medium with 25 ng/
mL TNF-α (Strahtmann Biotech, Hannover, Germany), 50 ng/mL IL-1ß (Strathmann Biotech) 
and 500 U/mL GM-CSF (Leucomax, Novartis Pharma, Arnhem, The Netherlands). Cells were 
washed and PBMC (1.5 x 105 cells in 200 μL) or purified CD8 T cells (0.5 x 105 cells in 200 μL) 
from the HLA-A2+ resolved HBV or the HLA-A2+ CMV-positive individual were added. An IL-10 
neutralizing antibody (BD Pharmingen) or an IgG1 isotype control (BD Pharmingen) was added 
to the culture in a concentration of 10 mg/mL when indicated. Recombinant IL-2 (20 U/mL) 
was added at the start of each culture and every 3 days of the culture. After a culture period 
of 9 days, the cells were harvested and the percentage of specific CD8 T cells was measured 
by flow cytometry. The cells were stained for 30 minutes at 37oC with a HLA-A2 restricted 
HBc18-27 specific tetramer (ProImmune) or a HLA-A2 restricted CMV-pp65 tetramer (provided 
by Dr. van Baarle), both labeled with a PE conjugate. As a control for staining an APC-labeled 
HLA-A2 restricted HBpol816-824 (SLYADSPSV) specific tetramer was used. The cells were washed 
and stained for CD3-FITC (Immunotech) or CD3-PE (Becton Dickinson) and CD8-APC (Becton 
Dickinson) or CD8-FITC (Dako), washed again and analyzed by flow cytometry. 
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IL-10 ELISPOT
The production of IL-10 by mDC was measured using an ELISPOT kit (Sanquin, Amsterdam, 
The Netherlands) according to the manufacturers’ instructions. Freshly isolated mDC of 5 
chronic HBV-patients and 5 healthy controls were cultured in triplicate in a flat bottom plate 
in a concentration of 4x104 cells in 200 mL of culture medium with 25 ng/mL TNF-α, 50 ng/mL 
IL-1ß and 500 U/mL GM-CSF or 500 U/mL GM-CSF alone (negative control) for 24 hours at 37oC. 
The next day cells were transferred to a flat bottom anti-IL-10-coated 96-wells plate (Millipore, 
Molsheim, France) and incubated for another 24 hours at 37oC. As a positive control total PBMC 
(2x105 cells per well) of chronic HBV patients or healthy controls were stimulated with 5 mg/
mL phytohemagglutin (PHA; Murex, Paris, France). Cytokine spots were visualized by a biotin-
labeled antibody against IL-10 and their numbers were established by using a Bioreader 3000 
from BioSys (Karben, Germany).
Statistical analysis
Data are expressed as mean±SEM, unless indicated otherwise. Data were analyzed and 
compared to baseline results with SPSS 11.5 for Windows (SPSS, Chicago, IL) using a Wilcoxon 
matched pairs signed rank sum test. The Mann-Whitney was used to compare variables 
between two independent groups of patients. In all analyses a p-value of <0.05 was considered 
statistically significant. 
REsUlts
Reduced expansion of HBcore-specific CD8 T cells by mDC of chronic HBV patients
To investigate the capacity of mDC of chronic HBV patients to expand HBV-specific CD8 T cells, 
purified mDC of chronic HBV patients or healthy controls were pulsed with HBcore peptide and 
cultured with total PMBC or purified CD8 T cells from a resolved HBV individual, known to have 
HBV-specific memory T cell responses. Expansion of HBV-specific CD8 T cells was determined 
by flow cytometry using an HBcore-specific pentamer. Figure 1 shows flow cytometry dot 
plots of a representative experiment. Pulsing mDC with HBcore-specific peptide showed clear 
expansion of HBcore-specific CD8 T cells. No aspecific binding was observed when a pentamer 
recognizing HBV polymerase-specific CD8 T cells was used (Fig. 1). 
The capacity of purified mDC, isolated from chronic HBV patients, to expand HBcore-specific 
CD8 T cells was first studied in PBMC cultures. Figure 2 shows that the expansion of HBcore-
specific CD8 T cells is significantly less by mDC isolated from chronic HBV patients as compared 
to mDC from healthy controls. The percentage of HBcore-specific CD8 T cells was more than 
two-fold reduced after stimulation with mDC derived from chronic HBV patients compared to 
healthy controls (respectively 4.08 ± 0.80 versus 8,57 ± 1.26 (mean ± SEM)). To exclude possible 
influence of CD4 T cells or other cells on the expansion of HBV-specific CD8 T cells, purified CD8 
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T cell cultures were also used. The results using purified CD8 T cells showed a similar reduced 
expansion of HBcore-specific CD8 T cells by mDC of chronic HBV patients compared to mDC of 
healthy controls (respectively 2.22 ± 0.31 versus 5.02 ± 1.19 (mean ± SEM) Fig. 2). 
Myeloid dendritic cells of chronic HBV patients produce IL-10
IL-10 plays an important role in inducing viral persistence [19-21]. To investigate whether IL-10 
could play a role in the reduced expansion of HBV-specific T cells, we determined the produc-
tion of IL-10 in the supernatant of mDC from chronic HBV patients and healthy controls during 
24 and 48 hours of culture with maturation factors. Unfortunately, the concentration was 
below the detection limit of the kit (data not shown). Therefore, a more sensitive technique was 
used. Purified mDC were cultured with maturation factors for 24 hours after which they were 
transferred to an IL-10 ELISPOT plate for another 24 hours. An increased number of IL-10 specific 
spots were found in cultures of mDC of chronic HBV patients as compared to healthy control 
mDC. It must be noted however that only two out of five patients and healthy controls showed 
measurable IL-10 spots and that inter-person variability was high (Fig. 3).  MDC cultured without 
maturation factors hardly produced IL-10. As a control for the IL-10 ELISPOT assay, total PBMC 
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fig. 2 the capacity of mDC isolated from chron-
ic HBV patients and healthy controls to expand 
HBc-specific CD8 t cells from a resolved HBV 
patient. 
Purified mDC were pulsed with HBcore18-27 
peptide for 2 hours, washed and cultured with 
total PMBC or purified CD8 T cells from a HLA-A2 
matched resolved HBV patient. Gray bars repre-
sent mDC isolated from healthy controls (n=14) 
and black bars are mDC from chronic HBV pa-
tients (n=14). HBcore18-27 CD8 T cells are given 
as % of total CD8 T cells. Data are expressed as 
mean±SEM, *p<0.05.
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fig. 1 flowcytometry dot plots of co-cultures of mDC and CD8 t cells. 
Left panel: When mDC were pulsed with HBcore-specific peptide an expansion of HBcore-specific CD8 T cells was 
detected using a double staining for CD8 and a labeled HLA-A2 restricted HBcore18-27 specific pentamer. Middle 
panel: Expansion of HBcore-specific CD8 T cells with a HBcore18-27 specific pentamer was not detectable when 
mDC were pulsed without peptide. Right panel: Staining of HBcore-specific CD8 T cells with a labeled HLA-A2 
restricted HBpol18-27 specific pentamer showed no aspecific binding.
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of the HBV patients and controls were stimulated with PHA. No difference in IL-10 spots in total 
PHA-stimulated PBMC was observed between chronic HBV patients and healthy controls (data 
not shown).
Neutralizing IL-10 restores the reduced expansion of HBcore-specific CD8 T cells by mDC of chronic HBV 
patients
Next, we investigated whether blocking IL-10 could overcome the reduced CD8 expansion by mDC. 
For this purpose, during co-culture of mDC and CD8 T cells a neutralizing antibody to IL-10 or isotype 
matched control antibody was added. As expected seen the minimal IL-10 production, neutralizing 
IL-10 in the co-culture of mDC of healthy controls had no effect on CD8 T cell expansion. Figure 
4 shows that neutralizing IL-10 completely restored the reduced capacity of mDC of chronic HBV 
patients to expand HBcore-specific CD8 T cells compared to isotype matched and healthy controls. 
The expansion of CMV-specific CD8 T cells by mDC of chronic HBV patients is only slightly reduced
In order to examine if the reduced expansion of CD8 T cells by mDC from chronic HBV patients 
was HBV-specific, the capacity of mDC to expand CD8 T cells specific for CMV was investigated. 
To this end purified mDC from chronic HBV patients or healthy controls were pulsed with an 
HLA-A2-restricted CMV peptide pp65 and the expansion of CMV-specific CD8 T cells from a 
healthy CMV-carrier was determined with a CMV-specific tetramer. The results show that mDC 
of chronic HBV patients have a slightly reduced capacity to expand CMV-specific CD8 T cells as 
compared to mDC of healthy controls, in the absence of neutralizing IL-10 or isotype control 
antibodies (respectively 39.6 ± 3.84 versus 48.2 ± 4.89 (mean ± SEM) Fig. 5). However, no 
difference in CMV-specific CD8 T cells expansion was observed in the presence of neutralizing 
IL-10 or isotype control antibodies. 
Chapter 2 Fig. 3
Healthy controls HBV patients
0
50
100
150
200
250
300 mDC -
mDC + maturation factors
IL
-1
0 
sp
ot
s/
40
.0
00
 m
D
C fig. 3 Production of Il-10 by purified mDC of 
healthy controls and chronic HBV patients.
Purified mDC (40.000 per well) were cultured with 
or without maturation factors for 24 hours after 
which they were transferred to an IL-10 ELISPOT 
plate for another 24 hours. The number of IL-10 
spots per 40.000 cells is depicted. Data are ex-
pressed as mean±sd; healthy controls n=2; HBV 
patients n=2.
29CD8 expansion by mDC of chronic HBV patients
DIsCUssIon
The exact mechanism by which HBV escapes immunity in chronically infected patients is still 
not known. Previously, we demonstrated significant functional impairment of mDC of patients 
with chronic HBV infection as compared to healthy volunteers and patients with chronic inflam-
matory liver disease of non-viral origin [11]. MDC of chronic HBV patients showed a decreased 
capacity to upregulate co-stimulatory molecules, produce pro-inflammatory cytokines and 
stimulate allogeneic T cells. Thus far, it is unknown what the consequence of dysfunctional 
mDC is on the expansion and number of HBV-specific CD8 T cells in chronic HBV patients.  
This study shows that mDC of chronic HBV patients are less capable to expand HBcore-
specific CD8 T cells as compared to mDC isolated from healthy controls. The reduced expansion 
was observed using PBMC, as well as using purified CD8 T cells, excluding a possible difference 
in allostimulatory effect by class II mismatch. Although the difference in the expansion of 
CD8 T cells was similar using whole PBMC cultures or purified CD8 T cells, the percentages of 
HBcore-specific CD8 T cells were smaller using purified CD8 T cells as compared to whole PBMC 
cultures. Most likely this is caused by the production of cytokines such as IL-2 by other cells 
than CD8 T cells, present in the whole PBMC cultures. In our experiments alloreactivity by class 
I mismatch was minimal, since there was no significant difference in expansion of HBV-specific 
CD8 T cells between HBV patients and controls without the addition of peptide i.e. background 
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response. The use of effector T cells of only one person with a resolved HBV infection is one of 
the limitations of the present study. Furthermore, testing of a broader panel of HBV peptides 
could be included as a next step, to observe the expansion of HBV-specific CD8 T cells with 
other specificity then HBcore18-27. 
Recent attempts to elucidate the causes of impairment of antiviral immunity have pointed 
to an important role for the immunomodulatory cytokine IL-10 in the ability to establish viral 
persistence [19-21]. Induction of IL-10 production by the host during chronic infection appears 
to be one of the viral means to suppress antiviral immune responses. Especially in the case of 
a viral infection in which continuous activation of CD8 T cells could lead to extensive, even 
fatal, tissue damage, dampening of the immune response is very important to improve the 
outcome for the host. Also in the pathogenesis of chronic HBV a role for IL-10 has been shown 
[22,23]. These studies showed an increase in IL-10 production in chronic HBV patients non-
responsive to IFN-α or IFN-α and ribavirin combination therapy. Various cell types including 
lymphocytes, macrophages and DC can be involved in IL-10 production. We have previously 
shown that IL-10 production by mDC was decreased after reduction of the viral load by adefovir 
treatment, resulting in an increased T cell stimulatory function [13]. The current study shows 
that an increased number of mDC of chronic HBV patients produced IL-10 compared to mDC of 
healthy controls as evaluated by ELISPOT assay, although more patients and controls should be 
included before solid conclusions can be drawn. Neutralization of IL-10 completely restored the 
impaired induction of HBV-specific CD8 T cells by mDC of chronic HBV patients. Further studies 
should focus on the phenotype and function of the HBV-specific CD8 T cells with regards to 
IL10. The sensitivity to IL-10 might be increased by increased expression of the IL-10 receptor 
for example. Also here it would be important to include HBV-specific CD8 T cells from several 
patients and investigate CD8 T cells specific for different HBV epitopes.
The reduced expansion was partly HBV specific, since the expansion of CMV-specific CD8 
T cells was not significantly reduced and adding neutralizing IL-10 antibody had no effect on 
the CMV-specific CD8 expansion. The preferential reduced capacity of mDC from chronic HBV 
patients to expand HBcore-specific CD8 T cells might be explained by the fact that the expan-
sion of CMV-specific CD8 T cells is about 5 to 10-fold more fiercely. The amount of IL-10 produced 
by mDC of chronic HBV patients is possibly less capable to reduce this major response. Another 
factor that could possibly play a role is the difference in binding affinity of the two peptides for 
the A2-restricted T-cell receptor. Ideally, the effect of IL-10 on HBV- and CMV-specific CD8 T cell 
expansion should be studied using CD8 T cells from the same individual, but in practice it is 
difficult to find an individual with both an acute resolved HBV and CMV infection. 
The pathogenesis behind the functional impairment of mDC is not clear up till now. Reports 
are available that HBV can be detected on or within mDCs but viral replication in mDC has never 
been shown [24,25]. On the other hand, recently it was shown viral load reduction by adefovir 
treatment, lead to a substantial recovery of mDC, as shown by increased production of IL-12 
and TNF-α, decreased Il-10 production and an increased allostimulatory capacity. In vitro, the 
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presence of both HBV particles and HBV surface proteins directly influenced the function of 
mDC isolated from healthy controls [14]. Together this implicates that viral particles or antigens 
can indeed directly affect the function of mDC. To further support this conclusion, the correla-
tion with HBV viral load and the mDC capacity to produce IL-10 and expand HBV-specific T cells 
could be calculated for each individual patient included in the extended study.
In vivo the effect of mDC impairment is combined with several other immune modulating 
effects, such as a defect in CD4 T cell help and the presence of regulatory T cells and therefore 
the overall end-result is much more dramatic [26,27]. For an efficient CD8 T cell response in vivo 
also an efficient helper T cell response is necessary. Up till now, assessing the capability of mDC 
to induce a HBV-specific CD4 T cell response has not been done. If mDC and CD4 T cells from 
the same patients would be used, the defect can be present in mDC as well as in CD4 T cells. 
In conclusion, the results presented in this study show that mDC of chronic HBV patients are 
besides earlier described functional defects also impaired in their capacity to expand preferen-
tially HBV-specific CD8 T cells responses, which was IL-10 dependent. In this case the expansion 
of preexisting HBV-specific CD8 T cells was studied, but one could imagine that priming of 
naive HBV-specific responses might be even more affected. Priming of naive responses requires 
more steps such as uptake, processing and presenting of HBV antigens. In vivo the impairment 
of mDC may lead to a handicapped immune system that is incapable of mounting an efficient 
immune response against HBV. Novel therapeutic strategies directed against the functional 
impairment of mDC may be able to overcome HBV chronicity.   
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aBstRaCt
Chronic Hepatitis B virus (HBV) infection is the result of an inadequate immune response 
towards the virus. Myeloid dendritic cells (mDC) of chronic HBV patients are impaired in their 
maturation and function, resulting in more tolerogenic rather than immunogenic responses, 
which may contribute to viral persistence. The mechanism responsible for altered mDC func-
tion remains unclear. HBV infected patients display large amounts of HBV particles and viral 
proteins, especially the surface antigen HBsAg, in circulation, which allows multiple interac-
tions between the virus, its viral proteins and DC. To assess whether HBV directly influences 
mDC function, the effects of HBV and HBsAg on human mDC maturation and function were 
investigated in vitro. As already described for internalization of HBV by DC, the present study 
shows that peripheral blood-derived mDC of healthy controls also actively take up HBsAg in 
a time-dependent manner. Cytokine-induced maturation in the presence of HBV or HBsAg 
resulted in a significantly more tolerogenic mDC phenotype as demonstrated by a dimin-
ished upregulation of co-stimulatory molecules and a decreased T cell stimulatory capacity, 
as assessed by T cell proliferation and IFN-γ production. In addition, the presence of HBV 
significantly reduced IL-12 production by mDC. These results show that both HBV particles 
and purified HBsAg have an immune modulatory capacity and may directly contribute to the 
dysfunction of mDC in chronic HBV patients. The direct immune regulatory effect of HBV and 
circulating HBsAg particles on the function of DC can be considered as part of the mechanism 
by which HBV escapes immunity.
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IntRoDUCtIon
Hepatitis B virus (HBV) infects the liver as primary target, resulting in the majority of cases in 
self-limiting acute hepatitis, which confers protective HBV specific T and B cell responses [1,2]. 
Nevertheless, more than 350 million people are chronically infected with HBV, as the result of 
a complex interaction between the replicating virus and an inadequate immune response. The 
immune system evolved to recognize and eliminate foreign antigens. However, if the immune 
system by any reason has become tolerant to HBV, the HBV-specific T and B cell responses are 
generally undetectable [3,4]. The exact mechanism by which HBV escapes immunity is still not 
known. 
Dendritic cells (DC) play an important role in anti-viral immunity and have the unique capacity 
to activate naive T cells and stimulate B and natural killer cells [5,6]. Both circulating and tissue-
resident immature DC sample the environment for the presence of foreign antigens and upon 
activation, DC migrate to lymphoid tissues to initiate immune responses. Depending on their 
maturation status, represented by the expression level of co-stimulatory and HLA molecules 
and the capacity to produce pro-inflammatory cytokines, DC can induce either immunity or 
tolerance [7,8]. Immature and semi-mature DC are associated with tolerogenic responses, so 
in the context of HBV a defect in the maturation process of DC may lead to tolerogenic T cell 
responses and HBV persistence. We and others have previously shown that a specific subset 
of DC, the myeloid dendritic cells (mDC), of chronic HBV patients are indeed impaired in their 
capacity to mature compared to mDC of healthy controls, as shown by a decreased capacity 
to upregulate co-stimulatory molecules, produce pro-inflammatory cytokines and stimulate 
T cells [9,10]. Monocyte-derived DC (moDC) are also reported to be functionally impaired by 
the presence of HBV [11,12] although deficits remained minor in other studies [13]. Whether 
HBV directly interferes with DC function is not known. In theory, the different steps of binding, 
uptake and subsequent replication of HBV could all compromise DC function. Contradictory 
results have been reported about the possible presence and active replication of HBV in in 
vitro-generated moDC of chronic HBV patients [11,14]. Concerning circulating mDC, viral DNA 
could be detected in a subset of chronic HBV patients but no evidence was found for viral 
replication in these cells [15]. These observations have been confirmed and expanded by a 
study of Untergasser et al. that demonstrates that moDC are capable of internalizing HBV, but 
do not allow HBV replication [16]. 
Although HBV seems to be incapable to replicate in DC, the binding and uptake of viral 
particles by these cells may introduce some functional changes. The liver and peripheral blood 
of HBV infected individuals can reach levels of 109-1010 infectious particles per ml, which allows 
multiple interactions between the virus and DC. In addition, the liver and peripheral blood 
of HBV patients contain large amounts of viral proteins, especially the HBV surface antigens 
[17,18]. The HBV envelop consists of small (S), middle (M) and large (L) surface antigens, gener-
ally referred to as HBsAg. All three surface antigens contain a common S domain, both M and 
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L proteins contain a preS2 domain and L exclusively contains a preS1 domain. S is the main 
component of both HBV virions and HBsAg subviral particles, while M and L are highly enriched 
on HBV virions. HBsAg is secreted from infected hepatocytes as subviral particles, which can 
accumulate up to 100 µg/ml in peripheral blood. The high amounts of HBsAg in the circulation 
of patients can theoretically contribute to the hampered immune response. Whether HBsAg 
interacts with DC is not known. Therefore, the aim of the present study is to assess the nature 
of interaction between HBsAg or HBV and myeloid DC, and the possible role of this interaction 
for the persistence of HBV infection. 
matERIals anD mEtHoDs
HBV surface antigens
The following viral antigens were kindly provided by M. van Roosmalen (bioMérieux, Boxtel, The 
Netherlands) and listed in Fig. 1: pepsin treated HBsAg particles immunopurified from sera of 
patients infected with HBV of serological subtypes ad and ay (patient serum derived HBsAg; aa 
1-226) [19] and recombinant (r)HBsAg (aa 1-281, subtypes ad and ay) purified from transfected 
Chinese Hamster Ovary (CHO) cells. Cell lysates of non-transfected CHO cells served as a nega-
tive control. Representative Coomassie stained protein gels and western blots of patient serum 
derived and recombinant HBsAg, provided by M. van Roosmalen, show the native p24 and the 
glycosylated gp27 forms of the S protein and the two glycosylated forms of the M protein, the 
latter only present in recombinant HBsAg. The higher molecular weight bands represent dimer 
and trimer forms of HBsAg (Fig. 1B). HBsAg was used at a final concentration of 1 µg/ml.
HepG2.2.15 derived HBV
HepG2.2.15 cells [20,21] were grown until confluence in Williams’ E medium (Gibco, Paisley, UK) 
supplemented with 5% fetal calf serum (FCS, Hyclone, Logan, UT) and HBV particles were con-
centrated from the medium as described before [16]. As a negative control, the same procedure 
was followed with supernatant from untransfected HepG2 cells. Unless otherwise stated, HBV 
particles were used at a multiplicity of infection (MOI) of 100.
Isolation of mDC from peripheral blood
Peripheral blood mononuclear cells (PBMC) were isolated from healthy control blood using Ficoll-
Isopaque gradient centrifugation. In total, blood from 24 different healthy donors was obtained (15 
male and 9 female; median age (range) 30 (23-54) years). All healthy controls gave written informed 
consent before blood donation and the institutional ethical committee gave declaration of no 
objection for this study. Myeloid DC (BDCA1+) were isolated from PBMC by negative depletion with 
anti-CD19-conjugated microbeads, followed by positive selection using anti-BDCA1-PE and PE-
conjugated microbeads using the mini-MACS system (Miltenyi Biotec, Bergisch Gladbach, Germany) 
39HBV surface antigen impairs mDC function
as described previously [9]. The purity and viability of the isolated mDC were determined by flow 
cytometry by staining for BDCA1 and CD20 (to ensure the absence of contaminating BDCA1+CD20+ 
B lymphocytes) and trypan blue and 7AAD staining (Becton, Dickinson and Company (BD), Franklin 
Lakes, USA), respectively. Isolated mDC were cultured in DC medium consisting of RPMI 1640 (Bio 
Whittaker, Verviers, Belgium) containing 10% FCS (Hyclone, Logan, UT), penicillin (50 IU/ml), strep-
tomycin (50 µg/ml) and GM-CSF (500 U/ml; Leucomax, Novartis Pharma, Arnhem, The Netherlands). 
HBsAg binding and uptake by mDC
Isolated mDC were incubated for 2 or 18 hours with rHBsAg in the presence of GM-CSF (500 U/ml, 
Leucomax) and antigen uptake was stopped by cold wash in PBS containing 1% FCS and 0.02% 
NaN3. Intracellular staining was performed according to the manufacturer’s protocol (IntraPrep, 
Beckman Coulter, Fullerton, CA), HBsAg was stained with anti-HBsAg-FITC (recognizing subtypes 
ad and ay, Acris Antibodies GmbH, Hiddenhausen, Germany) and detected by flow cytometry 
(FACScalibur, BD). Negative controls were incubated without antigen or with antigen at 4°C. 
Cytospin slides with 15.000 mDC were fixed in 4% paraformaldehyde in PBS and permea-
bilized with 0.1% saponine (Merck, Darmstadt, Germany). After blocking with 0.1% saponine, 
10% normal mouse serum (CLB, Amsterdam, The Netherlands) and 10% normal human plasma 
(Sanquin, Amsterdam, The Netherlands), slides were stained for 5 hours with anti-HLA-DR-APC 
(clone L243, BD) and anti-HBsAg-FITC (Acris Antibodies GmbH) at 4ºC. After PBS wash, slides 
were sealed with Vectashield/DAPI (Vector Laboratories Inc., Burlingame, United States). Sig-
nals were captured with a Zeiss Laser Scanning Microscope 510 Meta JNI.
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Expression of cell surface molecules on mDC
Isolated mDC (30x103/200μl) were matured in the presence of HBV, HBsAg or the appropriate 
controls. After 24 hours, cells were harvested and stained with combinations of anti-BDCA1-PE 
(Miltenyi Biotec), anti-CD80-FITC (clone MAB104, Immunotech, Marseilles, France), anti-CD86-
APC (clone 2331, BD), anti-HLA-DR-PerCP (clone 243, BD) and anti-CD40-APC (clone 5C3, BD). 
Cells were analyzed by flow cytometry with corresponding isotype-matched control antibodies 
to determine background staining. 
Cytokine production by mDC
Isolated mDC (40x103 cells/200μl) were stimulated in culture medium containing synthetic 
double-stranded poly[I:C] RNA (20 µg/ml; Sigma-Aldrich, St. Louis, MO) and recombinant 
human IFN-γ (1000 U/ml; Strathmann Biotech) in the presence of HBV, HBsAg or the appropriate 
controls. Supernatants were harvested after 24 hours. TNF-α and IL-10 levels were determined 
by ELISA from Biosource International (Nivelles, Belgium) and IL-12p70 was determined by 
ELISA from Diaclone (Besançon, France).
T cell stimulatory capacity of mDC
T cell stimulatory capacity of mDC was determined in an allogeneic mixed lymphocyte reaction 
(MLR). Isolated mDC were matured in the presence of HBsAg, HBV or the appropriate controls 
in culture medium containing IL-1β and TNF-α in a 96-well culture plate (10x103 or 5x103/200 
μl). After 24 hours, culture medium was removed and untouched isolated CD3+ T cells (Miltenyi 
Biotec) from a buffy coat were added (1.5x105/200 μl) and cultured for six days. As a positive 
control, T cells were stimulated with phyto-haemagglutinin (PHA; 5 mg/ml; Murex, Paris, France) 
or anti-CD3 (100 ng/ml; clone UCHT1, eBioscience, San Diego, CA) and anti-CD28 (1 µg/ml; clone 
CD28.2, eBioscience). Supernatant was harvested at day 5 to determine IFN-γ production by 
ELISA (U-CyTech, Utrecht, The Netherlands). During the last 16 hours of a 6 day culture period, 
0.5 mCi [3H]thymidine (Amersham, Little Chalfont, UK) was present per well to determine T 
cell proliferation. All measurements were performed in triplicate. In a subset of experiments, 
the percentage of regulatory T cells was determined at day 5 by Foxp3 staining according to 
the manufacturer’s protocol. Briefly, T cell surface markers were stained with a combination of 
anti-CD25-PE (clone M-A251, BD) and anti-CD4-PerCP (clone SK3, BD). The cells were fixed and 
permeabilized with fixation/permeabilization and permeabilization buffer (eBioscience) and 
anti-Foxp3-APC (clone PCH101, eBioscience) was present during permeabilization. Cells were 
analyzed by flow cytometry and CD4+CD25highFoxp3+ cells were defined as regulatory T cells.
Statistical analysis
All experimental conditions were paired analyzed against their controls. Data on co-stimulatory 
molecules and cytokine expression were analyzed using the non-parametric Wilcoxon Signed 
Ranks Test with two-tailed p-values. Comparison of the data from MLR and IFN-γ production 
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was performed after logarithmic transformation of raw data. A mixed linear model with subject 
specific random effects was used with the Satterthwaite approximation method for correction 
of degrees of freedom. This method allows inclusion of all individual values obtained from 
triplicate measurements. Data from cytokine expression and MLR are normalized and given as 
percentages of the appropriate control. Data from expression of co-stimulatory molecules are 
expressed as mean±SEM. A p-value of <0.05 was considered statistically significant.
REsUlts
HBsAg is internalized by mDC
Although HBV is not capable to replicate within mDC, HBV particles and HBV DNA are detected 
on the surface or within DC [11-13,16]. To investigate whether HBsAg is also taken up by mDC, 
isolated mDC (Fig. 2A) were cultured in the presence of rHBsAg. Intracellular FACS analysis 
showed an increase of HBsAg uptake over time, increasing from 4±1% after 2 hours, to 27±2% 
after 18 hours. Control mDC incubated at 4°C showed no increase in HBsAg positivity, indicating 
that HBsAg internalization is an active process (Fig. 2B,C). To confirm the uptake of HBsAg, 
confocal microscopy was performed on cytospin slides of mDC incubated with rHBsAg or CHO 
control lysates. HBsAg was detected within the cytoplasm of mDC (Fig. 2D) and the percentage 
of HBsAg positive mDC increased to 12±1% after overnight culture (data not shown). No 
staining was detected in cells incubated with CHO control lysate. 
HBsAg inhibits the upregulation of co-stimulatory molecules on mDC
Freshly isolated mDC from peripheral blood express only low levels of the co-stimulatory mol-
ecules CD40, CD80 and CD86. TNF-α/IL-1β-induced maturation results in a strongly increased 
expression of these co-stimulatory molecules (Fig. 3A-C) that is required for proper T cell activa-
tion. Since mDC are capable of internalizing HBsAg, the effect of HBsAg on mDC maturation 
was studied. CHO derived rHBsAg significantly inhibited upregulation of CD86 and also the 
upregulation of CD40 and CD80 tended to be inhibited. Next to the recombinant proteins, also 
patient serum-derived HBsAg was examined for its effect on mDC maturation. Both subtypes 
ad and ay of serum-derived HBsAg significantly inhibited the upregulation of CD40 and CD86 
(p<0.05). Like the subviral protein HBsAg, purified HBV particles, which are also known to bind 
and be taken up by mDC, significantly inhibited the upregulation of CD40 and CD80 during 
TNF-α/IL-1β induced maturation compared to control conditions (Fig. 3D-F). Neither HBsAg, nor 
HBV did affect cell viability (data not shown).
HBV but not HBsAg inhibits the production of IL-12 after in vitro stimulation
Next to co-stimulatory molecules as important players in T cell activation, also cytokines pro-
duced by DC influence their T cell stimulatory capacity and their ability to polarize T cells. To 
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study the effect of HBsAg and HBV on the cytokine expression profile of mDC levels of IL-10, 
TNF-α and IL-12p70 were determined after 24 hr maturation in the presence or absence of 
HBsAg or HBV. Non-stimulated mDC did not show detectable levels of cytokine production 
(data not shown), whereas activated mDC clearly produced IL-10, TNF-α and IL-12 within 24 hr. 
No difference in expression levels of these cytokines was observed in the presence of serum 
derived or recombinant HBsAg (Fig. 4A-C). Also HBV particles did not influence the production 
of IL-10 and TNF-α (Fig. 4A,B). Interestingly, the presence of HBV particles induced a significant 
4-fold reduction in the production of IL-12 (p=0.028, Fig. 4C,D). 
Both HBV and HBsAg inhibit the T cell stimulatory capacity of mDC
Since both the expression of co-stimulatory molecules and the production of cytokines like 
IL-12 play a major role in T cell activation by DC, the effects of HBsAg and HBV on the T cell 
2 h 18 h
0
10
20
30
no HBsAg control
HBsAg (4°C)
HBsAg (37°C)
%
 H
Bs
Ag
+ 
m
D
C
Chapter 3 Figure 2
A B
HLA-DR-APC DAPI
HBs-FITC overlay
C D
2 hr
control HBsAg 4°C HBsAg 37°C
0.5 1.5 3.2
0.7 30
BDCA1 
C
D
20
BDCA1 
7A
AD
Purity Viability
18 hr
FSC 
1.8
H
Bs
Ag
fig. 2 HBsag is actively internalized by mDC. 
(A) Phenotypic analysis of isolated mDC. Purity and viability were checked by anti-CD20-FITC and 7AAD staining 
respectively. (B, C) mDC were incubated in the presence of GM-CSF with or without recombinant HBsAg during 
2-18 hr at either 4°C or 37°C. After incubation, mDC were washed and HBsAg uptake was determined by flow cy-
tometry. Data demonstrate a representative experiment (B) and the quantification of 6 independent experiments 
with mDC from different donors (mean±SEM) (C). (D) Cytospins of mDC cultured in the presence of HBsAg were 
stained for HLA-DR and HBsAg as described in Materials and Methods. Cell nuclei were visualized with DAPI. Two 
representative mDC were selected by confocal microscopy, one HBsAg positive and one negative.
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stimulatory capacity of mDC were determined in an allogeneic MLR. Matured non-treated mDC 
induced T cell proliferation which varied between different donors (range 4215-40977 cpm; 
ratio mDC:T = 1:15). Maturation of mDC in the presence of serum-derived HBsAg subtype ad 
reduced the T cell proliferation approximately 1.7-fold (Fig. 5A,B). Likewise, the T cell proliferation 
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fig. 3 HBsag and HBV inhibit upregulation of co-stimulatory molecules during mDC maturation. 
MDC were activated with TNF-α and IL-1β during 24 hr, in the presence of 1 µg/ml patient serum derived or CHO 
recombinant HBsAg (subtype ad and ay), HBV particles (MOI of 100) or the appropriate controls. The expression 
levels of co-stimulatory molecules CD40, CD80 and CD86 were determined by flow cytometry. (A, B, C) Mean 
fluorescence intensities of untreated mDC before (grey line) and after maturation (black line) of a representative 
experiment. (D, E, F) Quantification of the mean fluorescence intensities of CD40, CD80 and CD86 expressed on 
mDC matured in the presence of HBsAg and HBV, or the appropriate controls (n=8, mean±SEM, *p<0.05).
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fig. 4 HBV but not HBsag reduced Il-12 production by mDC. 
MDC were stimulated with poly(I:C) and IFN-γ in the presence of 1 µg/ml patient serum derived or CHO recombi-
nant HBsAg (subtype ad and ay), HBV particles (MOI of 100) or the appropriate controls. After 24 hr, supernatants 
were harvested and examined for the production of IL-10 (A), TNF-α (B) or IL-12 (C, D). (A, B, C) Normalized data 
derived from 6 independent experiments with different donors are shown as mean±SEM percentage compared 
to appropriate control. (D) Mean IL-12 production of stimulated mDC of 6 donors in the absence or presence of 
HBV particles. *p<0.05.
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fig. 5 HBsag and HBV inhibit antigen presentation capacity of mDC. 
MDC were activated for 24 hr with TNF-α and IL-1β in the presence of 1 µg/ml HBsAg or HBV particles (MOI of 100) 
or the appropriate controls and cultured for 6 days with allogeneic T cells. (A) Representative experiment of the ef-
fect of serum derived-HBsAg on the T cell stimulatory capacity of mDC, measured by 3H-thymidine incorporation 
in proliferating T cells (ratio mDC:T cells = 1:15) (B) Normalized data derived from 6 independent experiments with 
mDC isolated from different donors are shown as mean±SEM percentage compared to appropriate control. (C) 
Representative experiment of IFN-γ production after 5 days of co-culture of HBsAg-treated mDC and allogeneic T 
cells (ratio mDC:T cells = 1:15). (D) Normalized IFN-γ production in a subset of the same experiments as in (B) was 
determined and shown as mean±SEM percentage compared to appropriate control (n=4). (E, F) Representative 
experiment of the effect of HBV particles on the T cell stimulatory capacity of mDC measured by T cell proliferation 
(E) and IFN-γ production (F).  *p<0.05
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was inhibited in the presence of HBsAg subtype ay. Comparable to serum-derived HBsAg, 
recombinant HBsAg significantly reduced the T cell stimulatory capacity compared to control 
conditions (mean reduction: HBsAg ad 35±5% p=0.012, HBsAg ay 35±3% p=0.034, rHBsAg ad 
22±7% p=0.007 and rHBsAg ay 33±9% p=0.0006; Fig. 5B). This effect was dose-dependently 
regulated and already observed with an HBsAg concentration of 0.1 µg/ml. HBsAg-induced 
inhibition reached a plateau at a concentration of 1 µg/ml.
Next to T cell proliferation, IFN-γ produced during these MLRs was measured in the super-
natants after 5 days of culture. Non-treated mDC induced IFN-γ production which ranged 
between 3.7 and 71 ng/ml. HBsAg-treated mDC reduced induction of IFN-γ production by T 
cells to the same extent as observed for proliferation (Fig. 5C,D). HBsAg inhibited neither PHA 
nor anti-CD3/anti-CD28 induced T cell proliferation, indicating HBsAg has no direct effect on T 
cell proliferation (data not shown). HBV particles reduced the T cell stimulatory capacity of mDC 
to a similar extent as HBsAg as demonstrated by the significantly reduced T cell proliferation 
(mean reduction 34±6%, p<0.0001 Fig. 5E). Furthermore, HBV-treated mDC reduced the induc-
tion of IFN-γ production by T cells by approximately 2-fold (Fig. 5F). Thus, HBV as well as HBsAg 
inhibit mDC maturation and function, thereby giving rise to more tolerogenic mDC.  
HBV and HBsAg-treated mDC do not induce regulatory T cells
One of the possible mechanisms by which HBsAg and HBV-treated mDC can reduce T cell 
proliferation is the induction of regulatory T cells, which can actively suppress T cell responses. 
The induction of this T cell subset during MLRs was analyzed by the expression of the regulatory 
T cell-specific transcription factor Foxp3 [22]. After 5 days of culture with non-treated mDC, 
approximately 2,5% of CD4+ T cells could be defined as regulatory T cells (CD4+CD25highFoxp3+, 
Fig. 6). No difference in regulatory T cell numbers was observed when T cells were stimulated 
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fig. 6 HBV and HBsag-treated mDC do not induce 
regulatory t cells. 
MDC were activated for 24 hr with TNF-α and IL-1β in 
the presence of 1 µg/ml HBsAg or HBV particles (MOI 
of 100) or the appropriate controls and cultured for 5 
days with allogeneic T cells. The percentage of regula-
tory T cells within the CD4+ cell fraction was deter-
mined by intracellular FACS staining. The number 
in the upper right quadrants indicates the percent-
age of regulatory T cells (CD4+CD25highFoxp3+). 
Representative dot blots of triplicate measurements 
of two independent experiments are shown.
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with HBsAg or HBV-treated mDC. Interestingly, both HBsAg and HBV-treated mDC showed less T 
cell activation as indicated by the lower percentage of CD4+CD25highFoxp3- T cell subset (Fig. 6). 
DIsCUssIon
The liver and peripheral blood of HBV infected individuals can reach levels of 109-1010 infectious 
HBV particles per ml and 100 µg/ml of circulating HBsAg, which allows multiple interactions 
between the virus and DC. The present study demonstrates that myeloid DC actively internalize 
HBsAg and that the presence of either purified HBsAg or intact viral particles during mDC 
maturation gives rise to mDC with a significantly less immunogenic phenotype and function 
as demonstrated by the reduced expression of co-stimulatory molecules and decreased T cell 
stimulatory capacity. 
Due to their pivotal role in anti-viral immunity, viruses, such as HBV, might have evolved 
to interfere with the function of DC to escape the host immune response. It has been 
demonstrated that DC of chronic HBV patients display a less immunogenic function compared 
to DC of healthy controls [9-11,23]. This DC impairment was recently challenged by a study 
of Tavakoli [24]. However, in that study only five to eight chronic HBV patients were included 
in the functional assays and the experiments were performed with cryopreserved instead of 
freshly isolated material, which may have strong impact on the function. HBV particles and 
HBsAg reduced the immunogenicity of mDC in vitro, which indicates a possible immune escape 
mechanism of HBV by the virus itself and/or by the production of subviral particles, i.e. HBsAg. 
The similar tolerogenic effects of HBsAg and HBV could easily be explained by the fact that 
the HBV envelop consists mainly of HBsAg. No major difference was observed between native 
patient serum derived HBsAg and CHO recombinant HBsAg although the latter contains not 
only S but also M forms of HBsAg. HBsAg subtypes ad and ay are very similar proteins according 
to charge and protein folding [25,26] and indeed showed comparable results in all assays. These 
data suggest that HBsAg, either as subviral particles or as part of the viral envelop, is at least 
partially responsible for the impaired mDC function observed in chronic HBV patients. This is in 
line with data from a HBsAg/HLA-A2 transgenic mouse model showing that high serum levels 
of HBsAg were able to induce T cell tolerance [27]. Whether HBsAg can also be detected on or 
within mDC of chronic HBV patients in vivo needs to be addressed in future studies. 
Recombinant yeast-derived HBsAg has been shown to interact with monocytes through the 
LPS binding protein and the LPS receptor CD14, resulting in diminished LPS-induced monocyte 
activation. Using differentiated THP-1 cells as a model for monocytes, HBsAg was shown to 
reduce the LPS-induced TNF-α production through interference with the activation of ERK-1,2 
and JNK-1,2 kinases [28,29]. The lack of effect of HBsAg on TNF-α production by mDC in the 
present study might be explained by differences between cell types and stimuli.  
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The direct effect of HBsAg on monocytes might be the explanation for the impaired function 
of DC generated from monocytes of chronic HBV patients [11]. In addition, the presence of 
HBV during the generation of monocyte-derived DC resulted in moDC with a reduced T cell 
stimulatory capacity and reduced IL-12 production [12]. Although in the latter study this might 
be more an effect of HBV on monocytes than on DC, also in the present study HBV was able to 
reduce IL-12 production by DC. Since IL-12 is a strong Th1 polarizing cytokine, the inhibitory 
effect of HBV on IL-12 production might partially explain the impaired Th1 response observed 
in chronic HBV patients. This hypothesis is supported by the fact that a 5-log reduction in viral 
load induced by the nucleoside analogue adefovir, strongly increased the capacity of mDC of 
chronic HBV patients to produce IL-12 [23]. In the latter study, also the T cell stimulatory capac-
ity of mDC increased, which might be the result of a decreased viral load as well as decreased 
HBsAg levels in adefovir treated patients. 
The additional tolerogenic effect of HBV over HBsAg with regard to the IL-12 production 
might be explained by the presence of the preS1 antigen on the viral envelop of HBV particles, 
which is not present in purified HBsAg, or by the presence of capsid protein or viral DNA. 
Nevertheless, both HBsAg and HBV diminished the T cell stimulatory capacity of mDC. Whether 
the reduction of co-stimulatory molecules on mDC could completely explain their decreased 
T cell stimulatory capacity, or that additional pro-inflammatory signals are decreased and/or 
regulatory signals are increased by HBsAg and HBV remains to be elucidated.
It has been previously reported that peripheral blood of chronic HBV patients contains an 
increased proportion of regulatory T cells compared to both individuals who have resolved 
their HBV infection and healthy controls [30]. This observation is apparently not caused by the 
effect of HBV and HBsAg on mDC, since both HBV and HBsAg-treated mDC did not significantly 
induce regulatory T cells in an allogeneic MLR. The observed reduction in T cell outgrowth and 
T cell activation as defined by high expression of CD25 might therefore be the result of T cell 
anergy or deletion induced by HBV and HBsAg-treated mDC. 
The results of the present study might seem in contrast with several studies showing activa-
tion of DC after HBsAg-loading or during vaccine therapy, but these studies either added cyto-
kines or uric acid to induce DC activation [31,32], or used an alum adjuvant containing HBsAg 
vaccine [33]. Of note, even though the routinely used HBsAg vaccination contains aluminium 
salts as an immune stimulatory adjuvant, about 5% of all HBV-vaccinated individuals do not 
develop a protective immune response, which is still not understood [34]. Therefore, it seems 
that only in the presence of immune activating stimuli a proper response to HBsAg could be 
induced, although even under this condition some individuals fail to develop an HBsAg-specific 
response. Further proof of the low immunogenicity of HBsAg is derived from studies on HBV-
specific CD8+ T cell populations: in contrast to HBV core-specific CD8+ T cells which are associ-
ated with viral control, HBV envelop-specific CD8+ T cells are characterized by an altered, HBV 
tolerant, phenotype. In addition, the frequency of HBV envelop-specific CD8+ T cells is very low 
and they can only occasionally be found in the setting of high levels of HBV replication [35,36].
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Next to HBV and HBsAg, serum of a subgroup of chronic HBV patients also contains HBeAg 
that could, in theory, also contribute to impaired mDC function. HBeAg has been described 
to be involved in T cell tolerance in a mouse model [37] but the exact function of HBeAg is 
still controversial [38]. The presence of either baculo- or Escherichia coli-derived recombinant 
HBeAg did not lead to a change in mDC function (data not shown).
In conclusion, these results show that both HBV particles and purified HBsAg have an 
immune modulatory capacity and may directly contribute to the dysfunction of mDC in chronic 
HBV patients. The direct immune regulatory effect of HBV and circulating HBsAg particles on the 
function of DC can be considered as part of the mechanism by which HBV escapes immunity. 
Successful immunotherapy of chronic HBV patients should therefore aim first on reduction of 
viral load and viral antigens in order to restore the immune system and thereafter on boosting 
the immune system to clear the chronic infection. 
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aBstRaCt
Hepatitis B virus (HBV) is a DNA virus that infects the liver as primary target. Currently, a high 
affinity receptor for HBV is still unknown. The dendritic cell specific C-type lectin DC-SIGN is 
involved in pathogen recognition through mannose- and fucose containing carbohydrates 
leading to the induction of an anti-viral immune response. Many glycosylated viruses subvert 
this immune surveillance function and exploit DC-SIGN as a port of entry and for trans-infection 
of target cells. The glycosylation pattern on HBV surface antigens (HBsAg) together with the 
tissue distribution of HBV would allow interaction between HBV and DC-SIGN and its liver-
expressed homologue L-SIGN. Therefore, a detailed study to investigate the binding of HBV 
to DC-SIGN and L-SIGN was performed. For HCV, both DC-SIGN and L-SIGN are known to bind 
envelope glycoproteins E1 and E2. Soluble DC-SIGN and L-SIGN specifically bound HCV virus 
like particles, but no interaction with either HBsAg or HepG2.2.15 derived HBV was detected. 
Also, neither DC-SIGN nor L-SIGN transfected Raji cells bound HBsAg. In contrast, highly man-
nosylated HBV, obtained by treating HBV producing HepG2.2.15 cells with the α-mannosidase I 
inhibitor kifunensine, is recognized by DC-SIGN. The α-mannosidase I trimming of N-linked oli-
gosaccharide structures thus prevents recognition by DC-SIGN. On the basis of these findings, 
it is tempting to speculate that HBV exploits mannose trimming as a way to escape recognition 
by DC-SIGN and thereby subvert a possible immune activation response. 
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IntRoDUCtIon
Hepatitis B virus (HBV) infects the liver as primary target, resulting in the majority of cases 
in self-limiting acute hepatitis. Nevertheless, more than 350 million people are chronically 
infected with HBV worldwide [1]. Despite the high incidence of infection, a cellular receptor for 
HBV entry is still unknown. Several putative binding factors have been described for the HBV 
surface antigens, such as human serum albumin [2], asialoglycoprotein receptor [3], heparin 
[4] and mannose binding lectin [5], but their exact role in HBV attachment and uptake remains 
unclear [6].
HBV is a DNA virus, consisting of a core particle enveloped by small (S), middle (M) and 
large (L) surface antigens, generally referred to as HBsAg. All three surface antigens contain a 
common S domain, both M and L proteins contain a preS2 domain and L exclusively contains a 
preS1 domain [7]. The liver and peripheral blood of HBV infected individuals can reach levels of 
109-1010 infectious particles per ml. In addition, HBsAg is secreted from infected hepatocytes as 
spherical subviral particles and filaments, which can accumulate up to 100 µg/ml in peripheral 
blood [7,8]. S is the main component of both HBV virions and HBsAg subviral particles, while 
M and L are highly enriched on HBV virions. Post-translational modifications of the surface 
antigens are crucial for HBV life cycle; myristoylation of the preS1 domain is essential for 
infectivity [6,9], while inhibition of N-glycosylation of the preS2 domain prevents secretion 
of viral particles [10,11]. Recently, post-translational N-glycosylation of the preS1 domain has 
been reported as well and although it seems dispensable for HBV morphogenesis it might be 
involved in viral attachment [12].
The first step in clearance of a viral infection involves recognition of the virus by the 
innate immune system, mediated through host pattern recognition receptors (PRR) such 
as Toll-like receptors and C-type lectins [13,14]. C-type lectins recognize highly conserved 
pathogen-derived carbohydrate structures, leading to internalization, antigen processing and 
presentation to T cells [14]. A prototypical member of the C-type lectin family is the dendritic 
cell-specific lectin DC-SIGN [15], which recognizes a broad range of glycosylated pathogens 
through mannose- or fucose-containing carbohydrates, including HIV-1, hepatitis C virus, Ebola 
virus, Dengue virus, measles virus, human herpesvirus 8, SARS coronavirus, cytomegalovirus, 
Mycobacterium tubercolosis, Helicobacter pylori, Streptococcus pneumonia and Neisseria menin-
gitidis [16-18]. The outcome of this interaction is pathogen-dependent. Many of these DC-SIGN-
binding pathogens have evolved to subvert the immune surveillance function of DC-SIGN for 
their own benefit and re-direct the internalization route to non-lysosomal compartments for 
protection and transmission to target cells [16]. Some pathogens can also modulate adaptive 
immune responses through interaction with DC-SIGN; e.g. Mycobacterium tuberculosis exploits 
DC-SIGN to escape immune surveillance by inhibition of the immunostimulatory function of 
dendritic cells [16,19].
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It is well established that envelope glycoproteins E1 and E2 of Hepatitis C virus (HCV) inter-
act with both DC-SIGN [15] and its homologue L-SIGN [20] expressed on sinusoidal endothelial 
cells in liver and lymph nodes. For HCV virus-like particles, DC-SIGN interaction leads to effi-
cient capture, internalization and transport to non-lysosomal compartments within immature 
dendritic cells, thereby protecting the virus from degradation [21,22]. Similarly, HCV virus-like 
particles interact with L-SIGN expressed on liver sinusoidal endothelial cells (LSEC) in situ, and 
are targeted to non-lysosomal early endosomes in L-SIGN transfected Raji cells [22]. DC-SIGN 
and L-SIGN are also thought to play an important role in HCV viral dissemination by transferring 
HCV from the circulation to hepatocytes, the main HCV target cells [23]. 
Several reports have shown the presence of HBV on or within dendritic cells [24-27], sug-
gesting the involvement of a dendritic cell-specific receptor such as DC-SIGN. Patient-derived 
HBsAg is preferentially internalised by human LSEC in a mixed culture with human hepatocytes 
(K. Esser and U. Protzer, unpublished data) – as it has also been reported for duck HBV [28] 
- implying a potential interaction between HBV and L-SIGN. The HBV glycosylation pattern 
together with the cellular localization prompted us to investigate the possible role of both 
DC-SIGN and L-SIGN in binding of HBV.  
matERIals anD mEtHoDs
Antibodies and viral glycoproteins
The following antibodies were used: DC-SIGN and L-SIGN specific antibody AZN-D2 [29]; mouse 
anti-DC-SIGN conjugated with fluorescein isothiocyanate (FITC) (clone DCN46; BD Biosciences, 
San Jose, CA); mouse anti-HCV E2 (4H6B2; Innogenetics, Ghent, Belgium); sheep anti-HBsAg 
preS1, mouse anti-HBsAg preS2 and biotinylated human anti-HBsAg (F-9H9-E, all kind gifts of 
R. Heijtink, Erasmus MC, Rotterdam, The Netherlands); rabbit anti-HBsAg-FITC (Acris Antibodies 
GmbH, Hiddenhausen, Germany); peroxidase-conjugated goat anti-human immunoglobulin 
G1 (Jackson Immunoresearch, West Grove, PA); peroxidase-conjugated rabbit anti-FITC 
(Dako, Glostrup, Denmark); peroxidase-conjugated goat anti-mouse (Caltag; Carlsbad, CA); 
peroxidase-conjugated streptavidin (Dako). 
Recombinant HBV surface antigen HBsAg (containing both S and preS2 domains) purified 
from transfected Chinese Hamster Ovary (CHO) cells was kindly provided by M. van Roosmalen 
(bioMérieux, The Netherlands). Yeast cell-derived HCV glycoproteins E1 and E2 reconstituted as 
virus like particles (VLP) were kindly provided by S. Depraetere (Innogenetics, Belgium). 
HepG2.2.15-derived HBV
HepG2.2.15 cells [30] were grown until confluence in Williams’ E medium (Gibco, Paisley, UK) 
supplemented with 5% fetal calf serum (FCS, Hyclone, Logan, UT). Secreted HBV and subviral 
particles were concentrated from the medium as described before [27], to a final concentration 
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of 0.96x10E9 HBV particles/ml. To enrich for HBV over subviral particles, HepG2.2.15 culture 
supernatants were loaded on a PBS equilibrated 1 ml bed volume Hi TrapTM Heparin HP column 
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden). After fifteen column volumes PBS wash, 
HBV particles were eluted in 20 ml elution buffer (350 mM NaCl, 20 mM Tris/HCl, pH 7.4) and 
collected in elution fractions of 2 ml at a flow rate of 1 ml/min. Elution fractions were dialyzed 
against PBS. As a negative control, the same procedure was followed with supernatant from 
untransfected HepG2 cells. The elution fractions were assessed for the presence of HBV particles 
with L, M and S-specific ELISA, by capturing HBV with anti-preS1, anti-preS2 and anti-S specific 
antibodies respectively. Bound HBV was detected with a biotinylated human anti-HBsAg 
(F-9H9-E). Quantification of HBV particles was done by COBAS® TaqMan HBV Test (Roche Diag-
nostics GmbH, Mannheim, Germany) after viral DNA isolation using the High Pure System Viral 
Nucleic Acid Kit (Roche Diagnostics). To generate highly mannosylated HBV, HepG2.2.15 cells 
were treated with the α-mannosidase I inhibitor kifunensine (5 days, 20 µg/ml; Calbiochem, 
Darmstadt, Germany). Untreated HepG2.2.15 cells and kifunsine treated HepG2 cells served 
as negative controls. The final concentrations of highly mannosylated and native HBV were 
1.4x10E8 and 2.2x10E8 HBV particles/ml, respectively. 
Cells
Stable Raji transfectants expressing wild-type DC-SIGN or L-SIGN were generated as previously 
described [31, 32]. Monocyte-derived dendritic cells (moDC) were cultured from monocytes in 
the presence of IL-4 and GM-CSF (500 and 800 U/ml, respectively; Schering-Plough, Brussels, 
Belgium). At day 6, the phenotype of the cultured moDC was confirmed by flow cytometric 
analysis [22]. Expression levels of DC-SIGN and L-SIGN on transfected Raji cells and moDC were 
determined by flow cytometry with the DC-SIGN and L-SIGN specific AZN-D2 antibody. 
Plant lectin ELISA
Heparin purified, glycan modified or native HepG2.2.15-derived HBV were captured on 
enzyme-linked immunosorbent assay (ELISA) plates (Maxisorb, Nunc, Roskilde, Denmark) with 
mouse anti-preS2. Recombinant HBsAg (0.5 µg/well), HCV VLP (0.25 µg/well) and mannan (0.25 
µg/well; Sigma-Aldrich, St. Louis, MO) were coated directly onto the plate for 18 hours at 4°C. 
After blocking with 1% bovine serum albumin for 1 hr at 37°C, the following biotinylated plant 
lectins were added for 2 hr at room temperature at a concentration of 5 µg/ml: Con A (Conca-
valin A; recognizes α-glucose and α-mannose), GNA (Galanthus nivalis agglutinin; α-mannose), 
WGA (Wheat germ agglutinin; N-acetylglucosamine), PNA (Arachis hypogaea agglutinin; 
β-galactose, N-acetylgalactosamine), RCAII (Ricinus communis agglutinin; β-galactose, 
N-acetylgalactosamine) or LTA (Lotus tetragonolobus agglutinin; fucose; all from Sigma Aldrich 
[33]). Lectin binding was detected using peroxidase-conjugated streptavidin and absorbance 
was measured at 450 nm. 
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Recombinant DC-SIGN-Fc binding ELISA
The DC-SIGN-Fc binding assay was performed as previously described [34]. In short, recombi-
nant HBsAg (0.5 µg/well), HepG2.2.15-derived HBV and HepG2 controls were captured on Maxi-
sorb ELISA plates (Nunc) with mouse anti-preS2. HCV VLP (0.25 µg/well) were coated directly on 
the plates. After blocking with 1% bovine serum albumin for 30 min at 37°C, soluble DC-SIGN-Fc 
was added and bound DC-SIGN was detected after incubation with peroxidase-labelled anti-
human immunoglobulin G1 antibody. Specificity of DC-SIGN-Fc binding was determined by 
blocking with either mannan (100 µg/ml; Sigma-Aldrich) or EGTA (10 mM; Sigma-Aldrich). 
To assess the coating efficiency, HBsAg and HBV were detected with biotinylated human 
anti-HBsAg (F-9H9-E) and HCV VLP were detected with mouse anti-HCV E2 (4H6B2). HBV con-
centrated by centrifugation or purified by heparin column gave similar results in DC-SIGN-Fc 
binding assays.
Soluble DC-SIGN/L-SIGN lysate ELISA
Raji DC-SIGN/L-SIGN transfectants were lysed for 4 hours at 4°C in lysis buffer (1% NP40, 150 mM 
NaCl, 1 mM MgCl2 and 1 mM CaCl2 in PBS) supplemented with EDTA-free protease inhibitors 
(Roche Diagnostics, Penzberg, Germany). HBsAg, HBV and medium controls were captured on 
ELISA plates with a mouse anti-preS2 antibody. HCV VLP were coated directly on the plates. 
After blocking with 5% bovine serum albumin for 30 min at 37°C, Raji DC-SIGN/L-SIGN lysates 
were added for 2 hrs at RT. Bound DC-SIGN/L-SIGN was detected with a FITC-conjugated 
DC-SIGN/L-SIGN specific antibody (clone DCN46) followed by a peroxidase-conjugated rabbit 
anti-FITC antibody. Specificity of binding was determined in the presence of mannan (100 µg/
ml; Sigma-Aldrich). To assess the coating efficiency, HBsAg, HBV and HCV VLP were detected 
with specific antibodies. HBV concentrated by centrifugation or purified by heparin column 
gave similar results in soluble DC-SIGN/L-SIGN lysate ELISA.
Cellular DC-SIGN/L-SIGN bindings assay
Untransfected Raji cells, DC-SIGN or L-SIGN-transfected Raji cells and moDC were incubated 
with or without HBsAg (5 µg/ml) for 2 or 18 hours at 37°C and binding was measured by flow 
cytometry after intracellular staining with an anti-HBsAg-FITC antibody (Acris Antibodies 
GmbH). Uptake was compared to lectin-mediated binding of dextran-FITC (100 µg/ml, 40.000 
MW; Molecular Probes, Invitrogen, Carlsbad, CA). Specificity of binding was determined by 30 
min pre-incubation with mannan (100 µg/ml). 
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REsUlts
Characterisation of purified HBV particles
Secreted HBsAg subviral particles outnumber the HBV virions at least 100-fold in both patient 
serum and culture supernatant of HepG2.2.15 cells [7]. To enrich for HBV virions, culture super-
nantant of HepG2.2.15 cells was fractionated over a heparin column and different elution frac-
tions were assessed by HBV L, M and S-specific ELISA. The input fraction contained mainly the 
S protein, representing the relative high level of secreted spherical subviral particles (Fig. 1A). 
Elution fraction 1 and 2 however, were highly enriched for both M and L proteins confirming 
the increased level of HBV virions in these fractions. Quantification of HBV DNA of the input 
fraction and elution fraction 1-3 confirmed an almost 50-fold enrichment of HBV virions in frac-
tion 1 (0,026 to 1,27x109 HBV particles per ml, Fig. 1B). 
HBsAg and HBV do not interact with recombinant DC-SIGN-Fc
The interaction between DC-SIGN and recombinant HBsAg or HepG2.2.15-derived HBV was 
determined in a binding ELISA where coated HBsAg, HBV, HCV VLP or HepG2 medium controls 
were incubated with soluble recombinant DC-SIGN-Fc. The detected signal of the HepG2 
medium control was never above background. Strikingly, DC-SIGN did not interact with HBsAg 
nor with whole virus particles, whereas DC-SIGN did interact with HCV virus like particles, 
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fig. 1 Characterisation of purified HBV particles.
(A) HBV particles were purified from HepG2.2.15 cul-
ture supernatant by heparin column and both input 
and different elution fractions were assessed by L, M 
and S-specific capture ELISA. (B) Quantification of HBV 
particles in both input and elution fraction 1, 2 and 3 
by COBAS® TaqMan HBV Test.
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consisting of purified yeast recombinant E1 and E2 HCV envelope proteins (Fig. 2A and [22]). 
Specificity of binding was determined by blocking with either mannan, a yeast cell derived 
polycarbohydrate that competitively binds the carbohydrate binding site of mannose-specific 
lectins, or the calcium chelator EGTA, and both agents indeed reduced DC-SIGN binding to 
HCV to background level. Coating controls demonstrated that approximately equal amounts of 
HBsAg, HBV and HCV VLP were coated. 
Based on their oligosaccharide specificity, several plant lectins were used in a glycan analysis 
of HBsAg and heparin purified HBV (Fig. 2B). Strong binding to Con A, GNA, WGA, PNA, RCAII 
and LTA demonstrated the presence of high and/or complex mannose, N-acetylglucosamine, 
galactose and fucose containing carbohydrate structures on both HBsAg and HBV. For DC-SIGN-
glycoprotein interaction the high mannose and fucose containing oligosaccharide structures 
are most important [35]. Of note, carbohydrate structures on both HCV VLP and mannan mainly 
consist of mannose, as indicated by the exclusive binding to Con A and GNA.
HBsAg and HBV do not interact with soluble DC-SIGN from cell-lysates
To exclude the possibility that the lack of interaction between HBV and recombinant DC-SIGN 
was because of improper multimerization of DC-SIGN-Fc, binding of HBsAg and HBV to native 
DC-SIGN was studied with DC-SIGN derived from transfected Raji cells [31,32]. As described 
before, flow cytometric analysis of Raji transfectants showed high expression levels of DC-SIGN 
(Fig. 3A, [22]). In a bindings ELISA, coated HBsAg or HCV VLP were incubated with lysates of 
mock or DC-SIGN transfected Raji cells and bound DC-SIGN was detected with an anti-DC-SIGN 
antibody. DC-SIGN derived from Raji transfectants did not bind HBsAg nor whole HBV particles, 
whereas HCV VLP showed mannan-sensitive binding to DC-SIGN (Fig. 3B). Control incubation 
with anti-HCV and anti-HBsAg specific antibodies indicated equal amounts were coated. No 
background binding was observed for either HBsAg or HCV VLP using the lysate of untrans-
fected Raji cells (data not shown). 
HBsAg does not interact with cellular DC-SIGN
In addition to ELISA, HBsAg interaction with cellular DC-SIGN was also determined. DC-SIGN is 
highly expressed on moDC (Fig. 3A). Therefore, both Raji-DC-SIGN and moDC were incubated 
with HBsAg and binding was measured by flow cytometry. Neither DC-SIGN-positive Raji cells 
nor moDC interacted with HBsAg after 2 and 18 hr incubation (Fig. 3C and data not shown). 
In contrast, both DC-SIGN-transfected Raji cells and moDC efficiently internalised the DC-
SIGN ligand dextran-FITC in a mannan-sensitive manner (Fig. 3C). Mock transfected Raji cells 
remained dextran-FITC negative (data not shown). Figure 3D summarizes the results of two 
independent binding assays. 
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HBsAg and HBV do not interact with soluble L-SIGN 
In a similar manner, the interaction between cellular L-SIGN and both HBsAg and HBV was deter-
mined using L-SIGN-transfected Raji cells. Flow cytometric analysis showed L-SIGN expression 
levels equal to DC-SIGN expression (Fig. 4A, [22]). Soluble L-SIGN interacted neither with HBV 
nor with HBsAg in ELISA, whereas L-SIGN did interact with HCV VLP (Fig. 4B). Medium controls 
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fig. 2 HBV and its surface antigen HBsag do not interact with recombinant DC-sIGn. 
(A) DC-SIGN interaction with CHO-derived recombinant HBV surface antigen HBsAg and HepG2.2.15-derived HBV 
was determined in an Fc-based ELISA, as described in Methods. Supernatant of the non-virus producing cell line 
HepG2 was used as negative control and HCV VLP were used as a positive control. Specificity of binding was de-
termined in the presence of mannan or the calcium chelator EGTA. To assess the coating efficiency, HBsAg, HBV 
and HCV VLP were detected with specific antibodies. Data are shown as mean±sd of duplicate measurements; one 
representative experiment out of four is shown. (B) Glycan analysis of HBsAg and HBV by plant lectin ELISA. For 
abbreviations and detailed oligosaccharide specificity of the indicated lectins see Methods.
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fig. 3 HBsag and HBV do not interact with cel-
lular DC-sIGn. 
(A) Expression levels of DC-SIGN on DC-SIGN 
transfected Raji cells and monocyte-derived 
dendritic cells (moDC) were determined by 
fl ow cytometry with AZN-D2 (dark line). Filled 
graphs represent isotype controls. (B) HBsAg 
and HBV interaction with cellular DC-SIGN was 
determined by the soluble DC-SIGN lysate ELISA, 
as described in Methods. Interaction with HCV VLP 
was determined as a positive control. Specifi city 
of binding was determined in the presence of 
mannan. To assess the coating effi  ciency, HBsAg, 
HBV and HCV VLP were detected with specifi c 
antibodies. Data are shown as mean±sd of 
duplicate measurements; one representative 
experiment out of three is shown. (C, D) Interaction 
of HBsAg with DC-SIGN transfected Raji cells (n=2) 
or DC-SIGN expressing moDC (n=1) in culture 
was determined by fl ow cytometry, after 2 hr 
HBsAg incubation at 37°C. Specifi city of binding 
was determined by 30 min pre-incubation with 
mannan. Lectin-mediated binding of dextran-FITC 
to DC-SIGN was determined as a positive control. 
(C) Histogram plots of dextran-FITC (upper panel) 
and HBsAg (lower panel) binding to Raji DC-SIGN 
and moDC. Dotted lines represent background 
without substrate, bold black lines represent 
substrate binding at 37°C and grey lines show the 
specifi c inhibition with mannan. (D) Summary of 
DC-SIGN binding experiments, data are shown as 
mean±sd.
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were always at background level. Moreover, cellular L-SIGN expressed by Raji transfectants did 
not bind to HBsAg, while it bound dextran-FITC in a mannan-sensitive manner (Fig. 4C, D).
DC-SIGN binds highly mannosylated HBV
Thus, neither HBsAg nor HBV interacts with DC-SIGN or L-SIGN, whereas both C-type lectins 
interact with HCV and other viruses such as HIV-1. These data suggest that the N-linked gly-
cosylation of HBV is distinct from that of other viruses. To evaluate whether indeed native HBV 
glycosylation does not meet the requirements for DC-SIGN interaction, glycan modified HBV 
was generated by treating HBV-producing HepG2.2.15 cells with the α-mannosidase I inhibitor 
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fig. 4 HBsag and HBV do not interact with cellular l-sIGn. 
(A) Expression level of L-SIGN on L-SIGN transfected Raji cells was determined by flow cytometry with AZN-D2 
(dark line). Filled graph represents isotype control. (B) HBsAg and HBV interaction with cellular L-SIGN was deter-
mined by soluble L-SIGN lysate ELISA. Data are shown as mean±sd of duplicate measurements; one representative 
experiment out of three is shown. (C, D) Interaction of HBsAg with L-SIGN transfected Raji cells in culture was 
determined by flow cytometry, as described in Fig. 3. L-SIGN binding of dextran-FITC was determined as a positive 
control. (C) Histogram plots of dextran-FITC (upper panel) and HBsAg (lower panel) binding to Raji L-SIGN. Dotted 
lines represent background without substrate, bold black lines represent substrate binding at 37°C and grey lines 
show the specific inhibition with mannan. (D) Results of two independent L-SIGN binding experiments, data are 
shown as mean±sd. 
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kifunensine. Kifunensine causes the accumulation of Man7–9GlcNAc2 oligosaccharides on gly-
coproteins by inhibiting mannose trimming in the endoplasmic reticulum [36]. Carbohydrate 
analysis of glycan modified HBV indeed demonstrated an increased amount of mannose struc-
tures compared to native HBV, shown by a 2-fold increase in binding to the mannose-specific 
plant lectins Con A and GNA while binding to the N-acetylglucosamine-specific lectin WGA was 
unchanged (Fig. 5B). Control incubations with an anti-HBsAg specific antibody showed that 
similar amounts of native and highly glycosylated HBV were coated (Fig. 5A). The interaction 
between highly mannosylated HBV and DC-SIGN was studied by DC-SIGN-Fc-based ELISA (Fig. 
5C). Strikingly, HBV binding to DC-SIGN was observed after kifunensine treatment of the virus 
producing cells, and the binding could be inhibited by both mannan and EGTA. The protein 
structure of HBV is therefore compatible with DC-SIGN binding, but the native glycosylation, 
that exclusively determines DC-SIGN interaction, is not. This observation also excludes the 
possibility that lack of DC-SIGN-HBV interaction is observed due to too low sensitivity of the 
DC-SIGN assays used in this study. Supernatant of untreated HepG2.2.15 and HepG2 cells 
showed no binding to DC-SIGN. Minor background binding was observed with supernatant of 
kifunensine-treated HepG2 cells, due to the accumulation of large amounts of highly manno-
sylated proteins in the medium during treatment. These data indicate that mannose trimming 
of the oligosaccharide structures present on HBV prevents interaction with DC-SIGN. 
DIsCUssIon
One of the key questions in HBV biology focuses on the attachment and entry mechanisms 
used by HBV to infect hepatocytes, the main target cells. Several putative binding receptors 
are proposed, but none of them are confirmed as high affinity receptors for HBV. Related to 
the issue of HBV entry is the way HBV reaches the hepatocyte: Is there direct contact between 
HBV in the circulation and hepatocytes, possibly through fenestrations in the LSEC [37]? Or are 
other cell types involved in HBV dissemination, similar to HIV transport by dendritic cells for 
trans-infection of T cells [31] and HCV capture by LSEC promoting infection of hepatocytes [38]?
Since HBV surface antigens are glycoproteins, the involvement of a C-type lectin receptor in 
viral recognition seems plausible. The best-characterised C-type lectins are the dendritic cell-
expressed DC-SIGN and its LSEC-expressed homologue L-SIGN, both capable of recognizing 
a broad range of glycosylated pathogens, including viruses, bacteria and protozoa [16]. The 
fact that HBV has been found attached to both dendritic cells [24-27], and LSEC [28] leads to 
DC-SIGN and L-SIGN as likely candidate receptors.
The present study conclusively shows the lack of interaction between DC-SIGN and purified 
HepG2.2.15-derived HBV with its native glycosylation. Moreover, recombinant HBV surface anti-
gens were recognized by neither DC-SIGN nor L-SIGN. Glycan analysis of both HBV and HBsAg 
demonstrated that lack of DC-SIGN binding was not due to aberrant glycosylation of virions and 
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glycoproteins used in this study, since the observed glycosylation pattern was consistent with 
previously reported complex-type carbohydrate structures on HBV [39]. Notably, while mannose 
and N-acetylglucosamine seem to be present in similar amounts on both HBV and HBsAg, glycan 
structures on virions are enriched for galactose, N-acetylgalactosamine and fucose. This difference in 
observed glycosylation pattern might be the result of O-glycans present on the preS1 domain [39]. 
DC-SIGN has been shown to interact with high mannose-containing glycans on various 
viruses, such as HCV, HIV and Ebola [16]. Even though data demonstrate that these viruses can 
exploit DC-SIGN for their own benefit, the majority of the captured virus is degraded and routed 
into the antigen presentation pathway [40-42], thereby allowing the induction of an anti-viral 
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fig. 5 DC-sIGn specifically binds highly mannosylated HBV. 
Highly mannosylated HBV was generated by treating HBV producing HepG2.2.15 cells with the α-mannosidase I 
inhibitor kifunensine (20 µg/ml) for 5 days. Untreated HepG2.2.15 cells and kifunensine treated HepG2 cells served 
as negative controls. (A, B) Glycan analysis of untreated and mannosylated HBV by the mannose-specific lectins 
Con A and GNA and the N-acetylglucosamine-specific lectin WGA. In the coating control, the captured amount 
of untreated and mannosylated HBV is detected with an anti-HBS specific antibody. (C) The interaction of highly 
mannosylated HBV with DC-SIGN was studied by DC-SIGN-Fc ELISA, as described in Fig. 2. Specificity of binding 
was determined in the presence of mannan or EGTA. Supernatant of untransfected HepG2 cells is shown as me-
dium control. Data are shown as mean±sd of duplicate measurements; one representative experiment out of three 
is shown. 
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immune response. Although HBV glycoproteins are involved in viral recognition, as they are 
known to bind mannose binding lectin and the asialoglycoprotein receptor, here it is shown 
that α-mannosidase I trimming of N-linked oligosaccharide structures prevents recognition by 
DC-SIGN. HBV is thus recognized by DC-SIGN as soon as one of the enzymes in the formation of 
complex glycans, α-mannosidase I, is inhibited and highly mannosylated virions are generated. 
Previous reports have shown the importance of HBV glycosylation for viral secretion [11,43] and 
indeed we observe a decrease in secretion of highly mannosylated versus native HBV, under 
similar culture conditions.
We cannot rule out that patient sera contain a subpopulation of these highly glycosylated 
viremia that would allow interaction with DC-SIGN. Preliminary data on HBV derived from sev-
eral patient sera with a high viral load did not show binding to DC-SIGN-Fc (data not shown), 
thereby indicating that DC-SIGN may not be involved in recognition of HBV in vivo either. On 
the basis of our findings, it is tempting to speculate that HBV exploits mannose trimming as 
a way to escape recognition by DC-SIGN and thereby subvert a possible immune activation 
response. Further studies are needed to address this issue.
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aBstRaCt
Dendritic cells (DC) play a key role in anti-viral immunity. Direct interactions between DC and 
hepatitis B virus (HBV) may explain the impaired DC function and the ineffective anti-viral 
response of chronic HBV patients resulting in HBV persistence. Here, the interaction between 
HBV surface antigens (HBsAg) and DC and the receptor involved were examined by flow 
cytometry in blood and liver tissue of HBV patients. The in vitro data showed that the mannose 
receptor (MR) is involved in HBsAg recognition and uptake by DC. The presence of HBsAg-
positive DC was demonstrated sporadically in blood, but frequently in the liver of HBV patients. 
Interestingly, a positive correlation was found between HBsAg positivity and MR expression 
level in both liver- and blood-derived DC. These data suggest that in HBV infected patients, 
MR-mediated interaction between HBsAg and DC and subsequent impairment of DC predomi-
nantly occurs at the main site of infection, the liver.
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IntRoDUCtIon
In the majority of cases, infection with Hepatitis B virus (HBV) results in self-limiting acute hepa-
titis, due to a vigorous multi-specific T and B cell response [1]. However, worldwide more than 
350 million people are chronically infected with HBV [2] as the result of a complex interaction 
between the replicating virus and an inadequate HBV-specific immune response. The underly-
ing mechanism for this ineffective anti-viral immune response is not clear. 
Dendritic cells (DC) are key players in the anti-viral immune response and form a bridge 
between innate and adaptive immunity [3]. They are equipped with specialized pattern-recog-
nition receptors, including C-type lectins and Toll like receptors [4,5]. These receptors enable 
them to recognize and internalize pathogens resulting in antigen processing and presentation. 
The nature of the pathogen and the receptors involved in pathogen recognition determine 
the activation status of the DC, which in turn determines the quality of the immune response 
ranging from tolerance to immunity [6].
HBV primarily infects hepatocytes, but both in vitro and in vivo data indicate that the virus 
also interacts with DC. HBV DNA was demonstrated in isolated blood DC from chronic HBV 
patients [7-9]. Recently, we showed that HBV surface antigens (HBsAg) are internalized by 
blood-derived myeloid DC (mDC) in vitro, leading to impaired mDC function [10]. Also several 
in vivo studies describe the impaired function of mDC in chronic HBV patients [7,11,12]. This 
impaired mDC function was improved upon viral load reduction [12]. However, whether in vivo 
a direct immune regulatory effect of HBV on DC function exists, which receptor(s) are involved 
in this interaction and whether the impaired function of blood mDC could be explained by cir-
culating HBV and/or HBsAg is not known. Several putative binding factors have been described 
for HBsAg, such as human serum albumin [13], asialoglycoprotein receptor [14] and mannose 
binding lectin [15], but their exact role in HBV attachment and uptake remains unclear [16]. 
Since HBsAg are glycoproteins [17], the involvement of a C-type lectin in viral recognition by 
DC seems plausible. DC are known to express both type I and type II C-type lectins, including 
DEC-205 (CD205), mannose receptor (MR; CD206) and DC-SIGN (CD209), but the expression 
of the different C-type lectin family members depends on the DC subset and differentiation/
maturation state [5].
Most studies on pathogen interactions with human DC are performed with in vitro gener-
ated monocyte-derived DC, which exhibit functional and phenotypical features of, but are not 
identical to, circulating mDC. To unravel the possible interaction between HBV and mDC in vivo, 
we investigated the uptake of HBsAg, the receptor involved and the presence of HBsAg-positive 
mDC in blood and liver in vivo. 
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matERIals anD mEtHoDs
Isolation of mDC from peripheral blood 
All healthy controls gave written informed consent before blood donation. MDC (BDCA1+) 
were isolated from healthy control blood using anti-BDCA1-PE and PE-conjugated microbeads 
(Miltenyi Biotec, Bergisch Gladbach, Germany) as described previously [7]. MDC purity and 
viability were determined by flow cytometry (FACScalibur, Becton, Dickinson and Company 
(BD), Franklin Lakes, NJ). Gated on viable cells, the purity of isolated mDC ranged from 85 to 
95%. MDC were cultured in RPMI 1640 (Bio Whittaker, Verviers, Belgium) supplemented with 
10% FCS (Hyclone, Logan, UT), penicillin (50 IU/ml), streptomycin (50 µg/ml) and GM-CSF (500 
U/ml; Leucomax, Novartis Pharma, Arnhem, The Netherlands). 
Lectin-mediated endocytosis
MDC were directly used to study the endocytic capacity or first cultured for 18 hr, followed by 
2 hr incubation in the presence or absence of dextran-FITC (100 µg/ml; 40.000 MW, Molecular 
Probes, Invitrogen, Carlsbad, CA). For HBsAg binding and uptake, mDC were incubated for 18 hr 
with recombinant HBsAg (2 µg/ml, kindly provided by M. van Roosmalen, bioMérieux, Boxtel, 
the Netherlands) [10]. Antigen uptake was stopped by cold wash in PBS containing 1% FCS and 
0.02% NaN3. HBsAg was stained by intracellular staining with anti-HBsAg-FITC (Acris Antibodies 
GmbH, Hiddenhausen, Germany) as described before [10] and cells were measured by flow 
cytometry. This protocol detects both surface bound and internalized HBsAg. Lectin-mediated 
endocytosis was inhibited by 30 min pre-incubation at 37°C with mannan (100 µg/ml; Sigma-
Aldrich, St. Louis, MO), D-mannose, D-glucose, D-fructose, D-galactose, fucose, N-acetyl 
glucosamine, N-acetyl galactosamine (50 mM; Sigma-Aldrich), EGTA (20 mM; Sigma-Aldrich), 
neutralizing anti-MR (1-20 µg/ml; clone 19.2, BD) or neutralizing control antibody anti-DEC205 
(10 µg/ml; clone MG38, AbD Serotec, Kidlington, UK). Negative controls were incubated with-
out antigen or with antigen at 4°C. 
Lectin expression
MDC were lysed in Trizol (Sigma-Aldrich) directly after isolation and after 18 hr of culture. 
RNA was precipitated with 75% ethanol and isolated using Micro RNAeasy silica columns 
(Qiagen, Venlo, The Netherlands). cDNA was prepared using AMV reverse transcriptase 
according to the manufacturer’s protocol (Promega, Madison, WI). Real-time PCR (MyIQ, Biorad, 
Hercules, CA) was performed using primers for GAPDH (F: 5’-CCATGTTCGTCATGGGTGTG-3’; 
R: 5’-GGTGCTAAGCAGTTGGTGGTG-3’), DEC-205 (F: 5’-CCCTATGTCTGCAGGAAACCA-3’; 
R: 5’-TGCATCACAGCGGGTATCTG-3’) and MR (F: 5’-gtcttgggccacaggtgaa-3’; R: 5’- 
aaggcgtttggatagccaca-3’) with iQ SYBR Green supermix (Biorad) for 40 cycles and gene 
expression was calculated using the ΔΔCT method. Protein expression levels of MR and DEC-
205 were determined by flow cytometry after staining with anti-BDCA1-PE (clone AD5-8E7, 
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Miltenyi), anti-CD20-PerCP (BD), anti-CD205-FITC (clone MG38, eBioscience, San Diego, CA) and 
anti-CD206-APC (clone 19.2, BD) in PBS containing 1% FCS and 0.02% NaN3. 
HBsAg staining on patient-derived blood and liver tissue
Blood and percutaneous needle liver biopsies were obtained from 14 chronic HBV patients 
and 9 non-HBV patients with other liver diseases as part of their diagnostic evaluation. Control 
patients were negative for markers of prior HBV exposure. The medical ethical committee of 
the Erasmus MC declared to have no objections against the use of excess patient material and 
all patients gave informed consent before inclusion. Patient characteristics are given in Table 
1. Excess tissue from liver biopsy samples was collected in RPMI and grinded through a 70 µM 
nylon cell strainer (BD) to obtain a single cell suspension of mononuclear cells, which were 
stained with a combination of anti-BDCA1-PE, anti-CD14-PerCP (clone MOP9, BD), anti-CD20-
PacificBlue (clone 2H7, eBioscience), anti-CD45-AmCyan (clone 2D1, BD) and anti-CD206-APC 
followed by intracellular staining with anti-HBsAg-FITC. Cells were measured by 8-color flow 
cytometry (FACSCanto II, BD) and analyzed with BD FACSDiva software. MDC were identified 
as CD45+CD14-CD20-BDCA1+ and assessed for the presence of HBsAg and expression of MR. 
Only measurements with an mDC population of at least 100 events were included; background 
HBsAg-staining in control non-HBV patients was never above 2%. Hepatocytes were gated on 
forward/sideward scatter and CD45 negativity and assessed for presence of HBsAg. 
REsUlts
C-type lectin mediated endocytosis by mDC increases upon culture
Our previous study on HBsAg internalization by mDC showed an increased uptake over time 
[10], which might be mediated through C-type lectins considering the glycosylation pattern of 
HBsAg. Many reports describe C-type lectin expression and endocytic capacity of monocyte-
derived DC, but little is known about blood-derived mDC. Therefore, the capacity of C-type 
lectin mediated endocytosis of mDC and the culture-induced change in endocytic capacity was 
determined with the model substrate dextran-FITC. Directly after mDC isolation, uptake after 
2 hr culture in the presence of dextran-FITC is limited to approximately 15% mDC. Overnight 
culture in the presence of GM-CSF, followed by 2 hr dextran-FITC uptake, increased uptake to 
36±5% positive mDC (Fig. 1A). As expected, uptake of dextran-FITC could be blocked by addi-
tion of mannan, which competitively binds the carbohydrate binding site of mannose-specific 
lectins. In addition, dextran-FITC uptake was strongly reduced by addition of D-mannose, 
D-glucose, D-fructose, fucose, N-acetyl glucosamine and the calcium chelator EGTA (Fig. 1B). 
Galactose and N-acetyl-galactosamine did not inhibit dextran-FITC uptake by mDC, indicating 
that e.g. the galactose-specific asialoglycoprotein receptor and macrophage galactose-type 
C-type lectin are not likely to contribute to lectin-mediated endocytosis by mDC. 
74
C
ha
p
te
r 
5
C-type lectin expression on mDC
Since both HBsAg [10] and dextran-FITC uptake increased after overnight culture, the 
expression level of several C-type lectins on mDC was determined by real-time PCR before and 
after 18 hr of culture. No detectable signal over background was obtained for L-SIGN, ASGPR1 
and Endo-180 (data not shown). ASGPR2A and B mRNA could be detected in mDC directly 
after isolation, while mRNA levels diminished after mDC culture (data not shown). In contrast 
to the high level of DC-SIGN mRNA in monocyte-derived DC ([18], data not shown), DC-SIGN 
mRNA could not be detected in mDC directly after isolation, although it was present at very 
low levels after 18 hr of culture (data not shown). Also MR and DEC-205 mRNA are known to be 
expressed by monocyte-derived DC ([18], data not shown). In contrast, MR mRNA levels were 
undetectable in freshly isolated mDC, but increased 8- to 32-fold during the 18 hr culture period 
(Fig. 2A,B). DEC-205 mRNA was already present at high levels in mDC directly after isolation and 
was 2-fold reduced after culture (Fig. 2A,B). Flow cytometric analysis also showed an increase 
table 1 Patient characteristics
Patient # Age (yr) Sex Liver Disease Genotype Serum
Viral Loada,b
Serum ALTc
(U/l)
1 30 M HBV D 4.17*103 38
2 45 M HBV D 5.12*109 155
3 32 M HBV D 6.46*104 78
4 26 M HBV C 8.48*108 444
5 55 M HBV A 3.05*106 58
6 29 M HBV D 2.50*107 77
7 31 M HBV ND 4.34*103 28
8 39 F HBV D 7.16*105 30
9 27 F HBV ND 3.41*103 49
10 40 M HBV ND 2.25*1010 101
11 39 F HBV B 1.57*109 35
12 22 F HBV D 2.14*103 86
13 32 F HBV ND 2.37*108 46
14 28 F HBV ND 2.27*104 38
15 55 M HCV 3 ND 160
16 64 F HCV 1 9.86*105 182
17 48 M HCV 1 3.58*107 16
18 42 M LTxd NA NA 63
19 41 M Other NA NA 43
20 45 M HCV 4 ND 59
21 22 M HCV 1 2.55*107 43
22 36 F HCV 1 8.17*106 78
23 42 M HCV 1 2.84*106 92
NA, not applicable; ND, not determined
aHBV DNA and HCV RNA are given in geq/ml
bWithin 12 weeks of biopsy time point
cWithin 2 weeks of biopsy time point
dDue to primary sclerosing cholangitis
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of MR-positive mDC after 18 hr culture (Fig. 2C). DEC-205 was highly expressed on the mDC 
cell surface after isolation, but in contrast to the mRNA expression level, the protein expression 
level did not significantly change upon culture (Fig. 2D).
HBsAg internalization is mediated through the MR
The glycosylation pattern of HBsAg, and the increased HBsAg internalization combined with 
the increased MR expression upon mDC culture, indicated the MR as the most likely candidate 
for HBsAg uptake. The exact role of the MR in HBsAg internalization was studied by using 
mannan as inhibitor and more specifically, by blocking the receptor with increasing amounts 
of neutralizing anti-MR antibodies. Mannan significantly inhibited HBsAg uptake (Fig. 3A). 
Increasing amounts of neutralizing anti-MR antibody led to dose-dependent decrease of HBsAg 
uptake, with a maximum block using 10 µg/ml anti-MR (Fig. 3A). MR neutralization led to a 
significant 2-fold reduction of HBsAg uptake, compared to both medium control and presence 
of control antibody anti-DEC-205 (Fig. 3B; both p<0.007). No significant effect of neutralizing 
DEC-205 on HBsAg uptake was observed. 
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A B
fig. 3 In vitro HBsag uptake by mDC is mediated through the mR. 
HBsAg uptake after O/N culture was measured by flow cytometry. Specificity was determined by 30 min pre-
incubation with mannan, increasing amounts of neutralizing anti-MR antibody, or control anti-DEC205 antibody. 
Negative controls were incubated without HBsAg (-) or with HBsAg at 4°C. Data demonstrate a representative 
experiment (A) and the quantification of eight independent experiments (B)
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Intrahepatic mDC of chronic HBV patients contain HBsAg 
To examine whether also in vivo mDC are capable of internalizing HBsAg, either as subviral 
particle or as part of the infectious virion, we studied the presence of HBsAg in blood- and 
liver-derived mDC of chronic HBV patients. Blood and liver biopsy samples of patients with liver 
diseases other then HBV were used as negative controls. Gating strategies to identify blood and 
intrahepatic mDC populations were similar; except for the FSC/SSC gate since intrahepatic mDC 
were a bit smaller and less granular than blood-derived mDC (Fig. 4). Two out of 14 chronic 
HBV patients clearly contained HBsAg-positive mDC in the circulation (patient# 7 and 9, Table 
2), but in most patients blood-derived mDC were HBsAg-negative and HBsAg-staining did not 
significantly differ from control group (Fig. 5A). Strikingly, liver biopsies from 10 out of 14 HBV 
patients contained HBsAg-positive mDC, while no HBsAg positivity was detected in mDC of 
control liver biopsies. Paired analysis of blood- and liver-derived mDC of chronic HBV patients 
showed significantly higher amounts of intrahepatic HBsAg-positive mDC (Fig. 5A; 3.8±1% intra-
hepatic vs 1.4±0.3% blood-derived (mean±SEM) HBsAg–positive mDC; p=0.047). The number of 
HBsAg-positive mDC found in the liver varied between patients and positively correlated with 
the number of HBsAg-positive hepatocytes, the main target of HBV (Table 2, Fig. 5B, p=0.0017). 
table 2 HBsag and mR levels of blood- and liver-derived myeloid DC and hepatocytes 
Patient Blood mDC Liver mDC Hepatocytes
Total 
events
HBsAg+ (%) MR+ (%) Total 
events
HBsAg+ (%) MR+ 
(%)
Total 
events
HBsAg+ (%)
1 630 0.2 0.3 2318 2.8 3.5 22692 18.3
2 254 1.3 0.0 310 7.1 20.3 17989 16.9
3 484 1.9 11.8 915 0.3 9.3 9468 3.1
4 340 1.2 1.2 1200 0.1 5.1 13628 1.0
5 310 1.0 1.6 1668 4.0 5.8 9107 26.3
6 756 0.8 1.6 166 4.8 12.7 10233 18.2
7 1055 3.1 1.7 635 0.8 4.7 7557 16.4
8 1143 1.0 1.0 1351 3.0 5.9 20609 24.9
9 421 3.8 4.3 2349 0.8 2.4 16720 14.3
10 1240 0.6 1.0 1168 1.9 2.3 15227 0.8
11 1736 0.6 1.2 160 14.4 14.4 1360 44.5
12 400 1.0 1.8 362 3.3 20.7 14045 3.2
13 416 1.9 2.2 727 5.0 12.5 16002 26.5
14 141 0.7 1.4 1393 5.5 5.6 12737 73.4
15 146 0.7 10.6 367 1.1 6.8 9323 0.1
16 730 1.9 3.3 858 1.3 4.2 20330 0.1
17 546 1.1 4.6 564 1.8 10.3 13391 0.1
18 1000 0.7 1.8 356 1.1 12.9 12734 0.2
19 576 0.2 5.7 1350 0.5 7.2 16689 0.3
20 311 0.3 1.6 230 1.3 18.3 8227 0.2
21 624 1.3 1 1641 1.5 2.6 16194 0.5
22 484 1.9 6.4 1343 0.3 5.2 20143 0.2
23 429 0.7 1.6 1849 0.5 3.7 11329 0.4
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In vivo presence of HBsAg in mDC correlates with MR expression 
Since HBsAg is abundantly present in both blood and liver of chronic HBV patients, the HBsAg 
concentration cannot explain the difference in HBsAg uptake between blood- and liver-derived 
mDC. Thus the ligand specificity and/or the endocytic capacity should differ between blood- and 
liver-derived mDC. The in vitro experiments demonstrated a key role for MR in HBsAg uptake, 
but upregulation of this receptor by cell culture was a prerequisite for HBsAg internalization. 
Therefore, the MR expression level of blood- and liver-derived mDC of chronic HBV patients 
was studied. Intrahepatic mDC showed a significantly 4-fold higher MR expression compared 
to peripheral blood-derived mDC (Fig. 6A; 8.9±1.7% vs 2.2±0.8% MR-positive mDC; p=0.034). 
When individual patients were studied, a significant positive correlation was found between 
HBsAg positivity and MR expression level in both liver- and blood-derived mDC (Fig. 6B). 
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fig. 4 flow cytometric analysis of blood- and liver-derived mDC. 
Blood and liver biopsy samples of patients with chronic HBV and control patients with non-HBV related liver 
diseases were measured by flow cytometry after staining for anti-CD45, anti-CD14, anti-CD20, anti-BDCA1 and 
anti-HBsAg. The left panel shows the mDC gating strategy of a representative blood sample; the right panel shows 
a representative liver biopsy sample. MDC are identified as CD45+CD14-CD20-BDCA1+, within this population 
the percentage HBsAg positive cells was determined as shown for a representative control (patient# 23) and HBV 
patient (patient# 5).
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DIsCUssIon
DC are professional antigen-presenting cells with a critical role in the initiation and direction 
of anti-viral immune responses [3]. C-type lectins on DC recognize glycan structures expressed 
on pathogens, resulting in pathogen internalization followed by processing and antigen pre-
sentation on MHC molecules [5]. The present study provides insight in the level of interaction 
between mDC and HBsAg and the role of the MR in this interaction. We demonstrate that the 
MR is involved in the uptake of HBsAg by mDC in vitro and also show HBsAg-positive mDC in 
HBV infected individuals ex vivo. While only a minority of the chronic HBV patients contained 
HBsAg in blood-derived mDC, a significant number of liver-derived mDC of these patients con-
tained HBsAg, which correlated with MR expression. These data demonstrate that HBV interacts 
with mDC in vivo, especially at the main site of infection, i.e. the liver, and point towards a crucial 
role for MR in this interaction. 
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fig. 5 HBsag is mainly detected in liver-de-
rived mDC. 
(A) Blood- and liver-derived mDC populations of 
14 chronic HBV and 9 control patients were as-
sessed for presence of HBsAg (*p<0.05). (B) Liver 
biopsy samples were used to determine the 
presence of HBsAg-positive hepatocytes, gated 
on FSC/SSC and CD45 negativity. The correla-
tion between presence of HBsAg in hepatocytes 
and intrahepatic mDC was determined with the 
Spearman test (r=0.76, p=0.0017).
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Most circulating blood mDC were found to be negative for the MR, which was reflected 
by the lack of HBsAg ex vivo and the relative low capacity to take up dextran-FITC as a model 
substrate for lectin-mediated endocytosis. This low lectin-mediated endocytic capacity is in 
line with data of Kato et al. and in sharp contrast to the high dextran-FITC uptake by in vitro 
generated monocyte-derived DC [18]. Although it is known that expression of e.g. cell surface 
molecules such as C-type lectins varies [19], monocyte-derived DC are frequently used as a 
model for mDC. A clear example is the C-type lectin DC-SIGN: highly expressed on monocyte-
derived DC but not present on circulating blood mDC, as shown before [19] and confirmed 
here by real-time PCR analysis. Culture of mDC in the presence of GM-CSF enhanced dextran-
FITC uptake and sugar inhibition studies indicated that mannose-specific receptor mediated 
endocytosis mainly contributed to this binding. Real-time PCR combined with flow cytometric 
analysis on the expression of C-type lectins, indicated a role for the MR in binding and uptake 
of HBsAg by mDC. Blocking experiments with mannan and, more specifically, a neutralizing 
antibody against the MR confirmed the role of MR in HBsAg uptake by mDC in vitro. 
The MR expression on the cell surface of cultured blood-derived mDC and intrahepatic mDC, 
but not on circulating mDC in whole blood, likely reflects the difference in differentiation state 
and endocytic capacity between mDC present in blood and peripheral tissue. Plausibly, mDC 
are recruited to the site of infection, acquire the MR on the cell surface as a result of migration-
induced differentiation and subsequently internalize HBV and/or HBsAg. Whether MR expres-
sion is influenced by liver inflammation could not be determined, since control patients were 
also presented with liver inflammation, as indicated by the elevated alanine aminotransferase 
levels. A more definite answer could come from analysis of steady state livers, but without a 
clinical need to obtain a liver biopsy such material is rarely available.
The expression of HBsAg by infected hepatocytes in almost all biopsy samples taken from 
chronic HBV patients included in this study and the correlation between the level of HBsAg 
positive-hepatocytes and -intrahepatic mDC, not only indicates that the biopsy sample was 
taken at a site of active HBV infection, but also shows that the virus-DC interaction takes place 
at the site of infection.  
Next to the MR, other classes of C-type lectins have been described to interact with HBsAg. 
Chong et al. have demonstrated that HBsAg can interact with soluble mannose-binding lectin 
leading to complement activation, which could contribute to viral clearance by enhanced 
phagocytosis [15] and may explain the potential contribution of mannose-binding lectin poly-
morphisms in HBV disease progression (reviewed in [20]). Furthermore, the asialoglycoprotein 
receptor, expressed by e.g. liver sinusoidal endothelial cells (LSEC) and hepatocytes, has been 
shown to interact with HBV virions through the preS1 domain of HBsAg [14]. Since LSEC are 
also known to express MR [21], the MR could play a role in the capture and transportation of 
HBV virions across the liver endothelium to infect adjacent hepatocytes, comparable to the 
model proposed by Knolle et al. [22]. Whether the MR could also play a role in the infection of 
hepatocytes is not known. In this study we observed that approximately 10% of hepatocytes 
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express the MR (data not shown), possibly contributing to the capture of HBsAg and/or HBV 
virions. 
Although C-type lectin DEC-205 belongs to the same family as the MR and is highly 
expressed on mDC, it does not interact with HBsAg. A difference in ligand specificity is the obvi-
ous explanation, although DEC-205 ligands still need to be determined [23]. More surprisingly 
is the observed recognition of HBsAg by MR, but not by DC-SIGN [24]. Whereas most pathogens 
recognized by the MR also show interaction with DC-SIGN, e.g. Mycobacterium tuberculosis 
and HIV [25], the subtle differences between ligand specificity of DC-SIGN and MR, namely the 
recognition of complex mannose structures versus end-standing mannose residues [26], leads 
to major differences in HBsAg recognition. 
In contrast to pathogen recognition by e.g. Toll like receptors, interaction with C-type 
lectins DC-SIGN and MR does not induce DC maturation [27]. Thus the MR mediated HBsAg 
uptake in the absence of a Toll like receptor signal may lead to HBV/HBsAg-specific tolerance, 
which could be further supported by the microenvironment of the liver. From unpublished 
observations we know that neither HepG2.2.15-derived HBV nor HBsAg are able to induce DC 
maturation. Moreover, both HBV and HBsAg can directly reduce the immunogenicity of DC in 
vitro, which indicates a possible immune escape mechanism of HBV by the virus itself and/or by 
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fig. 6 Correlation between presence of 
HBsag and mR expression level in mDC 
of chronic HBV patients. 
(A) MR cell surface expression of blood- 
and liver-derived mDC of 14 chronic HBV 
patients was measured by flow cytometry 
(mean±SEM MR-positive mDC, *p<0.05). 
(B) The correlation between HBsAg posi-
tivity and presence of MR on blood- and 
liver-derived mDC was determined with 
the Spearman test (r=0.62, p=0.0005).
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the production of HBsAg [10,28]. Although there are conflicting data published, several studies 
demonstrated an impaired DC function in chronic HBV patients, which could at least partially 
explain HBV persistence [7,9,11,12,29,30]. This immune regulatory effect of HBV is supported by 
the fact that an adefovir-induced viral load reduction strongly increased the capacity of mDC 
of chronic HBV patients to produce IL-12 and to stimulate T cell activation [12]. The finding 
that only two out of 14 chronic HBV patients demonstrated HBsAg-positive mDC in blood, is 
comparable to a study by Untergasser et al., showing HBV DNA positive mDC in one out of five 
patients [8]. In contrast, two other studies show HBV DNA in mDC of either half the patient 
population [7] or even in 10 out of 12 patients [9]. Diversity between patient cohorts included 
in each study might explain part; another important difference is the detection method of HBV. 
In conclusion, the present study for the first times shows the involvement of the MR in bind-
ing of HBsAg. The immune competence of chronic HBV patients combined with the relative 
low level of interaction between HBV/HBsAg and mDC in peripheral blood indicates that HBV 
especially interferes with mDC function in the liver. Whether the MR is directly involved in the 
immune regulatory effects of HBV and HBsAg remains to be elucidated. 
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aBstRaCt 
Chronic Hepatitis B virus (HBV) infection is caused by inadequate anti-viral immunity. Toll like 
receptor (TLR) crosslinking in plasmacytoid dendritic cells (pDC) leading to interferon-α (IFN-α) 
production is crucial for effective anti-viral immunity. HBV infection lacks IFN-α induction in 
animal models and patients and chronic HBV patients display impaired IFN-α production by 
pDC. Therefore, the effect of HBV on the function of human pDC was examined in vitro. In con-
trast to influenza or HSV, HBV did not activate pDC nor induced cytokine production. Moreover, 
combined exposure to either CpG or Lox to trigger TLR9 or TLR7 respectively, demonstrated 
that HBV dose-dependently reduced TLR9-induced pDC function, whereas TLR7-induced pDC 
function was hardly affected. In line, HBsAg binding to pDC was strongly enhanced upon TLR9, 
but not TLR7 triggering. HBV inhibited CpG-induced upregulation of co-stimulatory molecules, 
production of IFN-α, TNF-α, IP-10 and IL-6 and pDC-induced NK cell function without affecting 
cell viability. The immune regulatory effect of HBV on purified pDC was even further enhanced 
by addition of monocytes to the cultures. Analyzing different HBV proteins revealed that 
HBeAg, but especially HBsAg is involved in suppression of pDC function. In line, HBV as well 
as HBsAg abrogated the CpG-induced mTOR-mediated phosphorylation of S6, subsequent 
phosphorylation of IRF7 and transcription of IFN-α genes.  
Thus, HBV fails to activate pDC and inhibits TLR9-induced mTOR-mediated pDC function via 
a direct effect on pDC that can be further enhanced by monocytes, which may both contribute 
to HBV persistence. The findings that HBV is not only a weak inducer of innate immunity, but 
also actively interferes with pDC function may aid in the design of novel treatment strategies 
for chronic HBV.
87HBV inhibits pDC function
IntRoDUCtIon
Hepatitis B virus (HBV) infects the liver as primary target and may elicit progressive liver injury 
leading to increased risk of developing liver cirrhosis, liver failure and liver cancer [1]. Chronic 
infection with HBV is the result of an ineffective anti-viral immune response towards the virus 
[1,2]. The exact mechanism by which HBV escapes immunity is still not known. 
In general, the immune system is alerted and evokes a number of mechanisms that are aimed 
at eradicating the viral attack immediately following viral infection. The initial response to viral 
infection is the rapid release of type I interferons (IFN), IFN-α and IFN-ß, which is observed for 
most viruses studied [3]. These IFN enhance the first defense against viral infections and have 
several direct effects in modulating both innate and adaptive immune cells. Indications of the 
role of type I IFN during HBV infection are mostly based on studies in chimpanzees, since this is 
the only animal that can be infected with HBV. In sharp contrast to other viruses including Hepa-
titis C virus, chimpanzees infected with HBV showed a complete lack in the induction of type I 
IFN and in IFN-response genes during the early stages of infection [4]. It is difficult to study the 
early events of acute HBV infection in humans. Nevertheless, it was recently shown that type I 
IFN responses are also lacking in acute HBV patients [5]. Plasmacytoid dendritic cells (pDC) are 
the principal producers of type I IFN and play a central role in immune responses against viral 
infections [6,7]. PDC respond to viruses and other pathogens primarily through the recognition 
of pathogen-associated molecular patterns by two intracellular Toll-like receptors (TLR), TLR7 
and TLR9, which recognizes single stranded RNA and unmethylated DNA motifs, respectively 
[8,9]. TLR-triggering activates pDC to rapidly produce high levels of type I interferons, but also 
other cytokines, including TNF-α and IL-6, and cell surface co-stimulatory molecules. In this way 
pDC exert a direct anti-viral effect by producing factors that inhibit viral replication, but they 
also activate natural killer (NK) cells and T lymphocytes allowing further priming and regulation 
of anti-viral immunity [6,10,11]. 
Circulating blood pDC numbers seem to be unaffected by HBV, but functional deficits in pDC 
from chronic HBV patients have been reported [12]. In these studies, impaired IFN-α production 
by pDC from chronic HBV patients was observed after stimulation with SAC [13], HSV [14], or 
DNA containing CpG motifs [15,16] as compared to healthy controls. Concerning blood-derived 
pDCs, viral DNA could be detected in a subset of chronic HBV patients but no evidence was 
found for viral replication in these cells [13,17]. The presence of HBV DNA in or on pDC in vivo 
indicates a direct interaction between pDC and viral particles. Moreover, additional interactions 
between pDCs and HBV-derived proteins present in circulation, such as HBeAg or HBsAg, which 
can reach levels of 100 µg/ml in peripheral blood [18], may also impact pDC function. Given 
the central role that these cells play in both innate and adaptive antiviral immune responses, 
understanding the mechanisms whereby pDC interact with and respond to HBV may provide 
fundamental insights into the regulation of HBV-specific immunity and the development of 
HBV chronicity. 
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The present study shows that HBV does not activate pDC, but inhibits pDC function via 
a direct effect on pDC that can be further enhanced by monocytes. Analyzing different HBV 
proteins revealed that HBeAg and especially HBsAg are involved in HBV-mediated suppression 
of pDC function by interfering with TLR9-induced S6 phosphorylation. These data demonstrate 
that HBV is not only a weak inducer of innate immunity, but also interferes with pDC function 
which may contribute to HBV persistence.
matERIals anD mEtHoDs
HBV, proteins and TLR ligands
HepG2.215-derived HBV particles were generated and purified as described before [19]. 
Recombinant CHO-derived HBsAg and recombinant HBeAg or HBcAg derived from E. coli are all 
from Prospec (Rehovot, Israel). G.M.G.M. Verjans and G.F. Rimmelzwaan (both Dept of Virology, 
Erasmus MC) provided HSV-1 (MOI 10) and influenza virus (strain H1a, MOI 0.2), respectively. 
Synthetic TLR ligands used include CpG-2336 (class A 10 mg/ml, Coley Pharma, Düsseldorf, 
Germany) and Loxoribine (Lox 0.4 mM, Invivogen, San Diego, CA).  
Purification and activation of pDC
PBMC and pDC were isolated from peripheral heparinized blood samples or from buffy coats 
obtained from healthy blood donors using Ficoll density gradient centrifugation. For pDC isola-
tion,  Ficoll density gradient centrifugation was followed by CD19+ cell depletion and positive 
BDCA4+ pDC selection using a PE-conjugated monoclonal anti-BDCA-4 antibody and anti-PE 
MACS microbeads according to the manufacturer’s instructions (Miltenyi Biotec, Bergisch Glad-
bach, Germany) or FACSorting (FACS Aria, Beckton Dickinson, Alphen a/d Rijn, The Netherlands). 
Isolated pDC were analyzed for purity and viability using anti-BDCA2-FITC (Miltenyi) and 7-AAD 
(eBioscience, San Diego, USA) by flow cytometry and only used for experiments if more than 
95% pure and viable. Where indicated monocytes were either depleted from PBMC or purified 
with anti-CD14 MACS microbeads and LD-columns or MS-columns (Miltenyi), respectively, 
according to manufacturer’s instructions. Total PBMC (1x106 cells/ml) or pDC (2x104 cells/ml) 
were resuspended in RPMI 1640 (Lonza, Basel, Switzerland) containing 10% heat-inactivated 
fetal calf serum (FCS, Hyclone, Logan UT), 100 U/ml Penicillin, 100 mg/ml Streptomycin (Breda, 
The Netherlands) and IL-3 (20 ng/ml, Miltenyi) where indicated. 
NK cell activation
PDC were isolated from PBMC by FACsorting and CD3-CD56+ NK cells were isolated (purity and 
viability >95%) from PBMC from the same donor with an NK cell isolation kit (Miltenyi Biotec, 
Germany) according to the manufacturer’s instructions. pDC were co-cultured with 1x105 NK 
cells in a 1:5 ratio in RPMI 1640 containing 10% FCS, penicillin/streptomycin, Hepes and IL-3 
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either with or without CpG and HBV (200 geq/pDC). After 48h, supernatants were harvested for 
the detection of IFN-γ production by ELISA (eBioScience) and cells were harvested to examine 
NK cell activation by flow cytometry.
Flow cytometric analysis surface (bound) molecules
To evaluate the phenotype of pDC, cells were harvested and stained with combinations of anti-
BDCA4-PE (Miltenyi), anti-CD80-FITC (MAB104; Immunotech, Marseilles, France), anti-CD86-
APC (2331; BD Biosciences), anti-HLA-DR-PerCP (243; BD Biosciences) and anti-CD40-APC (5C3; 
BD Biosciences) in PBS containing 1% heat-inactivated FCS and 0.02% NaN3. HBsAg binding 
was detected with anti-HBsAg-FITC (Acris Antibodies GmbH, Hiddenhausen, Germany). To 
investigate NK cell activation, cells were stained with a combination of antibodies directed 
against CD56 (MY31), CD69 (L78) and CD25 (2A3, all BD Bioscience). Cells were analysed by 
flow cytometry (FACS CantoII or FACScalibur) and FACS Diva or CellQuest Pro software (all 
Beckton Dickinson, Alphen a/d Rijn, The Netherlands). Corresponding isotype-matched control 
antibodies were used to determine background staining.
Phospho-S6 and Phospho-IRF7 analysis
Total PBMC (1x106 cells/250 ml) or purified pDC (5x103 cells/250 ml) were stimulated in the 
presence or absence of HBV or viral proteins (5 µg/ml) at 37oC. After 5 -180 min, cells were 
fixed with 2 % formaldehyde, washed with PBS/1% FCS/0,02% NaN3 and incubated with 0.5 % 
Saponin. Antibodies against Phospho-S6 (pSer235/236, Bioké, Leiden, The Netherlands) and 
phospho-IRF-7 (pS477/pS479; K47-671, BD Biosciences) followed by goat-anti-rabbit-biotine 
(Dako, Glostrup, Denmark) were diluted in 0.5% Saponin and added for 15 minutes. Then, cells 
were stained with streptavidin-PerCP (BD Biosciences) and analyzed by flow cytometry. 
Quantitative PCR for IFN-α genes
Isolated pDC were stimulated for 2 or 4 hours with CpG in the absence or presence of HBV. Cells 
were lysed in Trizol (Sigma-Aldrich) and stored at -80°C until further use. RNA was precipitated 
with 75% ethanol and isolated using RNeasy mini colums (Qiagen, Venlo, The Netherlands). 
cDNA was synthesized with iScript cDNA synthesis kit (BioRad laboratories BV) according to 
manufacturer’s instructions. Real-time PCR was performed with the following primer pairs: 
GAPDH_F 5’-AGG TCG GTG TGA ACG GAT TTG-3’ and GAPDH_R 5’TGT AGA CCA TGT AGT TGA 
GGT CA-3’,  IFN-α2_F 5’-AAT GGC CTT GAC CTT TGC TT-3’ and IFN-α2_R 5’-CAG CTT GAC TTG CAG 
CTG AG-3’, IFN-α8_F 5’-TGG TGC TCA GCT ACA AGT CAT T-3’ and IFN-α8_R 5’-TAC CCA GGC TGT 
GAG TCT GA-3’ under standard conditions (annealing temperature 63°C; 40 cycli; MyIQ iCycler, 
Biorad). Gene expression was calculated using the ΔΔCT method.
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Cytokine production by pDC
IFN-α and TNF-α producing pDC were quantified by incubating the cells during the last 3h 
of 5h cultures with 10 µg/ml Brefeldin A (Sigma-Aldrich, St. Louis, MO). After harvesting, cells 
were stained with anti-BDCA4-PE (Miltenyi) and anti-CD123-biotin (BD Pharmingen, USA). After 
washing with PBS/1% FCS/0,02% NaN3, cells were fixed and permeabilized with Intraprep (Beck-
man Coulter, Miami, Florida, USA) according to the manufacturer’s instructions and stained 
with anti-IFNα-FITC (Kordia, Leiden, The Netherlands), anti-TNF-α-APC (Caltag-Medsystems, 
Buckingham, UK) and streptavidin-PerCP (BD Biosciences). The total amount of cytokines 
produced by purified pDC was determined after 24h of culture. Supernatants were examined 
for the production of TNF-α (eBioscience), IL-6 (Biosource International, Nivelles, Belgium), IL-8 
(Biosource), IP-10 (Invitrogen) and IFN-α (Bender Medsystems, Vienna, Austria) by ELISA. 
REsUlts
HBV does not activate pDC
HBV is a DNA virus that replicates via an RNA intermediate. In theory, HBV may thus be able to 
activate pDC via TLR7 and/or TLR9. To investigate whether HBV is able to activate pDC, PBMC 
were isolated from healthy controls and cultured in the presence of HBV. As a comparison, PBMC 
were also stimulated with known synthetic and viral TLR7 and TLR9 ligands including CpG, Lox, 
HSV-1 and influenza virus. Intracellular IFN-α was investigated in pDC after 5 hr incubation. 
Influenza virus and HSV-1 and CpG and to a lesser extent Lox induced pDC to produce IFN-α. 
In contrast, HBV did not give rise to IFN-α producing pDC (Fig. 1). Similar data were observed 
for TNF-α. 
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fig. 1 HBV does not activate pDC. 
PBMC were cultured in the presence or 
absence of HBV (100 geq/cell), CpG, HSV-
1, Lox or Influenza. After 5h, cells were 
harvested and IFNα and TNF-α producing 
pDC were determined as described in 
Materials and Methods. Similar data 
were observed for purified pDC. Data are 
presented as mean±SEM of 10 independent 
experiments with different donors.
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Though HBV was not able to induce cytokine production by pDC, the virus might be able to 
induce pDC maturation. Whereas viruses like HSV-1 and influenza as well as the synthetic TLR7 
and TLR9 ligands upregulated the expression of CD40, CD80, CD86, and to a minor extent HLA-
DR, HBV only marginally increased the expression of HLA-DR without affecting the expression 
of CD40, CD80 and CD86 (Table 1).
HBV directly interacts with pDC resulting in impaired cytokine production
To determine whether HBV mainly behaves as a stealth virus for pDC, or that it does has an 
active role in the regulation of pDC function, PBMC were activated in the presence or absence 
of HBV. HBV dose-dependently inhibited the CpG-induced IFN-α response by pDC, which could 
be already observed with 0.08 geq/cell (Fig. 2A). Similar data were found for CpG-induced 
TNF-α producing pDC (Fig. 2A). 
The reduced pDC function observed in PBMC cultures exposed to HBV does not mean that 
HBV directly interacts with pDC. Therefore, pDC were purified and exposed to CpG, either in the 
presence or absence of increasing doses of HBV. Again, HBV significantly reduced the capacity 
to produce IFN-α as demonstrated by reduced number of IFN-α producing pDC (Fig. 2B) and 
a reduction in total IFN-α produced (Fig. 2C). Although on a per cell basis more HBV particles 
seemed to be required for significant immune regulatory effects on purified pDC (Fig. 2C), the 
number of HBV genome equivalents per pDC present in pure pDC cultures compared to the 
±0.2% pDC present in total PBMC cultures was even 10-50 times less. 
Nevertheless, the relative inhibition of CpG-induced IFN-α producing pDC was more pro-
nounced when whole PBMC cultures were exposed to HBV. This was not simply due to positive 
selection on BDCA4 as suggested before [20], since negative selection of pDC revealed similar 
results (data not shown). Then whole PBMC were compared with PBMC depleted of monocytes, 
T, B or NK cells, and cultures of purified pDC were compared with purified pDC supplemented 
with CD3+, CD14+, CD19+, or CD56+ cells. These experiments revealed that especially CD14+ 
monocytes influenced CpG-induced IFN-α production.  PBMC depleted of monocytes showed 
table 1 Effect of HBV on pDC maturation
CD40 CD80 CD86 HLA-DR
control HBV control HBV control HBV control HBV
Medium 6.8±1.7 5.0±0.1 23±9 17±6 46±21 35±16 791±385 993±397
HBV 5.0±0.1 ND 17±6 ND 35±16 ND 993±397 ND
CpG 107±15 32±5* 89±25 60±26 122±33 47±20* 911±257 1251±419
HSV 62±21 50±19* 38±13 42±19 72±27 85±42 837±206 1100±425
Lox 44±3 44±5 73±21 89±27 101±21 115±32 1136±226 1368±377
Influenza 154±24 142±19 90±10 89±11 169±25 137±10 780±158 856±174
PBMC were cultured in the presence or absence of HBV (100 geq/cell), CpG, HSV-1, Lox or Influenza. After 24h, cells 
were harvested and the expression of CD40, CD80, CD86 and HLA-DR on pDC was determined by flow cytometry. 
Data are presented as mean±SEM fluorescent intensity of 3 independent experiments with different donors. 
Similar data were observed for purified pDC. ND, not determined; *p<0.05, paired t-test.
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fig. 2 HBV dose-dependenty inhibits production of Ifn-α and tnf-α by pDC. 
(A) PBMC were stimulated with CpG in the presence or absence of increasing doses of HBV. After 5h, cells were har-
vested and the frequency of IFN-α and TNF-α producing pDC were determined. Data are presented as mean±SEM 
of 6 independent experiments with different donors. (B) Purified pDC were stimulated with CpG in the presence 
or absence of 2500 geq/cell HBV for 5h. The frequency of IFN-α producing pDC was determined and expressed as 
mean±SEM of 18 independent experiments with different donors. (C) Purified pDC were cultured with different 
doses of HBV. After 24h, supernatants were harvested and total IFN-α production was determined by ELISA. Data 
are presented as mean±SEM of 16 independent experiments with different donors. *p<0.05, **p<0.01, p<0.001, 
paired t-test. (D) PBMC or PBMC depleted of CD14+ cells were cultured with CpG either in the presence or absence 
of HBV (100 geq/cell) for 5h. Intracellular IFN-α production by pDC was measured by flow cytometry. Data pre-
sented are mean±SEM of 6 independent experiments with different donors. *p<0.05, paired t-test. E: pDC were 
cultured alone or with purified CD14+ cells in a 1:5 ratio and stimulated with CpG in the presence or absence 
of HBV (1000 geq/pDC). Intracellular IFN-α production by pDC was measured by flow cytometry. Shown are the 
percentages IFN-α producing pDC within the BDCA4+CD123+ cells derived from a representative experiment out 
of 3 independent experiments.
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reduced numbers of IFN-α positive pDC (Fig. 2D), whereas the addition of monocytes to puri-
fied pDC cultures enhanced the frequency of IFN-α-producing pDC (Fig. 2E). Moreover, this 
monocyte-mediated IFN-α production by pDC was completely abolished by HBV (Fig. 2E). The 
other cell populations did not significantly contribute to IFN-α production by pDC (data not 
shown). These data demonstrate that HBV inhibits pDC function via a direct effect on pDC that 
can be further enhanced by monocytes.  
HBV inhibits CpG induced pDC maturation and function
Whether HBV also interferes with CpG-induced pDC maturation was examined by analysing the 
expression of co-stimulatory molecules on pDC. CpG resulted in upregulation of CD40, CD80 
and CD86, which was significantly inhibited by HBV (Table 1). To assess whether HBV could 
also interfere with pDC maturation and cytokine production induced by other pDC activating 
stimuli, purified pDC were activated with HSV-1, Lox and influenza virus either with or without 
HBV. As described above, HSV, influenza virus and the synthetic TLR ligands all induced pDC 
maturation albeit to a variable extent. HBV significantly inhibited HSV-induced CD40 expression. 
Most pronounced inhibitory effects of HBV were observed for CpG-induced pDC maturation as 
demonstrated by diminished CD40, CD80 and CD86 upregulation (Table 1). With regard to pDC 
function, HSV-1 and influenza virus induced pDC to produce both IFN-α (Fig. 3A,B) and TNF-α 
(Fig. 3C), whereas Lox mainly induced TNF-α. Except for CpG, HBV did not affect the cytokine 
production induced by these stimuli (Fig. 3). Since HSV-1 can trigger TLR9, but also other innate 
immune receptors, and Lox and influenza are known to trigger TLR7, the inhibitory effect of 
HBV seemed to be restricted to pure TLR9 triggering. 
HBV diminishes IFN-α transcription by inhibiting TLR9-induced phosphorylation of IRF7
It was recently found that TLR9-induced IFN-α production by pDC requires mTOR activation [21] 
resulting in phosphorylation of IRF7 followed by IRF7 translocation to the nucleus and IFN-α 
gene transcription. To assess whether HBV interferes with mTOR-induced IRF7 phosphorylation, 
pDC were stimulated with CpG or Lox or left untreated in the presence or absence of HBV, and 
analysed by intracellular flow cytometry for the presence of phosphorylated S6, a downstream 
target of mTOR [22]. As expected, CpG stimulation of pDC induced phosphorylation of S6 (Fig. 
4A). HBV significantly reduced the CpG-induced phosphorylation of S6, whereas Lox-induced 
S6 phosphorylation was hardly affected (Fig. 4B), which is compatible with the lack of inhibitory 
effects of HBV on Lox-stimulated pDC (Fig. 3). As a consequence, reduced CpG-induced IRF7 
phosphorylation (Fig. 4C) and reduced levels of IFN-α2 and IFN-α8 mRNA were detected by 
quantitative RT-PCR analysis of pDC cultured in the presence of HBV (Fig. 4D). 
HBV inhibits cytokine production and NK cell activation by pDC
Although pDC are known as the main producers of IFN-α, they produce more cytokines involved 
in anti-viral immunity. In addition, pDC are known to promote NK cell activation via pDC/NK cell 
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reciprocal interaction [11]. According to previous studies, stimulation of purified pDC by CpG 
resulted in the induction of TNF-α, IP-10 and IL-6 (Fig. 5A-C), whereas CpG did not affect the 
production of IL-8 (Fig. 5D). HBV significantly inhibited the CpG-induced production of TNF-α, 
as was already demonstrated by intracellular flow cytometry. CpG-induced production of IP-10 
and IL-6 were also inhibited, whereas the production of IL-8 was not significantly affected (Fig. 
5). Addition of pDC to purified NK cells resulted in strong NK cell activation within 48h as dem-
onstrated by the upregulation of CD69, CD25 and the induction of IFN-γ production (Fig. 5E,F; 
data not shown). NK cell activation was even further enhanced when pDC were stimulated with 
CpG as shown by the enhanced CD25 expression and increased IFN-γ production compared to 
non-stimulated cultures (Fig. 5E,F). Although HBV neither affected the pDC-induced upregula-
tion of CD69 nor CD25 on NK cells (Fig. 5E; data not shown), NK cell-derived IFN-γ production 
induced by CpG-activated pDC was significantly decreased (Fig. 5F).   
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A
fig. 3 HBV inhibits CpG-induced pDC 
function.
Purified pDC were cultured in medium 
or CpG, HSV-1, Lox or Influenza virus in 
the presence or absence of HBV (2500 
geq/cell) for 5h (A,C) or 24h (B). IFN-α 
production was determined by intracel-
lular flow cytometry (A) and ELISA (B), 
and TNF-α production was determined 
by flow cytometry (C). Data are ex-
pressed as mean±SEM of 3-10 indepen-
dent experiments with different donors. 
*p<0.05, paired t-test.
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HBsAg binds to pDC and suppresses their function
To unravel if the whole virus is required for HBV-induced modulation of pDC function or that 
also the single HBV proteins influence pDC function, HBsAg, HBcAg, and HBeAg were investi-
gated for their effect on CpG-induced IFN-α production. Dose response studies revealed that 
HBeAg and especially HBsAg, but not HBcAg dose-dependently reduced CpG-induced IFN-α 
production by purified pDC (Fig. 6A). In line, only HBsAg significantly inhibited CpG-induced 
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fig. 4 HBV inhibits s6 phosphorylation and Ifn-α gene transcription. 
(A) PBMC were cultured with CpG in the presence or absence of HBV (100 geq/cell). Cells were harvested and 
analysed for intracellular expression of phosphorylated S6 by flow cytometry. Data show the expression of phos-
phorylated S6 in BDCA4+CD123+ pDC and is representative for 8 independent experiments with different donors. 
Similar data were observed for purified pDC. (B) PBMC were cultured with or without CpG or Lox in the presence 
or absence of HBV (100 geq/cell). Cells were harvested and analysed for intracellular expression of phosphorylated 
S6 by flow cytometry. Data show the mean±SEM expression of phosphorylated S6 in BDCA4+CD123+ pDC in 
MFI from 6 independent experiments with different donors. *p<0.05, Wilcoxon signed rank test. (C) PBMC were 
cultured with CpG in the presence or absence of HBV (100 geq/cell) for 3h. Cells were harvested and analysed for 
intracellular expression of phosphorylated IRF7 by flow cytometry. Data present the mean±SEM percentage of 
cells positive for phosphorylated IRF7 in BDCA4+CD123+ pDC from 5 independent experiments with different 
donors. Similar data were observed with purified pDC. (D) Purified pDC were cultured with CpG in the presence or 
absence of HBV (2000 geq/cell) for 2 or 4h. Cells were harvested and IFN-α2 and IFN-α8 mRNA were determined as 
described in Material and Methods. Data are representative for 3 independent experiments with different donors.
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fig. 5 HBV inhibits cytokine production and pDC-induced nK cell activation. 
(A, B, C, D) Purified pDC were cultured with CpG in the presence or absence HBV (2000 geq/cell) for 24h. 
Supernatants were analysed for the presence of TNF-α (A), IP-10 (B), IL-6 (C) and IL-8 (D) by ELISA. Data demonstrate 
mean±SEM of 8 independent experiments with different donors. (E,F) PDC were cultured with NK cells either in the 
presence of CpG and/or HBV as described in Materials and Methods. After 48h, NK cell activation was determined 
by analyzing CD25 expression on CD56+ cells by flow cytometry (E) and NK cell function was determined by ana-
lyzing IFN-γ in culture supernatants by ELISA (F). Data show the mean±SEM of 7 independent experiments with 
different donors. *p<0.05, Wilcoxon signed rank test.
97HBV inhibits pDC function
phosphorylations of S6 (Fig. 6B) and IRF-7 (data not shown). Like HBV, HBsAg did not inhibit 
Lox-induced cytokine production by pDC (data not shown). 
Since HBsAg and HBV display similar immune regulatory effects on pDC with regard to TLR7- 
and TLR9-induced functional alterations and intracellular signalling, the interaction between 
HBsAg and pDC was studied in more detail. The lack of major interference with Lox-induced S6 
phosphorylation is in line with the limited effects of HBV/HBsAg on Lox-mediated pDC func-
tion compared to CpG and suggests that HBV/HBsAg especially interacts with pDC upon TLR9 
stimulation. Therefore, cells were cultured under standard conditions with or without CpG or 
Lox either in the presence or absence of HBsAg for 4h. In addition, cells were stimulated with 
CpG and Lox for 2h at 37°C, then cells put on ice and HBsAg was added. Subsequently, pDC 
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fig. 6 Especially HBsag inhibits pDC function. 
(A) Purified pDC were cultured with CpG in the presence or absence of increasing doses of HBcAg, HBeAg or HBsAg 
for 24h. Supernatants were harvested and analysed for IFN-α by ELISA. Data presented are mean±SEM of at least 
8 independent experiments with different donors. (B) PDC were cultured with or without CpG in the presence 
or absence of 5 µg/ml HBcAg, HBeAg, or HBsAg. Cells were harvested and analysed for intracellular expression 
of phosphorylated S6 by flow cytometry. Data are representative for 3 independent experiments with different 
donors. Open/thin histogram: non-stimulated pDC; open/thick: pDC+CpG; Filled: pDC+CpG+viral protein. (C) PDC 
were cultured with or without Lox or CpG and with or without HBsAg. After 4h, cells were harvested and surface 
bound HBsAg was detected by flow cytometry.
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surface binding of HBsAg was determined. In both types of experiments, a very low binding 
of HBsAg was observed in cultures with medium alone or Lox, whereas pDC stimulated with 
CpG strongly bound the HBV envelope protein (Fig. 6C). The preferential binding of HBsAg to 
CpG-stimulated pDC explains the ability of the virus to interfere especially with CpG-induced 
pDC function. Similar to the effect of the whole virus, HBsAg inhibited CpG-induced TNF-α (Fig. 
7A), IP-10 (Fig. 7B) and IL-6 (Fig. 7C) production without significantly altering the production 
of IL-8 (Fig. 7D). HBeAg also reduced TNF-α production, but did not significantly influence the 
secretion of the other cytokines. HBcAg did not modulate pDC function (Fig. 7). Of note, neither 
HBV nor its viral proteins reduced pDC viability as determined by flow cytometric analysis of 
intracellular active caspase-3 as well as the binding of Annexin-V and 7AAD (data not shown). 
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fig. 7 HBeag and especially HBsag inhibit cytokine production by pDC. 
Purified pDC were cultured with CpG in the presence or absence of 5 μg/ml HBcAg, HBeAg or HBsAg for 24h. 
Supernatants were harvested and analysed for TNF-α (A), IP-10 (B), IL-6 (C), and IL-8 (D) by ELISA. Data presented are 
mean±SD of duplicates representative for at least 6 independent experiments with different donors.
99HBV inhibits pDC function
DIsCUssIon
PDC play a central role in anti-viral immunity due to their rapid and profound release of type I IFN 
upon viral recognition. An initial type I IFN response directly after infection with HBV is seemingly 
lacking and patients chronically infected with HBV show functional deficits in pDC with regard 
to IFN-α production [4,5,12]. The present study demonstrates that HBV does not activate pDC as 
assessed by cytokine production and upregulation of co-stimulatory molecules. Moreover, HBV 
actively interfered with TLR9-induced pDC function, resulting in a dose-dependent inhibition 
of cytokine production and pDC maturation. HBsAg, and to a limited extent HBeAg, which were 
used in concentrations found in hepatitis B patients’ circulation [18], showed similar immune 
regulatory effects as HBV thereby demonstrating that the immune regulatory effects of HBV do 
not require active infection.
PDC respond to viruses primarily through the recognition of pathogen-associated molecu-
lar patterns including TLR9, which recognizes viral DNA [8,9]. Two factors seem to be key for 
the induction of large quantities of type I IFN in pDC: (a) the ability of the TLR ligand to bind 
its receptor in the early endosomal compartments [23,24] and (b) the phosphorylation and 
nuclear translocation of IRF7 [25]. HBV DNA is present in peripheral blood pDC isolations 
[17,26], but no evidence exists for HBV infection and viral replication in pDC. The lack of IFN-α 
production upon exposure to HBV could be due to the fact that HBV is not taken up by pDC 
and is therefore not able to reach TLR9. Here we showed that, although limited, HBsAg is able 
to bind to non-stimulated pDC. However, whether pDC are able to internalize HBV particles 
remains to be elucidated. Another explanation for the absent IFN-α induction is the active 
suppression of IFN-α production as was observed for CpG-induced type I IFN. The exposure 
to HBV not only lead to decreased pDC function, but also resulted in diminished pDC-induced 
NK cell function. The impaired crosstalk between different immune cells may partially explain 
the failing induction of effective anti-viral immunity. Whether the impaired DC-NK cell crosstalk 
could explain the defective IFN-γ production by NK cells circulating in patients with chronic 
hepatitis B [27] remains unknown. It was recently found that TLR9-induced IFN-α production 
by pDC requires mTOR activation [21]. How exactly mTOR regulates the production of type I 
IFN is not known, but one of the models proposed is mTOR-induced phosphorylation of S6K 
that promotes formation of the TLR9-MyD88 complex. As observed for HBV, pharmacological 
inhibition of mTOR by rapamycin reduced the production of CpG-induced IFN-α, TNF-α and IL-6 
(data not shown) [21]. Here, we demonstrated that HBV reduced the phosphorylation of S6, 
which was paralleled by reduced IRF7 phosphorylation and diminished IFN-α gene transcrip-
tion. The inhibitory effect of HBsAg was completely overlapping with HBV, as demonstrated by 
inhibition of S6 and IRF7 phosphorylation and production of IFN-α, TNF-α, IL-6 and IP-10, and 
was much stronger than the regulatory effect of HBeAg. At what level HBV and HBsAg interfere 
with mTOR-induced S6 phosphorylation remains to be elucidated. 
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The differential effects of HBsAg and HBeAg with regard to intracellular signalling and 
cytokine production, could be explained by the use of different receptors. Several putative 
binding factors have been described for HBsAg, such as human serum albumin, asialoglycopro-
tein receptor, and heparin, but their exact role in HBV attachment remains unclear [28]. Since 
HBV surface antigens are glycoproteins, the involvement of a C-type lectin receptor at the DC 
surface in viral recognition and blockade of TLR9-induced IFN-α production seems plausible. 
Crosslinking of the pDC-specific C-type lectin DCIR resulted in a specific TLR9, but not TLR7-
mediated inhibition of TNF-α and IFN-α [29], which is compatible to the immune modulatory 
effects observed for HBV. Simultaneous reduction in IFN-α, TNF-α and IL-6 production, as shown 
here for HBV, has also been reported for crosslinking the pDC-specific C-type lectin ILT7-FcεRIγ 
[30]. Several other viruses have been shown to block TLR9-induced pDC activation and func-
tion, but not TLR7-mediated activation, including HIV [31,32] and HCV [33,34], which may 
crosslink similar cell surface receptors as HBV. Whether also these viruses preferentially bind to 
TLR9-activated pDC compared to TLR7-activated pDC, as we found for HBV is not documented. 
Concerning HBV, the increased binding of HBsAg to CpG-stimulated pDC suggests the 
involvement of a factor, either membrane bound or soluble, that is strongly induced by TLR9 
triggering. The binding of HBV to BDCA-2 [35,36] to explain the inhibitory effect of HBV on 
pDC function seems therefore not very likely. BDCA-2 is highly expressed on non-stimulated 
pDC and is downregulated upon stimulation with CpG (data not shown). Furthermore, BDCA-2 
crosslinking is known to inhibit HSV and CpG-induced pDC function to a similar extent and in 
our hands crosslinking of BDCA-2 did not inhibit S6 phosphorylation (data not shown).   
The finding that HBV DNA is present in peripheral blood pDC isolates of a subgroup of 
chronic HBV patients [13,17] and the impaired pDC function in chronic HBV patients reported 
by several independent investigators, but challenged by others (reviewed in Woltman et al. 
[12]), might be explained by the molecular interaction between HBV/HBsAg and/or HBeAg and 
pDC combined with patient diversity. Host factors and disease state may influence the rate of 
interaction between HBV virions and/or subviral particles and pDC that could range between a 
rather weak interaction in case of non-stimulated pDC and a strong interaction with pDC under 
specific conditions.
The immune regulatory effect of both virions and viral proteins may partially explain the 
impaired cytokine production by pDC derived from patients chronically infected with HBV [12]. 
Not HBV DNA reduction alone, but especially loss of serum HBeAg during successful treatment 
of patients with potent anti-viral drugs was suggested to be responsible for partial restoration 
of circulating pDC numbers and the impaired IFN-α production by pDC [14,26]. These findings 
could be ascribed to the possible immune regulatory effect of HBeAg, as has been suggested 
before [37]. Furthermore, although HBV DNA levels decreased upon treatment with these anti-
viral drugs, serum HBsAg levels were not reported and could have been of influence on pDC 
function, as demonstrated in the present study. 
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The supportive effect of monocytes in regulating pDC function upon interaction with HBV 
has also been reported for HCV [38]. In contrast to HCV, we could not detect HBV-induced TNF-α 
or IL-10 in monocyte cultures and HBV-induced regulatory effects could not be overcome by 
IL-10 neutralization (data not shown). Interaction between HBV/HBsAg and monocytes have 
been reported [39], but so far the mechanism underlying monocyte-mediated regulation of 
pDC function is not known. 
Since a considerable number of patients chronically infected with HBV do not demonstrate 
an adequate response towards the virus upon treatment with the standard immune modula-
tory therapy, i.e. pegylated-IFN-α [40], novel anti-viral strategies are needed. For the treatment 
of chronic HCV, promising results were obtained with the TLR9 agonist CpG10101 [41]. The 
finding that HBV strongly interacts with CpG-activated cells may disrupt the anti-viral effects of 
such immune stimulating agents. Therefore, the data presented in the current study could be 
very useful for the design of novel immune modulatory strategies for the treatment of chronic 
HBV.
In conclusion, HBV does not activate, but actively interferes with S6K-induced pDC func-
tion. The data presented here provide new insight into the mechanism by which HBV is able 
to evade anti-viral immunity and may aid in the development of effective immunomodulatory 
therapies to clear the viral infection. 
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aBstRaCt
Toll-like receptor (TLR) triggering of plasmacytoid dendritic cells (pDC) is a key step in defense 
against viral infections, leading to the mass production of the anti-viral cytokine interferon-α 
(IFN-α). However, acute infection with Hepatitis B virus (HBV) fails to induce a strong anti-viral 
IFN-α response and pDC of chronic HBV patients have been shown to produce less IFN-α com-
pared to healthy controls. To investigate whether PEG-IFN therapy could restore the impaired 
pDC activation in chronic HBV patients, the effect of PEG-IFN treatment on TLR7/9-induced pDC 
function was examined in vitro and in vivo. 
Before start of PEG-IFN therapy, in vitro presence of IFN-α in pDC cultures increased the 
TLR9- and TLR7-induced IFN-α production, which could be blocked by neutralization of the 
IFN-α receptor. PEG-IFN therapy augmented TLR7 mRNA levels in pDC leading to increased 
IFN-α response after TLR7 triggering, while TLR9 mRNA levels were 2-fold reduced which 
diminished response to TLR9 triggering. Additionally, pDC became insensitive to the presence 
of PEG-IFN during culture. Both effects on TLR7/9 triggering and IFN-α sensitivity reversed to 
baseline levels at 24 weeks post PEG-IFN treatment. Similar data were obtained with isolated 
pDC, indicating that PEG-IFN therapy directly influences pDC function. No difference between 
reponders and non-responders to PEG-IFN-α therapy was observed. Thus, response to TLR7 and 
TLR9 specific ligands is differentially regulated during PEG-IFN therapy by a direct effect on 
TLR7 and TLR9 expression levels. This effect is directly caused by PEG-IFN therapy and could not 
be attributed to change in serum HBV load. 
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IntRoDUCtIon
Worldwide, more than 400 million people are chronically infected with Hepatitis B virus (HBV) 
[1]. Although risk factors such as age and route of infection for developing chronic HBV infec-
tion after acute exposure have been described, the exact mechanism by which HBV escapes 
immunity is still not known [2,3]. Characteristic of patients with chronic HBV infections is the 
ineffective anti-viral immune response towards the virus [4]. 
Plasmacytoid dendritic cells (pDC) are key players in anti-viral defense, due to their 
capability of mass production of the anti-viral cytokine interferon-α (IFN-α) upon viral infection 
[5,6]. Detection of viral genetic material and/or viral replication intermediates occurs trough 
intracellular immune receptors, including Toll-like receptors (TLR). These TLR reside in the 
endosomal compartments, where single-stranded RNA triggers TLR7 and double-stranded 
DNA containing CpG motifs triggers TLR9 [7]. Both TLR7 and TLR9 triggering of pDC lead to 
the secretion of excessive amounts of IFN-α and also other pro-inflammatory cytokines [8,9]. 
Next to a strong direct anti-viral effect, IFN-α activates macrophages, natural killer cells and T 
lymphocytes allowing further priming of anti-viral immunity [5].
A hampered IFN-α response during HBV infection could contribute to development of a 
chronic infection. In contrast to acute infection with other viruses such as Hepatitis C and Human 
Immunodeficiency Virus, chimpanzees which are acutely infected with HBV completely lack 
an initial type I IFN (IFN-α/β) response [10,11]. A recent study showed that type I IFN response 
in a rare cohort of acute HBV patients is also lacking [12]. In addition, several studies showed 
impaired pDC function from chronic HBV patients after stimulation with SAC [13], HSV [14], or 
CpG [15-17] as compared to healthy controls. This defective IFN-α production could be related 
to the observed reduction in TLR9 expression levels in pDC of chronic HBV patients [17]. Serum 
HBV load reduction by anti-viral therapy resulted in restoration of pDC numbers and function 
to near normal levels in some, but not all, patients [14]. Another study showed a slight increase 
in circulating pDC numbers, without improvement of pDC function upon therapy-induced viral 
load reduction [18]. This lack of pDC immune response restitution might be a clue why current 
anti-viral replication therapies do not lead to sustained viral eradication. The compromised IFN-α 
response of chronic HBV patients might explain the initial susceptibility to PEG-IFN therapy. 
Since PEG-IFN is an immune modelatory therapy, it might enhance the impaired pDC function of 
chronic HBV patients. Unfortunately, side effects such as flu-like symptoms, cytopenia and psy-
chiatric adverse events are frequently observed during PEG-IFN therapy [19]. Combined with the 
fact that sustained response after treatment discontinuation is only achieved in approximately 
30% of patients, it would be beneficial if response or non-response to therapy could be predicted 
at an early stage [19]. Here we investigated the effect of PEG-IFN therapy on pDC phenotype and 
function, in vitro and in vivo. Both unfractionated PBMC and purified pDC were used to distinguish 
between direct and indirect effects on pDC function. Furthermore, we investigated whether the 
PEG-IFN therapy-induced change in pDC function could predict the clinical response to therapy.
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matERIals anD mEtHoDs
Patients
Patient characteristics of 21 chronic HBV patients who underwent therapy with pegylated 
interferon-alpha 2a (PEG-IFN; 100 µg weekly) are given in Table 1. Serum HBV load and alanine 
aminotransferase levels (ALT) were determined at indicated time points as part of the patient’s 
diagnostic evaluation. Heparinized peripheral blood samples were obtained at baseline and 
after 12, 24, 36, 48 weeks of therapy from patient 1-12 and after 4, 12 and 48 weeks from 
patients 13-21. A follow up sample was obtained 24 weeks after treatment, from patients that 
were not receiving anti-viral therapy at that moment. Patients 1-9, who were recruited from the 
multicenter PARC study, were enrolled in the Erasmus MC and received PEG-IFN monotherapy. 
All participants gave informed consent before inclusion. 
table 1 Patient characteristics
Patient # Age 
(yr)
Sex HBV 
Genotype
Viral load
(geq/ml)
ALT
(U/l)
HBeAg Response to therapy
1 34 m D 8,95E+04 76 E- Marked
2 31 m D 9,53E+06 443 E- Marked
3 52 m A 4,53E+05 63 E- Marked
4 36 m D 3,55E+07 99 E- Poor
5 30 f E 3,78E+07 109 E- Poor
6 47 m D 7,27E+03 183 E- PoorA
7 35 f D 4,28E+04 47 E- Marked
8 35 m D 1,84E+06 61 E- Marked
9 34 m D 8,88E+07 427 E- Marked
10 42 m A 1,03E+10 96 E+ PoorB
11 37 m A 2,10E+09 92 E+ Poor
12 41 m A 2,40E+09 113 E+ Sustained
13 42 m A/G 1,12E+10 196 E+ Marked
14 27 m C 1,87E+07 186 E- Poor
15 19 m C 3,43E+04 32 E+ Marked
16 32 m D 5,38E+08 123 E- Marked
17 58 m A 6,50E+06 88 E- PoorC
18 49 m A 1,21E+06 38 E- Marked
19 43 m D 5,02E+08 136 E- Marked
20 57 m D 6,53E+07 129 E- Marked
21 17 f C 7,42E+08 106 E+ Poor
Poor: <3log10 HBV copies/ml decline in viral load; Marked: >3log10 HBV copies /ml decline in viral load; Sustained: 
<3log10 HBV copies/ml at EOF
A Switched to adefovir after 12 weeks
B Switched to adefovir after 48 weeks
C Switched to entecavir after 12 weeks
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Isolation of pDC from peripheral blood of chronic HBV patients
Peripheral blood mononuclear cells (PBMC) were isolated from blood samples using Ficoll-
Isopaque gradient centrifugation. PDC (BDCA4+) were isolated from PBMC by negative 
depletion with anti-CD19-conjugated microbeads, followed by positive selection using anti-
BDCA4-PE and anti-PE-conjugated microbeads using the mini-MACS system (Miltenyi Biotec, 
Bergisch Gladbach, Germany). The purity and viability of the isolated pDC were determined 
by flow cytometry (FACScalibur, Becton, Dickinson and Company (BD), Franklin Lakes, NJ) by 
staining for BDCA4, BDCA2 and 7AAD (eBioscience, San Diego, CA). Isolated pDC were cultured 
at 37°C in DC medium consisting of RPMI 1640 (Bio Whittaker, Verviers, Belgium) containing 
10% FCS (Hyclone, Logan, UT), penicillin (50 IU/ml) and streptomycin (50 µg/ml; Invitrogen Ltd, 
Paisley, UK). 
Effect of IFN-α on pDC phenotype
Isolated pDC (≥1x10E4 pDC/200 µl) were cultured in round bottom 96-wells plates for 22 or 44 
hr with IL-3 (10 ng/ml; Strathmann Gmbh & Co, Hamburg, Germany) in the presence or absence 
of 40U/ml IFN-α (Schering-Plough Corporation, Kenilworth, NJ). PBMC (1x10E6/500µl) were cul-
tured under similar conditions in flat bottom 24-wells plates. Cells were stained for anti-BDCA4 
(Miltenyi), anti-CD123 (BD), anti-CD40 (BD), anti-CD80 (Beckman Coulter, Brea, CA), anti-CD86 
(BD), and anti-HLA-DR (BD) and expression levels were determined by flow cytometry. Total 
and absolute pDC numbers were determined by white blood cell count and flow cytometry 
after whole blood staining with fluorescein-conjugated anti-CD45 (Beckman), anti-BDCA4, 
anti-CD11c (BD) antibodies.
IFN-α production by pDC
Isolated pDC (≥5x10E3 pDC/200 µl) or PBMC (1x10E6/200µl) were cultured in round bottom 
96-wells plates. Cells were stimulated with LPS (negative control; 10 ng/ml) (Sigma- Aldrich, St. 
Louis, MO), CpG-A, CpG-B or CpG-C (TLR9; 10 µg/ml; Coley Pharmaceutical, Ottawa, Canada); 
loxoribin (Lox; TLR7; 400 µM; Invivogen, San Diego, CA); HSV-1 (moi 10; kind gift of Dr. G.M.G.M. 
Verjans); influenza virus (moi 0,2; kind gift of Dr. G.F. Rimmelzwaan) with or without 40U/ml IFN-
α. During the last 3 hr of culture brefeldin (10 µg/ml; Sigma-Aldrich) was present. Timecourse 
experiments with stimulation times varying from 3 to 24 hr indicated the highest IFN-α produc-
tion after 5 hr, therefore cells were stimulated for 5 hr in all IFN-α production assays. Intracellular 
IFN-α and TNF-α production was determined by flow cytometry, after blocking with PBS/0,1% 
BSA/0.5% humane serum, followed by (intra)cellular staining (Intraprep; Beckman Coulter) 
with anti-BDCA4-PE, anti-CD123-biotine, anti-streptavidine-PerCP (BD), anti-IFN-α-FITC (PBL 
Interferon Source, Piscataway, NJ ) and anti-TNF-α-APC (Invitrogen). Neutralization assays were 
performed with anti-type I IFN receptor (IFNAR; 10 µg/ml; PBL Interferon Source) or isotype 
control antibodies (10 µg/ml).
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RNA isolation and realtime PCR
PDC were lysed in Trizol (Sigma-Aldrich) and stored at -80°C until further use. RNA was precipitated 
with 75% ethanol and isolated using Micro RNAeasy silica columns (Qiagen, Venlo, The Netherlands). 
cDNA was prepared using AMV reverse transcriptase according to the manufacturer’s protocol 
(Promega, Madison, WI). Real-time PCR was performed for 40 cycles (LightCycler,  Roche Applied 
Science, Indianapolis, IN) with primers specific for TLR7 (F: 5’- CCAGTGTCTAAAGAACCTGGA -3’; R: 
5’ GGGACAGTGGTCAGTTGGTT -3’), TLR9 (F: 5’- CTGCCCAAATCCCTCATATC -3’; R: 5’- TGCAGAGTC-
TAGCATCAGG -3’) combined with a FAM-labelled probe (probe 30; Universal ProbeLibrary, Roche 
Applied Science) and reference gene Abl (F: 5’- TGGAGATAACACTCTAAGCATAACTAAAGGT -3’; R: 
5’ GATGTAGTTGCTTGGGACCCA -3’) combined with a FAM-labelled probe (Applied Biosystems, 
Foster City, CA). Gene expression was calculated using the ΔΔCT method [20].
REsUlts
IFN-α treatment slightly affects pDC phenotype in vitro
Short-term (24 hr) culture of isolated pDC of untreated chronic HBV patients in IL-3 alone induced 
pDC maturation, as shown by upregulation of HLA-DR and co-stimulatory molecules CD40, CD80 
and CD86 (Fig. 1). Exposure to IFN-α slightly interfered with pDC maturation by inhibiting the 
upregulation of HLA-DR, CD80 and CD86, whereas the expression of CD40 was slightly enhanced. 
Prolonged (44 hr) exposure to IFN-α showed similar effects on the expression of HLA-DR and 
CD40, but CD80 and CD86 expression ceased to differ from cells cultured in the absence of IFN-α. 
Similar results were obtained for pDC in cultures of unfractionated PBMC (data not shown).
IFN-α treatment improves pDC function in vitro
Using isolated pDC of untreated chronic HBV patients, TLR7 triggering by Lox and TLR9 trig-
gering by CpG-A resulted in 7±2% (mean±SEM) and 21±5% IFN-α positive pDC, respectively 
(Fig. 2A). Exposure to IFN-α during culture 2-fold increased the TLR7- and TLR9-induced IFN-α 
production. TLR7 and TLR9 triggering induced equal amounts of TNF-α producing pDC, which 
also increased in presence of IFN-α.
Stimulation of PBMC led to higher levels of IFN-α and TNF-α producing pDC, compared to 
isolated pDC (Fig. 2A). TLR9 triggering was studied in more detail by comparing responses to 
CpG-A, CpG-B and CpG-C. As expected, very little IFN-α was produced upon CpG-B stimulation, 
while CpG-C induced an intermediate number of IFN-α producing pDC. The presence of 
IFN-α significantly increased the number of IFN-α and TNF-α producing pDC with all stimuli. 
Neutralization of the IFN-α receptor on the cell surface of isolated pDC abolished the stimulatory 
effect of exposure to IFN-α during TLR9 triggering (Fig. 2B). IFN-α receptor neutralization lead 
to even less IFN-α production after CpG stimulation compared to control, suggesting that the 
IFN-α positive feedback loop is involved in CpG-A-induced IFN-α production. 
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Clinical outcome of PEG-IFN treatment of chronic HBV patients
To investigate whether the stimulatory effect of IFN-α with respect to the cytokine production 
could be found in vivo and whether these IFN-induced pDC alterations in vivo could be linked to 
clinical response to treatment, pDC phenotype and function were examined of chronic patients 
during PEG-IFN therapy. PEG-IFN therapy induced a more than 3log decline in serum HBV load 
in 13 out of 21 patients (62% responders). 24 weeks after treatment discontinuation serum 
HBV load remained below 1000 copies per ml in two of these 13 responders (Fig. 3A). One 
of these patients showed loss of serum HBsAg during therapy and is considered a sustained 
responder. In the other eight out of 21 patients no or only a poor decline in viral load was 
observed (38% non-responders). Three of these patients converted to anti-viral therapy with 
nucleotide reverse transcriptase inhibitors and were excluded from this study upon switch of 
therapy. ALT levels normalized during PEG-IFN therapy in both responder and non-responder 
groups. Five patients showed a raise in serum ALT levels off-treatment (Fig. 3B). 
IFN-α therapy affects numbers, phenotype and function of pDC in blood of chronic HBV patients
Chronic HBV patients receiving PEG-IFN therapy showed a marked reduction in circulating 
pDC numbers in peripheral blood, independent of the clinical outcome of therapy. In a com-
bined analyses of responders and non-responders, circulating pDC numbers declined from 
6405±1172 (mean±SEM) pDC/ml at baseline to 2740±635 pDC/ml after 12 weeks of treatment 
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fig. 1 Ifn-α affects pDC phenotype in vitro. 
Purified pDC obtained from blood of chronic HBV patients were cultured for 22 or 44 hr with IL-3 in the presence 
or absence of IFN-α. Surface expression of HLA-DR, CD40, CD80 and CD86 on CD123+BDCA4+ pDC was measured 
by flow cytometry directly after isolation and after culture. Data represent mean±SD of three independent experi-
ments with pDC of different donors.
112
C
ha
p
te
r 
7
(p=0.012). Similarly, the percentage of pDC in the CD45+ cell fraction decreased during PEG-IFN 
treatment in both responder and non-responder groups (Fig. 4A). After 24 weeks post PEG-IFN 
treatment, pDC numbers and percentages reversed to baseline levels.
Phenotypic analysis indicated that PEG-IFN therapy induced pDC activation, as shown by 
a significant increase in CD86 expression in the responder group during the first 12 weeks of 
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fig. 2 In vitro exposure to Ifn-α increased tlR7- and tlR9-induced cytokine production of pDC. 
(A) Cells were stimulated for 5 hr with LPS, CpG-A, CpG-B or CpG-C or Lox with or without IFN-α. Intracellular IFN-α 
and TNF-α were determined by flow cytometric analysis of CD123+BDCA4+ pDC present in either purified pDC 
(N=8) or unfractionated PBMC (N=9). (B) PBMC were CpG-stimulated with or without IFN-α in the presence of an 
IgG control or a type I IFN receptor (IFNAR) neutralizing antibody (N=5). Data was analyzed using the paired T test; 
NS non significant, * p<0.05, ** p<0.01, *** p<0.001.
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treatment (Fig. 4B: responders: 0 vs 12 weeks p=0.034). Although not significant, also pDC of 
non-responders expressed higher levels of CD86 (p=0.07). HLA-DR expression levels did not 
significantly differ during treatment compared to baseline in responders and non-responders. 
CD80 and CD40 could not be detected on circulating pDC before or during therapy (data not 
shown). Interestingly, PEG-IFN therapy had a drastic effect on pDC function. IFN-α production 
after TLR9 triggering diminished in both responder and non-responder groups, while response 
to TLR7 triggering highly increased during PEG-IFN therapy (Fig. 4C). These effects reversed 
to baseline levels 24 weeks post therapy and were not related to clinical outcome. Since all 
observed effects on pDC frequency, phenotype and function correlated only with PEG-IFN 
therapy and not with viral load or ALT levels, responders and non-responders were combined 
to study the effect of PEG-IFN therapy in more detail.  
Differential response to TLR7 and TLR9 stimulation of pDC of chronic HBV patients on PEG-IFN therapy
Combining data from responders and non-responders, TLR7-induced IFN-α production by pDC 
increased 5-fold during PEG-IFN therapy as compared to baseline (Fig. 5A). In contrast to the 
stimulatory effect of IFN-α on TLR9-induced cytokine production by pDC exposed to IFN-α 
in vitro, exposure to IFN-α in vivo (during PEG-IFN therapy) resulted in a 3-fold reduction in 
TLR9-induced IFN-α production (Fig. 5B). In contrast to the additive effect of IFN-α in cultures 
prior to treatment, supplementary in vitro exposure to IFN-α during PEG-IFN therapy did not 
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fig. 3 Clinical outcome of PEG-Ifn treatment of chronic HBV patients.
(A) Serum HBV-DNA levels and (B) serum ALT levels of responders (N=13) and non-responders (N=8) during 48 wk 
of PEG-IFN therapy.  Indicated timepoints are baseline (wk 0), on therapy (wk 12, 24, 36), end of therapy (wk 48) 
and end of follow up (wk 72).
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enhance pDC function. Both effects on TLR7/9 triggering and on sensitivity to supplementary 
IFN-α reversed to baseline levels at 24 weeks post PEG-IFN treatment. PEG-IFN therapy had no 
significant effect on IFN-α production upon stimulation with HSV or influenza virus after four 
weeks (data not shown) or any other timepoint measured (Fig. 5C). 
PEG-IFN therapy downregulates both TLR9-induced IFN-α and TNF-α production of pDC of chronic HBV 
patients
Response to TLR9 triggering was studied in more detail in a subset of patients during the 
first 12 weeks of PEG-IFN therapy. IFN-α production upon CpG-A, CpG-B and CpG-C stimulus 
diminished already after four weeks, as did the sensitivity to immune stimulation by IFN-α 
culture (Fig. 6A). PEG-IFN therapy also reduced the CpG-induced production of TNF-α, which 
was already visible after 4 weeks for CpG-A and after 12 weeks for CpG-B and CpG-C stimulation 
(Fig. 6B). Also in these experiments pDC lost sensitivity to the presence of IFN-α during culture 
already after 4 weeks of therapy. PEG-IFN therapy thus interferes with TLR9 response to all three 
classes of CpG, either directly or via an effect on other cell types within the unfractionated 
PBMC. 
PEG-IFN therapy directly interferes with pDC function
To investigate whether PEG-IFN therapy directly affects pDC function, TLR7 and TLR9 triggering 
of pDC of chronic HBV patients prior to and during therapy was performed with purified pDC. 
Upon PEG-IFN therapy, purified pDC showed exactly similar responses to TLR7 and TLR9 stimuli 
as pDC present within PBMC. IFN-α and TNF-α production after TLR9 stimulation by CpG was 
lost during therapy, as was the sensitivity to the immune stimulating effects of supplementary 
IFN-α (Fig. 7A). TLR7 stimulation of pDC obtained from HBV patients on therapy led to three 
times more IFN-α producing pDC after 4 weeks and two times more after 12 weeks, compared 
to cells obtained at baseline. TNF-α was produced in unaffected high levels after TLR7 stimula-
tion. All effects were reversed at 24 weeks post PEG-IFN therapy (data not shown).
PEG-IFN therapy causes differential regulation of TLR7 and TLR9 mRNA levels of pDC
To unravel the mechanism underlying the differential response to TLR7 and TLR9 triggering during 
therapy, the mRNA expression levels of TLR7 and TLR9 were investigated. In line with the functional 
data, RT-PCR analysis of purified pDC showed that PEG-IFN therapy significantly reduced TLR9 
mRNA levels (Fig. 8). TLR7 mRNA levels in pDC were 1.3-fold augmented after 4 weeks of therapy, 
this increase normalized in half of the patients after 12 weeks, which was compatible with the 
Lox-triggered IFN-α production at 4 and 12 weeks of treatment. Although inter-individual changes 
exist regarding the regulation of TLR7 and TLR9 mRNA levels, no difference was found between 
responders and non-responders to PEG-IFN therapy. These results indicate a direct effect of PEG-
IFN therapy on pDC function through differential regulation of TLR7 and TLR9 expression levels.
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fig. 4 PEG-Ifn therapy affects numbers, phenotype and function of pDC in blood of chronic HBV patients. 
(A) Total and relative pDC numbers in whole blood samples of chronic HBV patients on PEG-IFN therapy determined 
by white blood cell count and flow cytometry. (B) Surface expression of HLA-DR and CD86 on CD123+BDCA4+ 
pDC of chronic HBV patients on PEG-IFN therapy. Values were normalized by subtraction of the MFI of the IgG 
control staining. (C) Number of IFN-α producing pDC after TLR9-triggering (CpG-A) and TLR7-triggering (Lox) ob-
tained from blood of chronic HBV patients on PEG-IFN therapy. Data represent mean±SEM. Responders: N=7; non-
responders: N=5 before therapy, N=4 at end of therapy (wk 48) and N=3 at end of follow up (wk 72).
116
C
ha
p
te
r 
7
0 12 24 36 48 72 0 12 24 36 48 72
0
10
20
30
40
50
Lox + IFNαLox
w eeks
PEG-IFN-α therapy
End of follow up
Baseline
IF
N
- α
 p
os
 p
D
C
 (
%
)
0 12 24 36 48 72 0 12 24 36 48 72
0
20
40
60
80
InfluenzaHSV
w eeks
IF
N
- α
 p
os
 p
D
C
 (
%
)
Op den Brouw et al. Chapter 7 Figure 5
A
B
C
0 12 24 36 48 72 0 12 24 36 48 72
0
20
40
60
80
CpG A + IFNαCpG A
w eeks
IF
N
- α
 p
os
 p
D
C
 (
%
)
A
B
C
fig. 5 Ifn-α production after tlR7 and tlR9 stimulation of pDC of chronic HBV patients on PEG-Ifn therapy.
PBMC obtained from PEG-IFN treated chronic HBV patients were stimulated for 5 hr in the presence or absence 
of IFN-α and produced IFN-α was determined by flow cytometric analysis of CD123+BDCA4+ pDC. (A) Number of 
IFN-α producing pDC after Lox stimulation (N=12, wk 0 vs wk 12: p=0.0019). (B) Number of IFN-α producing pDC 
after CpG stimulation (N=17, wk 0 vs wk 12: p=0.0007). (C) Number of IFN-α producing pDC after stimulation with 
HSV-1 and influenza virus (N=12). Data represent mean±SEM and samples were analyzed using the paired T test.
117PEG-IFN alters pDC function
0 4 12 0 4 12 0 4 12 0 4 12 0 4 12 0 4 12
0
20
40
60
80
100
medium IFN-α medium IFN-α medium IFN-α
CpG-A CpG-B CpG-C
w eeks
TN
F-
α 
po
s 
pD
C
 (
%
)
Op den Brouw et al. Chapter 7 Figure 6
0
20
40
60
80
100 Baseline
PEG-IFN-α therapy
IF
N
- α
 p
os
 p
D
C
 (
%
)
A
B
0 4 12 0 4 12 0 4 12 0 4 12 0 4 12 0 4 12
0
20
40
60
80
100
medium IFN-α medium IFN-α medium IFN-α
CpG-A CpG-B CpG-C
w eeks
TN
F-
α 
po
s 
pD
C
 (
%
)
Op den Brouw et al. Chapter 7 Figure 6
20
40
60
80
100 Baseline
PEG-IFN-α therapy
IF
N
- α
 p
os
 p
D
C
 (
%
)
A
BB
A
fig. 6 PEG-Ifn therapy downregu-
lates both tlR9-induced Ifn-α and 
tnf-α production of pDC of chron-
ic HBV patients. 
PBMC of chronic HBV patients at 
baseline and at 4 and 12 weeks of 
PEG-IFN therapy were stimulated 
with CpG-A, CpG-B and CpG-C with 
or without IFN-α to determine intra-
cellular IFN-α (A) and TNF-α (B). Data 
represent mean±SEM; N=4.
Op den Brouw et al. Chapter 7 Figure 7
A
0 4 12 0 4 12 0 4 12 0 4 12
0
20
40
60
80
w eeks
IFN-αmedium IFN-αmedium
CpG-A Lox
TN
F-
α 
po
s 
pD
C
 (
%
)
0 4 12 0 4 12 0 4 12 0 4 12
0
20
40
60
PEG-IFN-α therapy
Baseline
IFN-αmedium IFN-αmedium
CpG-A Lox
w eeks
IF
N
- α
 p
os
 p
D
C
 (
%
)
B
*
**
**
***
*
NS
*
NS
**
***
***
***
NS
NS
NS
NS
A
B
fig. 7 PEG-Ifn therapy directly in-
terferes with pDC function. 
Purified pDC of chronic HBV patients 
at baseline and at 4 and 12 weeks 
of PEG-IFN therapy were stimulated 
with CpG-A and Lox with or with-
out IFN-α to determine intracellular 
IFN-α (A) and TNF-α (B). Data repre-
sent mean±SEM; N=7. On treatment 
samples were analyzed against the 
samples before treatment using the 
paired T test; NS non significant, * 
p<0.05, ** p<0.01, *** p<0.001.
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DIsCUssIon
PDC are key players in the anti-viral immune response. The strong initial type I IFN response 
upon viral infection, often considered as effective pDC activation, is lacking in acute HBV 
infection [11,12].  Moreover, patients chronically infected with HBV show functional deficits in 
pDC function [21]. Here we demonstrated that IFN-α increased pDC function with respect to 
the numbers of anti-viral cytokines-producing pDC upon TLR7 and TLR9 triggering in vitro, via 
the IFNAR-mediated positive feedback loop. In contrast, in vivo exposure to IFN-α enhanced 
TLR7-induced pDC function, but significantly decreased the response to TLR9 stimulation by 
upregulation of TLR7 and downregulation of TLR9 mRNA. IFN-α treatment in vitro had some 
positive effect on cell viability (not shown) and only showed a modest effect on pDC pheno-
type. Exposure to IFN-α in vivo led to a decrease in circulating pDC numbers which could be 
explained by either apoptosis or relocation of these cells. Apoptosis is not very likely since in 
vitro exposure to IFN-α slightly enhanced pDC survival; therefore migration seems the most 
plausible explanation. This would also explain the observed decrease in percentage of pDC 
within the CD45+ cell fraction. Only little PEG-IFN therapy-induced maturation was observed, 
which is likely underestimated in case of migration of activated pDC. Although IFN-α therapy 
provoked changes in pDC numbers, phenotype and function, none of these changes cor-
related with either viral load or serum ALT levels. We therefore conclude that the observed 
effects on pDC are directly caused by PEG-IFNα-2a therapy and are not predictive for treatment 
outcom. The rapid type I IFN response of pDC after detection of viral intrusion is supported 
by the IFNAR-mediated autocrine and paracrine positive feedback loop, leading to induction 
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fig. 8 PEG-Ifn therapy directly interferes with pDC function by differential regulation of tlR7 and tlR9 
mRna levels. 
RT-PCR analysis of purified pDC at baseline and at 4 and 12 weeks of PEG-IFN therapy. Data are normalized against 
expression of the reference gene Abl, the fold change compared to baseline of relative TLR9 and TLR7 mRNA levels 
are shown for 6 chronic HBV patients. On treatment samples were analyzed against the samples before treatment 
using the paired T test; NS non significant, * p<0.05, ** p<0.01.
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of IFN-α and IFN-stimulated genes [22]. In vitro activation of the feedback loop by the pres-
ence of supplementary IFN-α enhanced the response to all three classes of CpG in this study. 
Independent of treatment outcome, we have shown that the IFN-α feedback loop is completely 
abolished by PEG-IFN therapy. This might be an important mechanism to prevent overzealous 
IFN-α production, which could lead to chronic inflammatory diseases. A simple explanation of 
this phenomenon would be the disappearance of IFNAR from the cell surface of pDC during of 
PEG-IFN therapy, but this was not observed (data not shown). Interference with IFN-α signaling 
might be responsible instead.
Using DNA microarrays, response to PEG-IFN-α and ribavirin combination therapy of chronic 
HCV patients has been studied. The number of genes, including known IFN-stimulated genes, 
that were up- or down-regulated by PEG-IFN and ribavirin combination therapy was fewer in 
patients with a poor response than in those with an intermediate or marked viral response, 
but no specific regulatory gene could be identified as responsible for this global difference. 
Interestingly, increased levels of TLR7 mRNA were observed in patients with intermediate or 
good response to therapy in this study [23]. In our small patient population, no such trend was 
observed. Recently, several reports have shown a correlation between PEG-IFN and ribavirin 
combination therapy outcome in HCV patients and activation of proteins of Jak/STAT signaling 
route: presence of STAT6 in pretreatment samples [24] and absence of suppressor of cytokine 
signaling 3 (SOCS3) in the liver prior to treatment [25] predict positive treatment outcome, 
while impaired phosphorylation of STAT1 is found in treatment non-responders [26]. 
Apart from the effect on IFN-sensitivity, this study shows that long term exposure to PEG-IFN 
interferes with CpG-induced pDC function, but does not significantly affect the response to 
viral stimuli. In contrast, Goutagny and colleagues showed a reduced capacity to release IFN-α 
after HSV-1 stimulation of pDC from HCV-infected patients on IFN-α and ribavirin combination 
therapy [27]. The additive effect of the immunomodulator ribavirin on pDC function might be 
one of the explanations for the observed difference compared to this study. Among the other 
differences are the stimulation time, the detection method of IFN-α production and the type 
of chronic viral infection. The reduced HSV-induced IFN-α production might also simply be the 
result of reduced numbers of pDC within the PBMC population, a phenomenon we circum-
vented by using intracellular IFN-α detection of stimulated pDC. 
The fact that PEG-IFN-induced upregulation of TLR7 mRNA does not lead to enhanced 
response after influenza virus stimulus, might be explained by the higher initial response to 
influenza virus compared to the synthetic ligand Lox. This high level response indicates the 
involvement of other cellular receptors triggered by the virus. Similarly, the presence of other 
viral cellular receptors might explain why the decreased TLR9 mRNA levels coincide with 
diminished IFN-α response to CpG- but not HSV-triggering.  
Next to the here reported differences in mRNA levels of TLR7 and TLR9 inflicted by PEG-
IFN therapy, it would be informative to study the actual protein levels of these receptors in 
pDC. Currently, this cannot be achieved due to technical limitations. TLR7 and TLR9 reside in 
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endosomal compartments of pDC and so far no reliable flow cytometry staining can be per-
formed. Alternatively, cell pellets of pDC could be analysed by Western blot, but this requires an 
impractical amount of cells that can not be obtained from patients on therapy.
In line with previous studies, we observed that the three main classes of CpG oligonucle-
otides, CpG class A, B and C, have different patterns of immune activation. CpG-A induces more 
IFN-α, partially regulated via activation of the IFNAR-mediated autocrine feedback loop [28], 
which is not activated by CpG-B [29]. Here, we observed that total cytokine secretion after 
CpG-A stimulus is abrogated during PEG-IFN therapy since TLR9 levels are downregulated 
and functionality of the IFNAR-mediated feedback loop is lost. Cytokine secretion after CpG-B 
is independent of the IFNAR-mediated feedback loop and reduction is solely the result of 
reduced TLR9 levels. Indeed, CpG-B-mediated cytokine secretion is reduced to a lesser extent 
than CpG-A-mediated secretion. As expected, results of CpG-C stimulus are an intermediate of 
the effect of CpG-A and CpG-B stimuli. 
In conclusion, PEG-IFN therapy influenced total number and function of pDC of chronic HBV 
patients. In contrast to in vitro exposure to IFN-α which upregulates response to both TLR7 and 
TLR9 triggering, continuous exposure to IFN-α in vivo downregulates TLR9-and upregulates 
TLR7-induced pDC function. Although it might not seem particular relevant to investigate 
IFN-α production by pDC in patients who are receiving high amounts of PEG-IFN, analysis of 
IFN-α and TNF-α production is informative for pDC function in general, especially since NK or 
T cell crosstalk are difficult to study with such limited cell numbers. It is tempting to speculate 
that a diminished TLR9-induced pDC function in patients chronically infected with a DNA-
virus negatively contributes to response to treatment, which would explain the relative poor 
response to PEG-IFN therapy of chronic HBV patients in comparison to HCV patients. Although 
no relation with clinical outcome, these data will aid in a better understanding of the anti-viral 
immune response induced with PEG-IFN therapy and thereby help in design novel treatment 
strategies for chronic HBV infections. 
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Myeloid dendritic cells in Hepatitis B virus infection
This thesis focused on the role of dendritic cells (DC) in chronic HBV infection. Due to their 
critical role in anti-viral immunity, viruses, such as HBV, might have evolved to interfere with 
the function of DC to escape the host immune response. It has been demonstrated that DC of 
chronic HBV patients display a less immunogenic function compared to DC of healthy controls 
[1-4]. The functional experiments in these studies focussed on the capacity of DC to stimulate 
allogeneic T cells, measuring primarily CD4+ T cell proliferation. Next to this general DC deficit, 
in chapter 2 it is demonstrated that myeloid DC (mDC) are also impaired in HBV-specific CD8+ T 
cell proliferation. In chapter 3 a possible explanation for this phenomenon is given by showing 
that mDC actively internalize HBsAg and that the presence of either purified HBsAg or intact 
viral particles (in concentrations comparable to measured amounts in patient sera [5]) during 
mDC maturation gives rise to mDC with a significantly less immunogenic phenotype and func-
tion as demonstrated by the reduced expression of co-stimulatory molecules and decreased 
T cell stimulatory capacity [6]. HBV, but not HBsAg, also significantly decreased their ability to 
produce IL-12. This is in accordance with data from HBV transgenic mice, used as a model for 
chronic HBV carriers, which produce HBsAg, HBeAg and the viral genome. These mice show low 
immune efficiency, as defined by decreased overall specific antibody responses and reduced 
T cell stimulatory capacity of DC [7]. Also in an HBsAg/HLA-A2 humanized transgenic mouse 
model, high serum levels of HBsAg were able to induce T cell tolerance to HBsAg [8]. These 
data suggest that HBsAg, either as subviral particles or as part of the viral envelop, is at least 
partially responsible for the impaired mDC function observed in chronic HBV patients. This is 
supported by the fact that viral load reduction by the nucleotide analogue adefovir strongly 
increased the capacity of mDC of chronic HBV patients to produce IL-12 and to activate alloge-
neic T cells ex vivo [4]. This observation might be a direct effect of the decreased viral load and/
or circulating HBsAg levels in these nucleotide analogue-treated patients. However, it cannot 
be excluded that other immune parameters are modulated by the lower viral levels, such as 
reduced numbers of circulating regulatory T cells [9], which could be the result, as well as the 
cause for improved mDC function [10,11].
Although the envelope proteins of HBV are glycosylated, the active time-dependent uptake 
of HBsAg was not mediated through DC-SIGN (chapter 4, [12]). In chapter 5 the role of the 
mannose receptor in the binding and uptake of HBsAg is discussed. In circulating blood mDC 
the cell surface expression of the mannose receptor was generally very low, this was reflected 
by the lack of HBsAg uptake and the relative low capacity to take up dextran-FITC as a model 
substrate for lectin-mediated endocytosis. The presence of HBsAg-positive mDC was indeed 
demonstrated only sporadically in blood of chronic HBV patients, which positively correlated 
to expression of the mannose receptor. Hepatic mDC of chronic HBV patients were more fre-
quently involved in the recognition and uptake of HBV subviral particles, which is likely medi-
ated through the mannose receptor [13]. In contrast to pathogen recognition by e.g. Toll like 
receptors (TLR), interaction with the mannose receptor does not induce DC maturation [14]. 
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Thus the mannose receptor-mediated HBsAg uptake in the absence of a TLR signal may lead to 
HBV/HBsAg-specific tolerance. Indeed, in HBV transgenic mice, liver-derived DC were found to 
be impaired in the capability to stimulate naive T cells and produce cytokines, including IL-12 
and IFN-γ [15].
Since the mannose receptor is known to be expressed on macrophages, Kupffer cells in 
the liver biopsies of the same chronic HBV and control patients were also analysed by flow 
cytometry (Fig. 1A). The mannose receptor was present on approximately 7.5% of all CD14+ 
Kupffer cells, ranging from 0.7 to 15.7%. HBsAg could be detected on or within 3.6% of all Kupffer 
cells, ranging from 0.3 to 11.8%, as observed for mDC. Presence of HBsAg and MR expression 
of Kupffer cells showed a trend towards positive correlation (p=0.09, Fig. 1B). Kupffer cells can 
induce tolerance towards phagocytosed antigens by deletion of T cells through induction of 
apoptosis [16]. These results further imply that antigen presenting cells in the immunotolerant 
environment of the liver play a role in tolerance towards HBV. 
In healthy individuals, the immune response after pathogen invasion combines optimal patho-
gen clearance with minimal damage to the host. The immunosuppressive cytokine IL-10 is 
important in the maintenance of this balance through inhibition of cellular immune responses: 
IL-10 inhibits DC function (prevention of DC maturation, blocking of pro-inflammatory cytokine 
production and co-stimulatory molecules expression) leading to effector T cell unresponsiveness 
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fig. 1 Presence of HBsag and mR expression level in Kupffer cells of chronic HBV patients. 
Liver biopsy samples of patients with chronic HBV and control patients with non-HBV related liver diseases were 
measured by flow cytometry after staining for anti-CD45, anti-CD14, anti-CD206 (MR) and anti-HBsAg. (A) Kupffer 
cells are identified as CD45+CD14+, within this population the percentage HBsAg positive cells was determined 
as shown for a representative control and HBV patient. (B) The correlation between HBsAg positivity and presence 
of MR on Kupffer cells of 14 chronic HBV patients was determined with the Spearman test (r=0.47, p=0.09). MR/
CD206=mannose receptor; KC=Kupffer cell. 
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and differentiation of regulatory T cells [17]. In case the balance is lost, underproduction of 
IL-10 may contribute to inflammatory diseases such as asthma [18] and Crohn’s disease [19]. 
Overproduction of IL-10 is thought to be an important factor in persistence of viral infections 
[20] and elevated serum IL-10 levels have been found in HIV [21], HCV [22] and HBV patients 
[23]. In a mouse model for chronic viral infections, significant upregulation of IL-10 by antigen-
presenting cells was reported, leading to impaired T cell responses. Therapeutic administration 
of an antibody that blocks the IL-10 receptor restored T cell function and eliminated viral infec-
tion in the chronically infected wild type mice. Viral infection of IL-10-deficient mice resulted in 
the maintenance of effector T cell responses, elimination of virus and development of antiviral 
memory T cell responses [24]. The role of IL-10 in the chronicity of HBV infections is getting 
increasingly more attention lately. A recent study showed an induction of IL-10 during the 
acute phase of HBV infections, which was accompanied by increased levels of HBV vireamia and 
attenuation of NK and T cell responses [25]. HBcore triggered IL-10 production by monocytes 
and T cells after stimulation of chronic HBV patient-derived PBMC and frequencies of IL-10 
producing monocytes and T cells were significantly higher in patients with high HBV viral load 
and ALT levels [26,27]. Neither HBV particles nor HBsAg directly induced IL-10 production by 
isolated mDC in vitro (chapter 3 [6]). Nevertheless, using TNF-α and IL-1β as stimulation we 
demonstrated the presence of more IL-10-producing mDC in chronic HBV patients compared 
to healthy controls; IL-10 neutralization resulted in restoration of HBV-specific CD8 T cell expan-
sion (chapter 2). Earlier studies of our group showed that adefovir-induced viral load reduction 
reduced the number of regulatory T cells in the circulation of chronic HBV patients. However, 
this increased response was not related to decreased numbers of IL-10 producing cells [9]. The 
lack of decrease in IL-10 producing cells might be one of the reasons why viral load reduction 
by nucleos(t)ide analogues does not often lead to sustained anti-viral response. 
Plasmacytoid dendritic cells in Hepatitis B virus infection
Upon detection of signs of viral invasion, plasmacytoid dendritic cells (pDC) produce large 
amounts of the anti-viral cytokine IFN-α. Detection of viral genetic material and/or viral replica-
tion intermediates occurs in the endosomal compartments through TLR; single-stranded RNA 
triggers TLR7 and double-stranded DNA containing CpG motifs triggers TLR9 [28]. The rapid 
type I IFN response of pDC after detection of viral intrusion is guaranteed by the IFN-α autocrine 
and paracrine positive feedback loop. Interaction between IFN-α and IFN-α/β receptor (IFNAR) 
leads to activation of Jak/STAT signalling, phosphorylated STAT proteins then translocate to the 
nucleus where they assemble with the DNA-binding protein IFN-stimulated gene factor (ISGF)3γ 
to form the ISGF3 complex. ISGF3 functions as a transcription factor for genes containing an 
IFN-stimulated response element motif in their promoter region. Among the genes induced by 
the IFN-α feedback loop is IRF7. Translation and activation of IRF7 proteins in response to IFN 
are thought to be required for the induction of IFN-α gene transcription [29-31].
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In this virus-host interaction, it is in the interest of the virus to secure a niche for its existence 
and escape the host anti-viral response [32]. HBV seems to have indeed found a way to escape 
the primary type I IFN response of the host. Although HBV is a DNA virus which replicates 
through an RNA intermediate, no IFN-α production is triggered after incubation of HBV with 
pDC in vitro (chapter 6). Moreover, HBV infected chimpanzees do not demonstrate induction of 
IFN-α or IFN-β during the acute phase of infection [33]. It is difficult to study the early events of 
acute HBV infection in humans, since patients mostly present after onset of clinical symptoms 
(nausea and jaundice) observed 10-12 weeks after infection [34]. Bertoletti and Gehring made 
the interesting observation that the lack of early symptoms such as fever and malaise in HBV-
infected patients is indirect evidence of the defective type I IFN response during the acute 
phase of HBV infection [35]. One of the proposed mechanisms by which HBV escapes the first 
line defence of the host, is the localization of HBV replication within viral nucleocapsid particles, 
which renders viral RNA and DNA replication intermediates protected from recognition [33,35]. 
A simple explanation for the lack of IFN-α production after HBV exposure could also be that 
pDC are just not capable of binding and internalizing HBV. No signs of HBV replication within 
pDC have been reported, but since HBV DNA has been found on or within circulating pDC they 
seem at least capable of HBV binding [1,36]. A recent study proposed that HBsAg interacts with 
pDC through binding of the pDC specific C-type lectin BDCA2 [37]. In chapter 6 we showed 
that, although limited, HBsAg is indeed able to bind to non-stimulated pDC. However, the role 
of BDCA2 in HBsAg binding remains controversial. In our hands, BDCA2 is highly expressed on 
non-stimulated pDC and is downregulated upon stimulation with CpG, whereas the binding of 
HBsAg was strongly increased. In addition, TLR7-stimulated pDC showed a similar expression 
of BDCA2, but did hardly bind HBsAg, thereby indicating that BDCA2 cannot be the exclusive 
cellular HBsAg receptor on pDC.
Another mechanism of viral escape is the proposed direct interference of HBV with the IFN-α 
production or signalling pathway. TLR9-induced IFN-α production by pDC requires mTOR acti-
vation for interaction between TLR9 and MyD88 and subsequent IRF-7 phosphorylation and 
nuclear translocation in order to activate IFN-α gene transcription [38]. Chapter 6 described 
that the direct inhibitory effect of HBV on TLR9 triggering, leading to impaired pDC function 
and activation, is mediated through reduction of IRF-7 phosphorylation. In concordance it was 
recently shown that HBsAg directly reduced TLR9-mediated IFN-α production, by inhibition of 
IRF7 expression and nuclear translocation [37]. Several other reports describe the inhibition of 
IFN-α signalling by HBV at an upstream signal level using different cell lines. The polymerase 
protein of HBV has been shown to inhibit IFN-α induced activity of the MyD88 promoter at the 
STAT binding site, through inhibition of STAT-1 nuclear translocation [39]. Activation of STAT-1 
was also found to be inhibited by HBV both in vitro and in liver biopsies of chronic HBV patients 
[40]. All together these data suggest that HBV may escape immunity via ineffective pDC activa-
tion and/or active inhibition of pDC function. Disruption of the IFN-α signaling pathway is not 
unique to HBV: many other viruses exploit it to reduce antiviral IFN responses [41]. HCV proteins 
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are capable of selectively degrading STAT-1, to reduce accumulation of phosphorylated STAT-1 
in the nucleus, and to interfere with specific molecules of IFN-α signaling pathways activated 
upon recognition of viral RNA [11,42]. The filoviruses Ebola and Marburg encode proteins to 
interfere with IRF3 and IRF7 activation. In addition, Ebola virus prevents nuclear import of 
activated STAT-1, while Marburg virus acts more upstream by preventing STAT-1 phosphory-
lation [43]. Paramyxoviruses directly interact with STAT-1; this sequestration prevents STAT-1 
activation and thereby blocks IFN-α signalling [44]. More knowledge on these evasive viral 
strategies which potently disrupt the antiviral response of the host will lead to better strategies 
(e.g. therapeutic drugs or targeted vaccines) to control and prevent viral infection.
In chronic HBV patients, the impaired IFN-α signaling pathway leads to impaired IFN-α 
secretion as shown in several studies comparing pDC function in chronic HBV patients and 
healthy controls [1,45-48]. It has been suggested that downregulation of TLR9 levels in chronic 
HBV patients contributes to the impaired IFN-α production [48]. The proposed functional pDC 
impairment has been questioned by Tavakoli et al. In the comparison of CpG-induced IFN-α 
production of pDC of chronic HBV patients versus healthy individuals, they observed such con-
siderable variation between donors that no significant difference between the two groups was 
found [36]. Indeed we feel that some caution in the interpretation of the studies on impaired 
IFN-α production by pDC of chronic HBV patients is at place. We have observed not only large 
inter-person variability, but also an evident effect of age on CpG-induced IFN-α production 
(Fig. 2).
In detailed observation of patient and control characteristics, we found that the median age 
is higher and/or the range in age is broader of all patient populations reported [1,10,45,47,48], 
excluding the study with pediatric patients [46]. Age-related changes in human blood dendritic 
cell populations are getting more and more attention and we strongly recommend to carefully 
consider these effects in future study design [49-53]. 
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fig. 2 Inter-person variability 
and the effect of age on CpG-
induced Ifn-α production of pDC 
of healthy individuals versus 
chronic HBV patients. 
Total peripheral blood mononucle-
ar cells were isolated from healthy 
controls or chronic HBV patients. 
Cells were stimulated with CpG for 5 
hrs and intracellular IFN-α was mea-
sured by flow cytometry.
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The absence of IFN-α induction early in HBV infection, combined with the impaired IFN-α 
production during the adaptive immune response later in the infection, might contribute to the 
susceptibility of chronic HBV patients to PEG-IFN-α therapy. It is known that IFN-α has a direct 
inhibitory effect on HBV replication. In HBV transgenic mouse models, both IFN-α/β inhibit HBV 
replication through interference with the assembly of viral nucleocapsids [54]. Gene expression 
analysis of IFN-induced genes in HBV transgenic mouse livers revealed several cellular factors 
that are associated with IFN-α induced suppression of HBV replication, including components 
of the immunoproteasome, ubiquitin-like proteins and several GTP-binding proteins [55]. Next 
to this direct anti-viral effect, PEG-IFN-α therapy also has an immunomodulatory effect: IFN-α 
activates macrophages, natural killer cells and T lymphocytes allowing further priming of anti-
viral immunity [56]. Nevertheless, only approximately 30% of patients remain in the immune 
control phase after discontinuation of therapy [57]. The vast majority of patients might suffer 
from IFN-α-induced side effects, such as flu-like symptoms, cytopenia and psychiatric adverse 
events, without clinical benefit [58]. In chapter 7 we showed that PEG-IFN-α-2a therapy pro-
voked changes in pDC number, phenotype and function but could not overcome the initially 
observed impaired IFN-α production. Instead, PEG-IFN-α-2a interfered with the IFNAR feedback 
loop diminishing the sensitivity of pDC to IFN-α. Preliminary results on flow cytometric analysis 
of pDC samples before and during PEG-IFN-α-2a therapy ruled out that down regulation of 
IFNAR on the cell surface is responsible for this effect. Possible interference at other levels of 
the IFN-α signalling is currently under investigation. In contrast to in vitro exposure to IFN-α 
which upregulates response to both TLR7 and TLR9 triggering, continuous exposure to IFN-α in 
vivo downregulates TLR9-and upregulates TLR7-induced pDC function. Unfortunately, none of 
these changes correlated with viral load or ALT levels and are thus not predictive for treatment 
outcome.  
Since sustained viral response to PEG-IFN therapy is obtained only in a minority of chronic 
HBV patients, more effective immune modulation might enhance the sustained response rate. 
Therefore we compared DC function of patients on PEG-IFN monotherapy, with patients on 
PEG-IFN and ribavirin combination therapy. Ribavirin is a nucleoside analogue with putative 
immunomodulatory capacities and addition to PEG-IFN doubled the sustained response rate 
in chronic HCV patients [59]. This effect of ribavirin is attributed to a better restoration of the 
immune response, but the underlying mechanism is not known. Compared to PEG-IFN alone, 
which only induced a transient activation of pDC as demonstrated by increased expression of 
CD86 (chapter 7), combination therapy induced a much higher upregulation of CD80, CD86 as 
well as CD40 that sustained the whole treatment period (Fig. 3). At week 72, these parameters 
reversed or were slightly decreased compared to baseline. pDC function, as examined by 
CpG-induced IFN-α production, was dramatically reduced during treatment, but not different 
between the groups. The immunological differences between the treatment groups did not 
translate into a clinical effect since viral load decline and virological (HBV DNA <104 at week 
72), and biochemical responses (normalized ALT at week 72) were comparable in the two arms. 
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In conclusion, compared to PEG-IFN monotherapy, addition of ribavirin significantly enhances 
and prolongs DC activation, which may favour anti-HBV specific immunity but is not sufficient 
to improve virological and biochemical response rates in chronic HBV patients. Currently, the 
effects on other cell subsets, mDC, T cells and natural killer cells, are under investigation. 
ConClUDInG REmaRKs
This thesis focussed on the role of dendritic cells in chronic HBV. HBV surface antigens can 
directly interfere with both mDC and pDC function, although the effects are not of such a kind 
that they can solely account for the chronicity of HBV infections. The fact that chronic HBV 
patients do not frequently suffer from other opportunistic infections underlines this observa-
tion. Immunology is much like life itself: it is all about balance. Instead of one cell type being 
responsible, slight disturbances in functionality of all immune cell subsets, DC, natural killer cells 
and T cells, collectively result in tipping over the balance towards a chronic infection. Ongoing 
technical advantages make it possible to study the immune response at the site of infection: 
the liver. A start is made with this thesis to locally observe the phenotype of liver dendritic cells 
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fig. 3 Effect on pDC phenotype and function of PEG-Ifn-α-2a monotherapy versus PEG-Ifn-α-2a and riba-
virin combination therapy of chronic HBV patients. 
14 HBeAg-negative CHB patients who were randomized to receive PEG-IFNα-2a 180 mg weekly plus placebo (n=8) 
or ribavirin 1000-1200 mg daily (n=6) for 48 weeks, donated peripheral blood at baseline, at 12, 24, 36 and 48 
weeks of treatment and at 24 weeks after treatment. Plasmacytoid DC (BDCA4+) were analyzed for expression of 
CD40, CD80 and CD86 by flow cytometry. To determine pDC function, cells were stimulated with CpG for 5 hrs and 
intracellular IFN-α was measured by flow cytometry. Baseline characteristics were comparable between the two 
arms, 11/14 male, age was 41.8±3.3 yrs (mean±SEM), HBV DNA was 9.6±3.9x106 IU/ml, ALT level was 145±37 IU/L 
and also DC parameters did not differ.
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that are contributing to the chronic infection and already important differences with circulating 
dendritic cells were found. It is my prediction that future studies on the functionality of liver 
immune cells will reveal even more drastic changes, so the key to resolving chronic HBV infec-
tions lies in its origin: the liver. 
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Wereldwijd zijn er meer dan 400 miljoen mensen met een chronische Hepatitis B virus (HBV) 
infectie. Het gevaar van deze chronische besmetting is het optreden van leverschade met een 
verhoogd risico op levercirrose, leverfalen en leverkanker. Een goed functionerend immuunsys-
teem is in staat om een HBV infectie op te ruimen, maar in ongeveer 10 procent van de geïnfec-
teerde mensen gebeurt dit niet of niet voldoende, waardoor de acute infectie overgaat in een 
chronische infectie. De precieze oorzaak hiervan is onbekend. Uit voorafgaand onderzoek van het 
MDL-laboratorium naar dendritische cellen (DC), het celtype dat de anti-virale immuunrespons 
opstart en reguleert, is gebleken dat de functie van verschillende DC subtypes van chronische 
HBV patiënten afwijkt ten opzichte van gezonde controles. Naast een beschreven verminderde 
capaciteit van myeloïde DC (mDC) om CD4 T cellen te stimuleren, wordt in hoofdstuk 2 beschre-
ven dat mDC van HBV patiënten minder goed in staat zijn om HBV-specifieke CD8 T cellen te 
activeren, wat een effectieve anti-virale immuunrespons belemmert. Neutralisatie van het 
anti-inflammatoire cytokine IL-10 herstelt het vermogen van DC om CD8 T cellen te activeren. 
Hieruit blijkt dat IL-10 mogelijk een belangrijke rol speelt in de ontwikkeling van een chronische 
HBV infectie. Tot dusver is niet bekend of de verminderde DC functie veroorzaakt wordt door een 
directe interactie tussen de DC en het virus, of door de achterliggende chronische leverontste-
king. In hoofdstuk 3 is de interactie tussen mDC en HBV onderzocht en is vervolgens gekeken 
naar de gevolgen van deze interactie voor de anti-virale functie van mDC. Opname van HBV of 
HBV oppervlakte eiwitten leidt direct tot een functie afname van mDC. De interactie tussen HBV 
en de DC loopt echter niet via de welbekende pathogeen receptor DC-SIGN (hoofdstuk 4). De 
mannose receptor speelt wel een rol in de opname van HBV oppervlakte eiwitten door mDC. Uit 
onderzoek van bloed en leverbiopten van chronische HBV patiënten blijkt dat deze interactie 
voornamelijk in de lever plaatsvindt (hoofdstuk 5). Een ander subtype DC is de plasmacytoïde DC 
(pDC), die een belangrijke rol spelen bij de anti-virale afweer door de productie van interferon-α 
(IFN-α). In hoofdstuk 6 wordt beschreven dat HBV een directe negatieve invloed heeft op de IFN-α 
productie. Met name de IFN-α productie na triggering van de pathogeen receptor TLR9 wordt 
geremd in aanwezigheid van HBV, door een direct negatief effect op de IFN-α signaleringsroute. 
In vitro leidt IFN-α behandeling tot een verbetering van pDC functie (hoofdstuk 7). IFN-α therapie 
van chronische HBV patiënten leidt tot veranderingen in het aantal pDC, het fenotype en de 
functie. De IFN-α respons na stimulatie van TLR7 en TLR9 neemt respectievelijk toe en af, door 
regulatie van TLR7 en TLR9 mRNA levels. Bovendien verdwijnt de gevoeligheid van pDC voor de 
aanwezigheid van IFN-α, mogelijk door interferentie met de IFN-α signaleringsroute.
Samengevat tonen we met dit proefschrift aan dat HBV een negatief effect heeft op de functie 
van de twee belangrijke DC subtypes, mDC en pDC. Gecombineerd met specifieke individuele 
eigenschappen van de gastheer en de negatieve effecten van HBV op andere cellen van het 
immuun systeem, kan dit de balans laten doorslaan van een effectieve opruiming van HBV naar 
een chronische HBV infectie.

137Dankwoord
Dankwoord
Tijdens de afgelopen jaren heb ik op de fiets op weg naar het lab regelmatig gefantaseerd hoe 
heerlijk het zou zijn als mijn promotieonderzoek zo ver gevorderd was dat ik toe zou zijn aan 
het schrijven van het dankwoord. Nu het zover is, doe ik dat met een mengeling van blijdschap, 
opluchting en weemoed. Zoals Kaváfis de reis naar Ithaka beschreef: ik heb mijn promotie 
altijd als einddoel voor ogen gehad, maar de weg daarnaartoe was gelukkig “lang, vol avon-
tuur en rijk aan stof tot kennis” en daardoor misschien zelfs waardevoller dan de uiteindelijke 
bestemming. Op deze plek zou ik graag iedereen willen bedanken die daar een bijdrage aan 
geleverd heeft. Allereerst Rob de Man, aangezien deze reis bij het gesprek met jou begonnen 
is. Heel erg bedankt dat jij open stond voor mijn idee om in Rotterdam onderzoek te komen 
doen en mij geïntroduceerd hebt op het MDL-lab. Vervolgens mijn promotor, prof.dr. Janssen. 
Beste Harry, bedankt voor je steun en vertrouwen in goede en slechte tijden. Mede dankzij 
jouw bewonderingswaardige vermogen om in zeer korte tijd de relevantie en impact van 
experimenten en onderzoekslijnen juist in te schatten, is het lab in korte tijd uitgegroeid tot 
een grote en succesvolle afdeling. Bedankt dat ik daar onderdeel van mocht uitmaken. Renate, 
vanaf het begin af aan was je meer vriendin dan begeleider. We waren het niet altijd eens over 
de richting van mijn onderzoek, maar uiteindelijk heb jij aan de basis gestaan van veel van de 
hoofdstukken in dit proefschrift. Bedankt voor je onophoudelijke enthousiasme en interesse in 
mijn onderzoek, ook lang na je vertrek naar Delft. Beste Andrea, vanaf dag één heb jij op allerlei 
manieren een gedegen bijdrage geleverd aan mijn onderzoek, met discussies, ideeën en sug-
gesties. De sessies waarin we samen artikelen in allerlei stadia doornamen waren aangenaam 
en zeer productief, niet in het minst vanwege je fijne schrijfstijl. Bedankt ook voor de gesprek-
ken in de laatste fase van mijn onderzoek, over carrières en het leven daarnaast.
Een van de belangrijkste redenen voor het succesvol afronden van mijn onderzoek, was de 
ontzettend leuke sfeer onderling op het lab. Zeker in de beginfase toen de groep nog relatief 
klein was, werden alle hoogtepunten gezamenlijk gevierd en alle dieptepunten gezamenlijk 
weggespoeld bij Dizzy. De feesten in het parlement, karaoke borrels, ski vakanties, avonden op 
het terras, kampeerweekenden: Scot, Brenda, Marjon, Jeroen P, Alice, Patrick, Clara, Anthonie, 
Anouk, PJ, Martijn, Mark, Antoine, Jeroen F, Martine, Jan, Angela, Greta, Thanya, Ahmet, Eric, 
Arjan, Linda, Suomi, Lianne, Ayala en Viviana: zonder jullie was het leven op het lab maar 
saai geweest. Lieve Duygu, heel erg bedankt voor je bijdrage aan mijn onderzoek tijdens je 
afstudeerstage. Ik vond het mooi om je te zien uitgroeien van een lieve verlegen studente tot 
een bijna eigenwijze analist. Paula en Rekha, kloppend hart van de hepatitis groep, ontzettend 
bedankt voor jullie inzet, hulp en motiverende woorden op de goede momenten. En Rekha, ik 
waardeer het zeer dat je op de grote dag mijn paranimf wilt zijn. Luc, Jaap, Hanneke, bedankt 
voor jullie discussies over mijn onderzoek en suggesties voor experimenten. Andre, je zei altijd 
dat ik pas mocht promoveren als ik iets egoïstischer zou worden, volgens mij is het bijna gelukt. 
Met jouw heldere visie heb je een positieve bijdrage geleverd aan de vooruitgang van het lab 
138
D
an
kw
oo
rd
in het algemeen en van mij in het bijzonder. Iedereen van de dakpoli wil ik bedanken voor hun 
bijdrage aan mijn onderzoek, met name Martijn, Erik, Jur, Vincent en Jildou. Ik ben voor meer 
interactie tussen lab en kliniek!
Heleen, Anneke, Cokki en Lucille, jullie zijn de liefste research verpleegkundigen die je kunt tref-
fen. Lieve dames van het clinical research bureau, bedankt voor jullie hulp bij de PARC studie en 
de gezelligheid daarna. Marion, heel erg bedankt voor je efficiënte en opgewekte hulp tijdens 
formulier 1, 2, 3, en 4.
Beste Theo, uit de fijne samenwerking met jou zijn mijn twee lievelingshoofdstukken ontstaan. 
Ik ben ontzettend blij dat je in mijn commissie zitting wilde nemen. Irene en Marein, mede 
namens jullie leidden mijn reisjes naar Amsterdam uiteindelijk toch tot een artikel, bedankt 
voor jullie hulp. Dear Ulrike, thanks to you and the people in your lab I learned to pamper the 
HepG2.2.15 cells in such a way that they produced large amounts of virus. Many chapters of this 
thesis profited from my enjoyable days in your lab in Cologne. I’m honoured and pleased that 
you are willing to travel to Rotterdam to take place in my committee.
A very warm thank you to all organisers and participants of the Molecular HBV meeting, it was 
truly the most inspiring week of every year of my thesis.
Alle patiënten en gezonde vrijwilligers die geheel belangeloos bloed en/of biopten hebben 
gegeven wil ik in het bijzonder bedanken, zonder jullie was dit onderzoek niet mogelijk 
geweest. Mtijn dank is extra groot omdat ikzelf al licht in mijn hoofd word bij het zien van de 
naald.
Ik ben mijn onderzoek niet helemaal zonder kleerscheuren doorgekomen en wil graag 
mevrouw Sutterland, Annie Storm en mijn yoga juffie Rachel bedanken voor hun belangrijke 
bijdrage aan mijn herstelperiode.
Soms dreigde ik uit het oog te verliezen dat het leven buiten het lab belangrijker is dan het 
leven op het lab. Mijn lieve vrienden, vriendinnen en (schoon)familie wil ik heel graag bedanken 
voor hun interesse, steun en afleiding en vooral voor de eigenschap om het woord proefschrift 
af en toe te mijden.
Lieve René, van jou heb ik onderweg de mooiste les geleerd, namelijk dat “een grimmige 
Poseidon mij niet zal treffen als ik hem niet in mijn geest meedraag”. Met een leeg hoofd en 
mijn aandacht bij mijn voeten, slagen experimenten eerder en gaat het schrijven van artikelen 
soepeler. Lief beessie, met jou in de buurt kan ik alles aan, ik ben mede daarom heel erg blij dat 
je mijn paranimf wilt zijn. 
Lieve papa en mama, woorden schieten te kort voor jullie bijdrage aan dit geheel. Zonder jul-
lie zou ik letterlijk en figuurlijk niet zijn wie ik was, ik kan me geen fijnere ouders voorstellen. 
Begripvol, stimulerend, aandachtig; jullie weten altijd precies wat ik nodig heb en wanneer. Ik 
hou van jullie.
Tot slot Marc, liefde van mijn leven, vaak letterlijk ver weg, maar figuurlijk altijd dichtbij. Jij hebt 
de wonderlijk mooie gave overal waar je komt de wereld een stukje mooier te maken. Ik hoop 
dat ik dat nog heel lang van heel dichtbij mag meemaken. 
139Curriculum vitae
Curriculum vitae
Marjoleine Louise Op den Brouw werd op 24 augustus 1978 geboren in Dordrecht. Zij behaalde 
in 1996 haar VWO diploma aan het Develsteincollege in Zwijndrecht. In datzelfde jaar startte 
zij met haar studie Moleculaire Wetenschappen aan de Wageningen Universiteit. In de docto-
raalfase is haar wetenschappelijke interesse gewekt tijdens een afstudeeronderzoek aan het 
Laboratorium voor Virologie, waar ze onder begeleiding van dr. Wilfred IJkel en prof.dr. Rob 
Goldbach vier ORFs van het genoom van het Spodoptera exigua multicapsid nucleopolyhedro-
virus gekarakteriseerd heeft. Hierna heeft ze onder begeleiding van dr. Joop Jansen onderzoek 
gedaan naar de pathogenese van acute promyelocytaire leukemie, aan het Hematologisch 
Laboratorium van het UMC St Radboud te Nijmegen. Om haar ervaring in het wetenschappelijk 
onderzoek verder uit te breiden heeft ze een extra stage van een jaar verricht aan de Harvard 
Medical School in Boston. Onder begeleiding van dr. Marianne Boes en prof.dr. Hidde Ploegh 
heeft ze onderzoek verricht naar antigeen presentatie door MHC class II moleculen met behulp 
van een GFP-MHC class II muizenmodel. Na het behalen van haar doctoraalexamen in 2002, 
heeft zij anderhalf jaar onderzoek gedaan aan genregulatie in Drosophila melanogaster op de 
afdeling Moleculaire Celbiologie van het LUMC in Leiden, onder begeleiding van dr. David Baker. 
In 2004 is zij gestart met haar promotieonderzoek op de afdeling Maag-, Darm- en Leverziekten 
van het Erasmus MC. Onder leiding van promotor prof.dr. Harry Janssen en co-promotor dr. 
Renate van der Molen, later opgevolgd door dr. Andrea Woltman, heeft zij onderzoek gedaan 
naar het Hepatitis B virus waarvan de resultaten in dit proefschrift beschreven staan. Een 
gedeelte van dit onderzoek heeft zij uitgevoerd op de laboratoria van dr. Theo Geijtenbeek 
(Moleculaire Celbiologie en Immunologie, VUMC, Amsterdam), Mark van Roosmalen (Biomé-
rieux, Boxtel) en prof.dr. Ulrike Protzer (Institituut Medische Microbiologie, Keulen, Duitsland). 
Sinds juni 2009 is zij werkzaam bij Gilead Sciences als medical science liaison op het gebied van 
virale infectieziekten.

141Publications
Publications
op den Brouw mL, Binda RS, Geijtenbeek TBH, Janssen HLA and Woltman AM (2009) The 
mannose receptor acts as hepatitis B virus surface antigen receptor mediating interaction with 
intrahepatic dendritic cells. Virology 393(1): 84-90. 
op den Brouw ml, Binda RS, van Roosmalen MH, Protzer U, Janssen HLA, van der Molen RG and 
Woltman AM (2009) Hepatitis B virus surface antigen impairs myeloid dendritic cell function: A 
possible immune escape mechanism of HBV. Immunology 26 (2): 280-9. 
op den Brouw ml, de Jong MAWP, Ludwig IS, van der Molen RG, Janssen HLA, Geijtenbeek TB 
and Woltman AM (2008) Branched oligosaccharide structures on HBV prevent interaction with 
both DC-SIGN and L-SIGN. Journal of Viral Hepatitis 15(9):675-83. 
Roukens MG, Alloul-Ramdhani M, Moghadasi S, op den Brouw ml and Baker DA. (2008) 
Downregulation of vertebrate Tel (ETV6) and Drosophila Yan is facilitated by an evolutionarily 
conserved mechanism of F-box-mediated ubiquitination. Molecular and Cellular Biology 
28(13):4394-406. 
Boes ML, Bertho N, Cerny J, op den Brouw ml, Kirchhausen T and Ploegh HL (2003) T cells 
induce extended class II MHC compartments in dendritic cells in a Toll-like receptor-dependent 
manner. Journal of Immunology 171(8): 4081-8. 
Boes ML, Cerny J, Massol R, op den Brouw ml, Kirchhausen T, Chen J and Ploegh HL (2002) 
Trafficking of MHC class II molecules in live antigen presenting cells: endocytic structures that 
respond to antigen-specific T cell engagement. Nature 418(6901): 983-988. 
IJkel WF, Lebbink RJ, op den Brouw ml, Goldbach RW, Vlak JM and Zuidema D (2001) Iden-
tification of a novel occlusion derived virus-specific protein in Spodoptera exigua multicapsid 
nucleopolyhedrovirus. Virology 284 (2): 170-181. 

143Portfolio
Portfolio
Conferences
2009 Enhanced and prolonged activation of dendritic cells in chronic hepatitis B patients 
treated with a combination of PEG-IFN and ribavirin does not improve response to 
therapy compared to standard PEG-IFN therapy.
 Annual meeting of the American Association for the study of Liver Diseases, Boston, USA 
(poster)
2008 The mannose receptor as a putative hepatitis B virus receptor regulating intrahepatic 
dendritic cell function.
 Annual meeting of the American Association for the study of Liver Diseases, San Francisco, 
USA (Presidential Poster of Distinction)
 PEG-IFNα2a therapy of chronic HBV patients alters plasmacytoid dendritic cell function 
by affecting TLR7 and TLR9 levels.
 Annual meeting of the American Association for the study of Liver Diseases, San Francisco, 
USA (poster)
 PEG-IFNα-2a therapy of chronic HBV patients alters the endogenous TLR-induced IFNα 
production by plasmacytoid dendritic cells.
 Annual meeting of the Dutch Society of Gastroenterology and Hepatology, Veldhoven, the 
Netherlands (poster)
 Internalization route of hepatitis B surface antigen by myeloid dendritic cells is depen-
dent on HBV vaccination status.
 Annual meeting of the Dutch Society of Gastroenterology and Hepatology, Veldhoven, the 
Netherlands (poster)
2007 Trimming of branched oligosaccharide structures on HBV inhibits DC-SIGN binding.
 Annual meeting of the American Association for the study of Liver Diseases, Boston, USA 
(poster)
 Trimming of branched oligosaccharide structures on HBV inhibits DC-SIGN binding.
 International Meeting of the Molecular Biology of Hepatitis B viruses, Rome, Italy (oral)
 PEG-IFNα-2a therapy of chronic HBV patients alters the endogenous TLR-induced IFNα 
production by plasmacytoid dendritic cells. 
 International Meeting of the Molecular Biology of Hepatitis B viruses, Rome, Italy (poster)
144
Po
rt
fo
lio
2006 Impaired IFNα production in patients with chronic HBV: Effect of IFNα treatment in vitro 
and in vivo.
 Annual meeting of the Dutch Society of Immunology, Noordwijkerhout, the Netherlands 
(poster)
 Impaired IFNα production of chronic HBV patients: exogenous IFNα restores endog-
enous IFNα levels.
 Annual meeting of the American Association for the study of Liver Diseases, Boston, USA 
(poster)
 
 Impaired IFNα production of chronic HBV patients: exogenous IFNα restores endog-
enous IFNα levels.
 International Meeting of the Molecular Biology of Hepatitis B viruses, Vancouver, Canada 
(poster)
2005 Hepatitis B surface protein has an immunomodulatory effect on mDC.
 Annual meeting of the Dutch Society of Immunology, Noordwijkerhout, the Netherlands 
(poster)
 Functional impairment of mDC in chronic HBV patients: the role of HBV proteins.
 Annual meeting of the American Association for the study of Liver Diseases, San Francisco, 
USA (poster)
 
 Functional impairment of mDC in chronic HBV patients: the role of HBV proteins.
 International Meeting of the Molecular Biology of Hepatitis B viruses, Heidelberg, Germany 
(poster)
Courses
2006 Medical statistics and SPSS
memberships
2006 Member of the Dutch Society of Hepatology
2005 Member of the Dutch Society of Immunology

146
Po
rt
fo
lio
